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Therapeutic monoclonal antibodies (mAbs) can inhibit the function of tumour antigens (TA) and 
additionally those of IgG1 subclass can recruit natural killer (NK) cells to kill tumours via antibody-
dependent cellular cytotoxicity (ADCC). One such example is cetuximab, which is specific for the 
epidermal growth factor receptor (EGFR) that is overexpressed in more than 70% of colorectal 
cancer cases. Importantly the efficacy of cetuximab is limited in patients who have the low affinity 
FCγRIIIa (CD16) polymorphism, thus a glyco-engineered (GE) anti-EGFR mAb was developed 
called GA201GE (imgatuzumab), that reportedly mediates high affinity CD16 binding and 
enhanced ADCC, irrespective of CD16 genotype. In a similar vein, the anti-CD20 GE-mAb 
obinutuzumab (GA101GE) was developed to improve upon the unmodified anti-CD20 rituximab 
currently used in the treatment of B-cell malignancies. It is important to evaluate whether ADCC 
facilitated by therapeutic mAbs has the potential to stimulate CD8+ T-cell mediated immunity, 
which is essential for long-term tumour immune-surveillance. The complex cross talk between NK 
cells and dendritic cells (DC) is a precursor to the generation of TA-specific T cells. DC can ingest 
and process exogenous antigen released from target cells lysed by NK cells, and subsequently 
cross present TA epitopes to TA-specific CD8+ T cells. Cetuximab-activated NK cells are known 
to induce DC maturation but whether GE mAb-activated NK cells can induce DC maturation is 
currently unknown. This study therefore aimed to assess the ability of GE-mAbs to induce DC 
maturation and other functions necessary for the stimulation of adaptive immunity. An in vitro co-
culture model was established to assess interactions between tumour cells, NK cells, DC and TA-
specific CD8+ T cells. In keeping with a precedent set by previous studies of GE-mAbs, 
comparisons were made with wild type counterpart mAbs or clinically utilised unmodified mAbs. 
Principally, GE-mAbs were shown to induce NK-cell activation in terms of both activation marker 
up-regulation and cytokine production. Imgatuzumab-mediated NK-cell activation was achieved 
across various tumour-cell EGFR expression levels, indicating an ability to provoke responses to 
heterogeneous tumours and GE-mAb-activated NK cells were shown to induce DC maturation. 
Antigen uptake by DC and cross presentation of TA to TA-specific T cells were also examined in 
the presence of GE-mAbs. In a secondary manner, when compared at equivalent concentrations, 
GE-mAbs induced multiple measures of NK-cell function and DC maturation to a significantly 
greater extent than unmodified mAbs. These findings suggest that GE-mAbs may have greater 
potential to promote presentation of TA to CD8+ T cells than unmodified mAbs. 
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Chapter 1. Introduction 
 
1.1. Tumour immunology 
Cancer is the result of abnormal, uncontrolled proliferation and differentiation of cells. The 
multistep process by which normal cells are progressively transformed to malignancy is now 
known to require the sequential acquisition of mutations that arise as a consequence of damage 
to the genome. This damage can be inherited, or induced by carcinogens, radiation, chronic 
inflammation or viruses 1. Proto-oncogenes and tumour-suppressor genes are normal genes that 
control crucial functions such as cell division and survival. As genetic alterations accumulate in 
these genes, cells acquire a succession of abilities, defined by Hanahan and Weinberg as the 
hallmarks of cancer. They include the ability to sustain proliferative signalling, evade growth 
suppression, resist cell death, enable replicative immortality, induce angiogenesis, activate 
invasion/metastasis and (most recently acknowledged) evade immune destruction 2.  
The antigenic changes in malignant cells that are created by individual mutations during 
transformation can be subtle. In addition, the majority of antigens expressed by human cancer 
cells are non-mutated self-antigens also expressed in normal cells 1. Crucially, the immune 
system must discriminate between self and non-self in order to prevent auto-immunity. Self-
tolerance is acquired and maintained by a combination of central 3 and peripheral 4 education 
mechanisms. Transformed malignant cells that do not appear overtly foreign to the immune 
system are therefore ineffective at triggering immune responses. However, tumours are 
genetically unstable and continue to acquire mutations. Although increased virulence and immune 
escape can occur as a consequence of tumour evolution, this genome instability can also lead to 
aberrant expression of self-proteins and creation of new antigenic potentialities 1. 
 
1.1.1. Cancer immunosurveillance 
The mechanisms of tumour progression and tumour rejection are key concepts in the study of 
tumour immunology. A body of evidence exists indicating that components of the immune system 
are involved in controlling primary tumour development. This concept was first proposed by Paul 
Erlich in 1909. He suggested that “aberrante Keime” or mutant cells arise continuously and were it 
not for host defence mechanisms, cancer would occur at an enormous frequency (“in einer 
ungeheurer Frekvenz”) 5. At the time, so little was known about the composition and function of 
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the immune system that it was simply not possible to assess the validity of this theory. More than 
50 years later the idea of immune control of cancer resurfaced, fuelled by an enhanced 
understanding of the immune system. The suggestion of an anti-tumour immune response, 
formally re-introduced by Macfarlane Burnet 6 in 1957 and echoed shortly after by Lewis Thomas 
7, was later referred to as ‘cancer immunosurveillance’ 8, 9. Burnet and Thomas speculated that 
lymphocytes acted as sentinels, continuously recognising and eliminating nascent transformed 
cells to prevent manifestation of neoplasms. However, despite earlier demonstration of the 
existence of tumour antigens 10, subsequent studies by Stutman provided little support for the 
theory of cancer immunosurveillance. Of particular note were experiments showing that CBA/H 
strain nude mice did not form more carcinogen-induced tumours than their wild-type (WT) 
counterparts, nor did they show a shortened tumour latency period. Nude mice or 
immunocompetent mice (heterozygous for the nude mutation) were injected subcutaneously at 
birth with 0.1mg of the chemical carcinogen methylcholanthrene (MCA) and monitored for tumour 
incidence. After 120 days, 5 of 27 nude mice formed tumours at the injection site, with a mean 
time to tumour appearance of 90 days. Of the control immunocompetent mice, 7 of 39 formed 
tumours, with a mean time to appearance of 95 days 11. The similarity between nude and 
immunocompetent mice was maintained in subsequent experiments employing different doses of 
carcinogen in mice of different ages 12 and even when the observation period was extended to 
420 days 13. At least one other group corroborated these results 14. Stutman additionally showed 
that there were no significant differences in the incidence of spontaneous non-viral tumour 
formation between nude and wild-type mice 15. These findings were supported by the work of 
Rygaard and Povlsen who studied nearly 11,000 mice over a period of 3-7 months and showed 
no differences in spontaneous tumour formation 16. 
 
Based on these findings, the theory of cancer immunosurveillance resisted widespread 
acceptance, however, it is now clear that there were a number of caveats to these experiments. 
First, MCA requires biotransformation from its pro-form to its carcinogenic form via the aryl 
hydrocarbon hydroxylase enzyme pathway. The CBA/H mouse strain used in the Stutman studies 
expresses an isoform of the enzyme with high specific activity, thus these mice may have been 
more sensitive to MCA-induced tumour formation than other inbred mouse strains 17. Second, 
although Rygaard and Povlsen corroborated Stutman’s results using large numbers of nude mice, 
it is now considered that their monitoring periods of 3-7 months may have been too short to 
32 
 
observe spontaneous tumour formation when considering fully functional intrinsic tumour 
suppressor systems (such as p53) 18. Third, the nude mouse was considered immunologically 
deficient due to congenital absence of the thymus. Importantly, it is now clear that nude mice are 
not completely immunocompromised. Although they possess fewer T cells than wild-type mice, 
they have detectable populations of functional T-cell receptor αβ-bearing (TCR- αβ) lymphocytes 
19, 20, B cells and natural killer (NK) cells, which are not thymus dependent 21. 
 
Two key findings in the mid 1990s renewed enthusiasm for the concept of cancer 
immunosurveillance. First, it was discovered that endogenously derived interferon gamma (IFNγ) 
protected C57BL/6 host mice against the growth of transplanted tumours and the formation of 
chemically induced tumours 22. Second, it was observed that mice lacking perforin (C57BL/6 
perforin-/-) were more prone to spontaneous and chemically induced tumours than their wild type 
counterparts 23. The secretion of perforin and IFNγ are characteristics of natural killer (NK) cells 
and cytotoxic T-lymphocytes (CTL) 24, respectively important in mediating lymphocyte-dependent 
killing of tumour cells and activating auxiliary immune cells (discussed in section 1.4 onwards). 
Notably, perforin mutations have been documented in lymphoma patients 25. 
 
Evidence both supporting and opposing the principals of cancer immunosurveillance began to 
emerge. The logical prediction from these renaissance findings was that immunodeficient or 
immunosuppressed humans should show greater cancer incidence. Indeed, early studies of 
individuals with primary immunodeficiencies 26 and immunosuppressed transplant patients 27 
showed significantly higher relative risk of developing cancer. An approximate 4-fold increase in 
the incidence of de novo malignant melanoma has been reported after organ transplantation 28. 
When 608 University of Pittsburgh cardiac transplant patients were assessed for the occurrence 
of neoplasia over a 13-year period, the prevalence of lung tumours was 25-fold higher than in the 
general population 29. Additionally, the follow up of nearly 6000 Nordic renal transplant patients 
showed higher standardised cancer incidence ratios for malignant melanomas and ureter, kidney, 
bladder, colon, lung and endocrine tumours, compared to the general population 30. 
 
Thus, individuals with immune deficits have a higher probability of developing cancers with no 
known viral aetiology, however the majority of tumours in the immune-compromised are virus-
associated, and are linked to infection with Epstein-Barr virus, human herpes virus and human 
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papilloma virus 27, 31. Associations between different bacteria and higher incidence of various 
tumours have also been described, including Helicobacter pylori 32 and chlamydia 33; which 
fostered speculation that cancer immunosurveillance targeted transforming agents but not 
tumours per se. It is now well established that the induction of inflammation by bacterial and viral 
infections increases cancer risk. This may, in part, be due to the anti‐inflammatory reactions of 
antigen‐presenting cells, which release anti‐inflammatory cytokines such as IL‐10 and 
transforming growth factor‐β (TGF‐β) that inhibit effector-cell activation 34. Regulatory T cells 
(Tregs) are also presumed to act mostly in a pro-tumorigenic fashion through suppression of anti-
tumour immune responses 35. Also, despite the protective role of IFNγ demonstrated in mouse 
experiments, treatment with IFNγ had no benefit for patients with different tumour types 36, 37, 38.  
 
1.1.2. Cancer immunoediting 
The concept of cancer immunosurveillance evolved into the theory of ‘cancer immunoediting’ after 
Schreiber and colleagues summarised that the immune system can exert both tumour-inhibitory 
and tumour-promoting effects 39. Cancer immunoediting, illustrated in Figure 1.1, occurs in three 
sequential phases: elimination, equilibrium, and escape. Elimination, a refined view of cancer 
immunosurveillance, considers that innate and adaptive immunity work together to detect and 
destroy transformed cells long before they become clinically apparent. However, tumour cell 
variants that are not completely eliminated reach an equilibrium phase. In equilibrium, adaptive 
immunity constrains growth of clinically undetectable tumour cells but edits their immunogenicity; 
iteratively selecting for variants with poor immunogenicity and resistance to immune cell 
elimination. If the functional dormancy of equilibrium tumour cells is broken, the cells progress to 
the escape phase, during which edited tumours with reduced immunogenicity begin to grow 
progressively in an immunologically unrestrained manner. An immunosuppressive 
microenvironment is established, and the tumour eventually becomes clinically significant 40, 41. A 
key theme in the cancer immunoediting process is that tumour cells express antigens that 
distinguish them from their non-transformed counterparts. Tumour antigens (TA) expressed by 
tumours but poorly expressed or absent in healthy somatic tissue thus permit tumour recognition 









1.2. Classification of tumour antigens 
Some TA can be derived from exogenous foreign sources, such as the proteins involved in viral 
structure. The oncogenic human papillomaviruses (HPV) have been well-studied because 
individuals are commonly exposed to these viruses and additionally they have been implicated as 
co-factors in the pathogenesis of many cancers, including cervical cancer 43 and some forms of 
head and neck squamous cell carcinoma (HNSCC) 44. In 1991, van der Bruggen et al defined the 
first endogenous human TA in melanoma patients, melanoma antigen I (MAGE-I). MAGE-I was 
found to be exclusively expressed in melanoma cells and CTL raised from their melanoma patient 
were shown to specifically lyse autologous tumour, providing strong evidence of tumour 
recognition by the immune system 45. Ground breaking work by Ron Levy and colleagues was to 
follow, demonstrating the induction of immune responses in patients with B-cell lymphoma, 
against the surface-immunoglobulin idiotype expressed by their tumours. The tumours of patients 
with measurable disease regressed completely and these studies opened the field of monoclonal 









and characterised (documented by Vigneron et al 47). Most TA can be distinctly classified based 
on their aetiology as follows:  
 
1.2.1. Cancer testes antigens and embryonic antigens 
Cancer testes (CT) antigens are present in germ-line cells and tumours, but absent from other 
somatic tissues. Of the CT antigens, the aforementioned MAGE family are the best-defined 48. 
Embryonic antigens are expressed during early development but not post-natally; of which 
carcinoembryonic antigen (CEA) is best defined 49, 50. 
 
1.2.2. Post-translational modification 
Some TA are subject to post-translational modification (PTM) that can cause conformational 
changes or form new antigen epitopes; of which mucin-I (MUC-1) is a well-studied example. 
MUC-I is preferentially expressed on epithelial tumours but is hypoglycosylated in breast tumours, 
exposing regions of the MUC-I protein backbone that can be differentially recognised by 
antibodies 51. 
 
1.2.3. Mutated antigens (point mutations and chromosome abnormalities) 
These can be borne of point mutations, such as the range of mutations documented in the 
notorious p53 tumour suppressor 52; or fusion proteins that result in tumour-specific neoantigens, 
such as the breakpoint cluster region-abelson (BCR-ABL) tyrosine kinase protein created by 
reciprocal chromosomal translocation, seen in patients with chronic myeloid leukaemia (CML) 53, 
54. 
 
1.2.4. Overexpressed or aberrantly expressed antigens 
These antigens are expressed at low levels on healthy tissue but significantly overexpressed on 
tumour cells; which may expose cryptic or subdominant epitopes 55. One putative example and a 





1.3. Tumour elimination: the interaction between innate and adaptive 
effector cells 
Virtually every known cell type of the immune system is represented in the tumour 
microenvironment 56. The immune response to tumour cells can typically be divided into innate 
and adaptive components. Upon encounter with malignant cells, innate immune responses occur 
rapidly, within hours; but are non-specific 57. These early innate anti-tumour responses are 
mediated by NK cells, invariant NK T cells (iNKT cells) 58 and γδ T cells 59. Several studies have 
demonstrated tumour infiltration of the aforementioned effector cell types, endowed with the 
capacity to directly kill tumour cells in vitro 60, 61, 62, 63. However, the functional significance and 
complex interactions between tumour infiltrating effector cells are still being fully elucidated.  
Although adaptive responses may, in contrast take days to develop, this route of resistance 
efficiently targets individual antigens 57. With the help of NK cells and dendritic cells (DC) the 
adaptive response to tumours is driven by T cells and B cells and relies on somatic gene 
rearrangements to provide highly specific target recognition and long-term “memory” defence 
against subsequent encounters with the same antigen 60, 61, 64, 65. Thus the key to tumour 
elimination is the interplay between immune system effector cells, rather than the activity of one 
element alone. The immune cells, interactions and tumour types that influence this study are 
discussed further. 
 
1.4. Natural killer cells 
Natural killer (NK) cells are large granular lymphocytes that were serendipitously identified in 
1973 during the assessment of tumour directed cytotoxicity. The observation that NK cells were 
able to kill aberrant cells in the absence of antigen specific recognition later redefined them as 
sentinels of innate immunity, endowed with both cytotoxic and cytokine-producing functions 66, 67.  
Consistent with their role in immune surveillance, NK cells are widespread throughout lymphoid 
and non-lymphoid tissues, but represent a minor fraction of total lymphocytes from 2% to 18% in 
the peripheral blood of healthy human adults 68. 
 
1.4.1. NK-cell subsets 
Distinct NK-cell subsets have been defined in mice and humans based on phenotypic, functional 
and anatomical features. Human NK cells are classically identified by expression of the surface 
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marker CD56, absence of the lineage markers CD3 and CD19 and lack of T and B cell antigen 
receptors. Two major NK subsets exist in humans, distinguished primarily by their levels of CD56 
expression: CD56dim NK cells are mature, make up approximately 90% of the NK cells in 
peripheral blood, and predominantly mediate cytotoxic responses. In contrast, CD56bright cells are 
a more immature form, constituting approximately 10% of total NK cells, and considered primarily 
as cytokine producers that play a limited role in cytolytic responses 68. 
 
1.4.2. NK-cell receptors 
NK cells express a variety of activating and inhibitory receptors, respectively characterised by the 
presence of an immunoreceptor tyrosine activating motif (ITAM) or an immunoreceptor tyrosine 
inhibitory motif (ITIM) in their cytosolic domains. These receptors finely regulate NK cell 
activation; a process that relies on integration and amplification of multiple signalling pathways 69. 
NK cell receptors and their functional influence are summarised in Figure 1.2. Notable examples 
of NK-cell activating receptors discussed in this study include FcγRIIIa (CD16), KLRK1 (NKG2D) 









1.4.3. NK-cell killing: antibody dependent cellular cytotoxicity 
The NK-cell killing mechanism that is the primary focus of this report is known as antibody-
dependent cellular cytotoxicity (ADCC). B cells can produce antibodies, proteins such as 
immunoglobulin G (IgG) that can bind to the surface of tumour cells and to the CD16 receptor on 
NK cells; forming an immunological synapse (IS) that activates NK cells. Perforin proteins and 
serine proteases known as granzymes are sequestered in small preformed granules in the 
cytoplasm of NK cells. Upon NK-cell activation, these granules are released through specialised 
secretory vesicles, in close proximity to the tumour target cell. The perforin forms transient porous 
aqueous channels in the tumour cell membrane, through which granzymes diffuse into the 
cytosol; triggering caspase activation pathways and leading to programmed cell death or 
apoptosis 24. Importantly, apoptotic tumour particulate provides a source of TA for DC 70. NK cells 
activated by ADCC upregulate lymphocyte activation markers such as CD69 and are able to 
secrete large amounts of immunomodulatory soluble factors, such as the cytokines IFNγ and 
TNFα 71, 72, 73, 74. After detaching, NK cells can rapidly attack and “serial kill” up to 10 cells within a 
6-hour period 75. Notably, a common single nucleotide polymorphism (SNP) has been defined in 
exon 4 of the CD16 Ig-like domain (559G>T: rs396991). This SNP results in a 
valine/phenylalanine substitution at position 158 (V158F) that affects the affinity of CD16 for IgG. 
It has been described that the 158V variant increases CD16 affinity for IgG compared to the 158F 
variant 76. 
 
1.4.4. NK-cell killing: “missing self” 
The alternative mechanism by which NK cells kill involves lack of engagement of NK-cell 
inhibitory receptors. The ability shown by NK cells to spare normal tissues but not transformed 
cells was affectionately termed the “missing self hypothesis” and is mediated by natural 
cytotoxicity receptors (NCR) such as NKG2A and the majority of killer-cell Ig-like receptors (KIRs) 
bearing an immunoreceptor tyrosine inhibitory motif (ITIM) in their long cytoplasmic tailsa. Major 
histocompatibility (MHC)-absence activates the NK cells and culminates in the same cytotoxic 
granule release as described for ADCC. This natural cytotoxic capacity is augmented in the 
presence of interleukin (IL)-2, IL-12 and IL-18, the latter two synergistically 71. 
                                                       
a Notable exceptions being KIR2DS and KIR3DS, whose short tails have ITAMs in their transmembrane portions. 
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1.5. Dendritic cells 
The term dendritic cell (DC) was first coined by Ralph Steinman to describe a small subset of 
murine splenic cells exhibiting a peculiar tree-like morphology (derived from the Greek word 
‘dendron’ meaning tree) 77. DC have now been characterised with increasing precision. They can 
be found in virtually all tissues, although have a tropism for environments, such as lymphoid 
organs, the skin and both external and internal mucosae, where antigens are concentrated and 
most likely to be encountered 78. The immunostimulatory potential of DC is not limited to the 
elicitation of cellular immune responses, but also impacts humoral and innate immunity 79. 
 
1.5.1. Immature DC 
DC differentiate from common myeloid bone marrow progenitors. At an immature stage of 
development, they express low levels of co-stimulatory molecules such as CD80 and CD86 (B7.1 
and B7.2) and CD40, but are very efficient at engulfing extracellular material. Importantly, in the 
absence of appropriate maturation stimuli, immature DC (iDC) present antigens to T cells in the 
context of inhibitory signals, hence contributing to peripheral tolerance 80, which relies on both 
deletion of antigen specific T-cell clones and expansion of CD4+CD25+FOXP3+ regulatory T cells 
(Tregs) 81, 82, 83. 
 
1.5.2. Mature DC 
Several stimuli can induce the maturation of iDC, including damage-associated molecular 
patterns (DAMPs), microbe/pathogen-associated molecular patterns (MAMPs/PAMPs) and a 
plethora of cytokines and chemokines including IFNγ, tumour necrosis factor alpha (TNFα), IL-6, 
IL-1beta (IL-1β), prostaglandin E2 (PGE2), polyinosinic-polycytidylic acid (poly I:C) and 
lipopolysaccharide (LPS) 84. Mature DC (mDC) upregulate expression of major histocompatibility 
complex class I (MHC-I) and class II (MHC-II) molecules at their cell surface and secrete high 
levels of chemokines and cytokines (notably IL-12) 85, 86. In contrast to their immature 
counterparts, mDC exhibit a limited ability to engulf antigens, but attain the ability to migrate to 
lymph nodes due to upregulation of lymph node homing chemokine receptors such as CCR7; as 
well as efficiently present and cross present antigen 87. 
Many groups have studied the minimal requirements for induction of T-cell effector function in the 
context of antigen presentation. Notably, in 1999, Mescher and colleagues did so using a simple 
system of beads conjugated with MHC and antigen at different densities to provide signal 1; and a 
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panel of membrane co-stimulatory molecules including CD80 and CD86 to provide signal 2 88. In 
line with the co-stimulatory concept proposed by Lafferty 89, they were able to show that signals 1 
and 2 were sufficient for naïve CD8+ T cell proliferation and cytokine production. However, for 
cytotoxic effector function, a third signal, IL-12, was required 88, 90. DC maturation can be primarily 
defined by secretion of IL-12 and upregulation of the CD80/CD86, co-stimulatory molecules that 
provide the essential signals required for T-cell activation. This affords mDC highly efficient 
triggering of adaptive immune responses, to an extent exceeding all other professional antigen-
presenting cells (APCs) including B cells and macrophages. Crucially, because of their IL-12 
production, DC are the only APC capable of stimulating CD8+ naïve T cells 91. 
 
1.5.3. DC subsets 
There are several subsets of DCb that are morphologically, phenotypically and functionally distinct 
in addition to residing in the various anatomical locations. DC in human peripheral blood comprise 
three types: conventional or classical DC (cDC): CD1c+ (BDCA-1+) and CD141+ (BDCA-3+) 
myeloid DC; CD303+ plasmacytoid DC (pDC) and ‘slanDC’ 92, 93. To illustrate DC diversity by 
example: human CD14+ dermal DC produce high levels of IL-12, thus promoting the 
differentiation of naïve B cells into antibody-producing plasma cells. Circulating CD141+ human 
DC are highly efficient at cross-presentation, and are required for optimal responses to foreign 
antigens and TA. As the most abundant subset in peripheral blood, pDC, defined by their 
resemblance to plasma cells, constitute a morphologically peculiar subset of DC that produce 
high levels of type I IFN upon viral infection, yielding robust T-helper I (Th1) immune responses. 
This ability is shared by cDC, but pDC are endowed with a superior ability to detect DAMPs and 
MAMPs because they express a large panel of pattern recognition receptors, including several 
members of the toll-like receptor (TLR) family 94. DC subsets, receptors and anatomical locations 






                                                       















1.6. NK:DC crosstalk 
NK cells and DC occupy a functional niche at the interface between innate and adaptive 
immunity, able to influence both non-specific innate responses and antigen-specific adaptive 
responses as part of a complex crosstalk between NK cells, DC and T cells. 
 
1.6.1. NK-cell induced activation and maturation of DC 
NK cells enhance the immunostimulatory function of DC 71, 96, 97. Activated NK cells promote the 
differentiation and maturation of iDC as indicated by the upregulation of costimulatory molecules 
such as CD80, CD83 and CD86 on the surface of DC. This NK-cell-mediated DC maturation 
effect is dependent on direct cell-to-cell contact between NK cells and DC, involving engagement 
of NK-cell membrane associated activating receptors NKp30 (also known as NCR3) and DNAM-I 
(also known as CD226); and on the release of IFNγ and TNFα 71, 72, 73, 74, 98, 99. Activated NK cells 
also markedly increase IL-12 secretion by DC as well as TNFα release by DC to perpetuate DC 
maturation in an autocrine manner 98. In addition, activated NK cells are able to improve DC ability 
to stimulate both T-cell proliferation and IFNγ production by CD8+ T cells as well as differentiation 
of naïve CD4+ T cells into IFNγ producing Th1 cells 71, 73. 
 
1.6.2. NK-cell regulation of DC 
NK cells also play a crucial role in DC homeostasis. In peripheral tissues, iDC continuously 
sample the environment for antigens, whilst expressing low levels of MHC and co-stimulatory 
molecules. In this steady state, iDC are highly susceptible to lysis by autologous activated NK 
cells, but become resistant upon maturation. It is suggested that NK-cell-mediated removal of iDC 
prevents induction of regulatory T cells at sites of inflammation 72.  
 
1.6.3. DC activation of NK cells 
DC also play a crucial reciprocal role in the activation of NK cells. Mature DC can efficiently 
promote NK-cell proliferation and enhance the cytotoxic capacity of NK cells 72, in addition to 
modulating NK-cell cytokine production. DC mediated IFNγ production from NK cells is facilitated 
by the release of IL-12 and IL-15 by DC and is accompanied by increased expression of the 
activation marker CD69 on the surface of NK cells 71, 73, 98. This again occurs in a contact 
dependent manner, the importance of which was highlighted by Fernandez et al (1999) in the very 
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first study of NK:DC crosstalk 100. The bi-directional crosstalk between NK cells and DC demands 
further scrutiny because of its important role in shaping the immune response. The reciprocal 
activating interaction between NK cells and DC is illustrated in Figure 1.4. 
 
1.7. T cells 
T cells are effector lymphocytes that play a central role in adaptive immunity. T cells are borne of 
haematopoietic precursors that vacate the bone marrow and migrate to the thymus; from which 
the ‘T’ in their name is derived. As early T-cell precursors, these thymic immigrants do not 
express the CD3/T-cell receptor (TCR) complex and since they also lack CD4 or CD8 surface 
molecules are termed “double negative” (DN). Within the thymus T cells first undergo TCR-β gene 
segment rearrangement to express a pre-TCR. The process of variable, diversity and joining 
(VDJ) recombination is initiated by the recombination-activating gene (RAG) enzymes RAG-1 and 
RAG-2. This is followed by rearrangement of the TCR-α gene segment to eventually generate and 











1.7.1. Thymic selection 
The pre-TCR of a developing DN T-cell interacts with cortical epithelial cells. DN T cells which fail 
to express an appropriate pre-TCR die in the thymic cortex due to the lack of signalling. Those 
with successful interactions with self-MHC become CD4 and CD8 double positive (DP) and 
constitute the largest subpopulation in the thymus. During development of DP T cells, pre-TCR 
signalling leads to rearrangement of the TCR-α chain gene segments and consequently the 
expression of a mature αβTCR. Approximately 90% of the CD4+CD8+TCRαβ+ T cells do not 
recognise self-MHC and die by neglect within the cortex. The surviving T cells migrate from the 
thymic cortex into the medulla of the thymus, where they interact with DC. CD4+CD8+TCRαβ+ T 
cells that respond with appropriate low affinity binding to self-antigen presented on MHC-II 
molecules differentiate into CD4+ single positive T cells, while those that bind with low affinity to 
self-antigen presented by MHC-I differentiate into CD8+ single positive; a process known as 
positive selection. Apoptosis is triggered in T cells that bind with high affinity to self-peptide/MHC 
complexes; a process known as negative selection. T cells with appropriate TCRs exit the thymus 
to circulate in the periphery as naïve T cells, yet to encounter their cognate antigen. This stringent 
selection in the thymus (a state of central tolerance), results in deletion of over 95% of DP T cells 
prior to peripheral release, minimising the potential for auto-reactivity 101, 102. 
 
1.7.2. Antigen presentation to T cells 
APC are critical regulators of immunity that continuously survey their microenvironment, uptake 
antigenic material, then process proteins and present the resulting peptide fragments to antigen-
specific T cells in the context of MHC molecules. The capture of exogenous matter occurs via 
receptor-mediated endocytosis, pinocytosis and phagocytosis mechanisms. The mechanism of 
uptake determines the intracellular compartment to which antigen is delivered and may determine 
the type of T-cell epitopes generated 103. 
An area of focus in this report will be DC-mediated phagocytosis, defined as the engulfment of 
large particulate antigens. Many studies have demonstrated that DC can ingest apoptotic tumour 
particulate 104, 105, 106, such as that generated by NK-cell mediated ADCC. Actin remodelling allows 
for the formation of a cup like structure around the particle that eventually closes to form a 
phagosome. While trafficking through the endosome the phagosome becomes increasingly acidic 
due to delivery of H+ into its lumen. The phagosome becomes fused to enzyme-rich lysosomes 
and matures into a phagolysosome, leading to particle degradation. Although still poorly 
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understood, it is thought that some pathogens, including tumour cells, have evolved mechanisms 
to alter or impair the schedule of lysosomal degradation. Consequently, the ultimate fate of an 
ingested particle, i.e. its presentation, can differ, even within the same cell type 103. 
 
1.7.3. MHC antigen presentation pathways 
The process of antigen presentation requires a series of protein and organelle interactions that 
occur via two distinct pathways: MHC-I and MHC-II. MHC-II molecules are constitutively 
expressed on DC, macrophages and B cells, who, as a result, are often referred to as 
‘professional’ antigen presenting cells (APC). These cells are specialised to present antigens 
internalized from the extracellular space to CD4+ T cells 107. Conversely, intracellular/endogenous 
antigens encountered in the cytoplasm, nucleus and mitochondria are mainly channelled to the 
MHC-I processing pathway. Peptides derived by cytosolic proteolysis of such antigens are 
translocated into the endoplasmic reticulum (ER), where they encounter and may assemble with 
newly synthesized MHC-I molecules (expressed by virtually all cell types). The MHC-I pathway is 
responsible for the recruitment and activation of CD8+ T cells 103, 107. Cross-presentation by MHC-I 
is a distinct process in which antigens from phagocytosed particles and extracellular soluble 
proteins are internalized, bound by MHC-I and presented to CD8+ T cells. The cross presentation 
of exogenous antigen, such as that derived from apoptotic tumour particulate, is essential for 
effective anti-tumour immunity and is a process restricted to specific DC subsets in vivo 103, 107 
(discussed in section 1.7.7). 
 
1.7.4. MHC restriction 
Human MHC molecules are known as human leukocyte antigens (HLA) and are encoded by 
highly polymorphic genes, giving rise to the many different HLA proteins that distinguish 
individuals. T cells interact with both the HLA molecule and the bound peptide and are specific for 
peptides presented by autologous HLA molecules (self HLA-restriction) 108. 
 
1.7.5. MHC-II 
MHC-II molecules comprise two polymorphic integral membrane chains, α and β, both encoded 
within the MHC. Association of new synthesised α and β chains with invariant chain (also called Ii 
or CD74) in the ER facilitates MHC-II assembly and ER exit, and blocks the peptide binding site to 
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prevent binding of endogenous peptides. Ii also directs transport of MHC-II complexes to the 
endosomal pathway 107, 109. 
Ii is degraded by resident proteases within late endosomal MHC-II-containing compartments 
(MIIC), leaving only a fragment of Ii known as CLIP occupying the MHC-II peptide-binding site. 
Simultaneously, internalized exogenous proteins are also degraded by endosomal resident 
proteases, generating peptide MHC-II ligands. The structure of the MHC-II peptide-binding site 
accommodates peptide fragments typically 12-25 amino acids (aa) in length. Peptide exchange 
via CLIP dissociation and subsequent peptide binding to the MHC-II peptide binding site is 
facilitated by the MIIC-resident protein HLA-DM. Stable MHC-II:peptide complexes are then 
transported to the cell surface where they are presented to stimulate CD4+ T cells that express an 
appropriate TCR specific for the MHC-II:peptide complex 107, 109. 
Peptide loading onto newly synthesised MHC-II molecules can occur in multiple compartments of 
the endosomal pathway although this is primarily in an HLA-DM dependant manner and in late 
endosomal MIICs. By contrast, internalized MHC-II αβ dimers from the cell surface can be 
‘reloaded’ with peptides within the early endosomal system 107, 109. 
 
1.7.6. MHC-I 
MHC-I molecules assemble in the ER and comprise two chains: the polymorphic α or heavy chain 
and the non-polymorphic β2 microglobulin (β2m) light chain. ER export can only happen when 
assembly is complete, reliant on the binding of a peptide in the MHC-I peptide binding groove. 
These MHC-I binding peptides are usually 8-9 aa long, precursors of which are generated in the 
cytosol. The peptides are derived from ubiquitinated proteins undergoing degradation as part of 
cell protein recycling, incomplete translation products (DRIPs) that are partially degraded by the 
proteasome, and other misfolded proteins or retrotranslocated proteins from the ER cleaved by 
the proteasome or other cytosolic proteases 107, 110.  
Dedicated adenosine tri-phosphate (ATP)-dependent transporter associated with antigen 
processing (TAP)-1/2 proteins translocate these peptides into the lumen of the ER. They are then 
trimmed at their N-termini by ER proteases called ERAAPs and transferred from TAP onto folding 
MHC-I, facilitated by a ‘loading complex’. Once assembled, the MHC-I/β2m/peptide complexes 
are exported from the ER via the classical secretory pathway and are expressed at the cell 
surface. The loading of endogenously produced peptides onto MHC-I molecules plays a critical 
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role in the killing of transformed or virally infected cells because of the interaction between MHC-I 
and the TCR of CD8+ T cells 107, 110. 
 
1.7.7. Cross presentation by MHC-I 
Although some viruses can infect DC directly and generate MHC-I peptide ligands using this 
classical pathway, in many cases DC are not infected and therefore the antigens cannot be 
expressed by the DC themselves. However, DC can phagocytose antigens derived from other 
cells and cross-present peptides derived from these antigens on their own MHC-I. This pathway is 
particularly important in the context of anti-tumour immunity. Tumour cells are poor APC because 
they lack co-stimulatory molecules 111, 112 and can secrete immunosuppressive factors (discussed 
further in section 1.9.2) 113. They therefore require lysis, for example via NK-cell-mediated ADCC, 
and uptake of tumour-cell particulate by professional APC for presentation of TA to T cells. This 
pathway is illustrated in Figure 1.5. Two main intracellular models for cross-presentation have 











1.7.7.1. Cross presentation: the cytosolic pathway 
The cytosolic pathway provides a means by which DC can present peptides from internalized 
antigens that were present endogenously in other cell types, and thus stimulate relevant CD8+ T 
cells. After partial degradation in endosomes, exogenous-derived proteins are exported to the 
cytosol and processed by the proteasome in the same way as endogenous MHC-I processing. 
These exogenous proteasome-processed peptides are then loaded onto MHC-I molecules in the 
ER following TAP-dependent uptake 107, 110. 
 
1.7.7.2. Cross presentation: the vacuolar pathway 
In the vacuolar pathway, the peptides that bind MHC-I are derived from internalized exogenous 
proteins that were processed directly in endosomes and phagosomes. MHC-I molecules access 
endocytic compartments via recycling from the cell surface, and bind peptides independently of 
proteasomal degradation, TAP transporters and the MHC-I loading complex 107, 110.  
 
1.7.8. T-cell activation 
Like NK cells, T-cell activation is a multistep process. The first signal is received when the TCR 
binds its cognate peptide:MHC complex. T cells express several co-stimulatory receptors through 
which they receive their subsequent activation signals including CD28 and CTLA-4. Notably, 
CD28 is the only co-stimulatory receptor constitutively expressed by naïve T cells. These 
receptors engage the ligands CD80 and CD86 (collectively known as B7), which are expressed 
on APC. The second signal licenses mature T cells to respond to antigen fully (proliferation, 
cytokine secretion and cytotoxicity), while in naïve T cells the second signal allows proliferation 
and cytokine secretion, with a third signal, provided by IL-12 or IL-1β, enabling cytotoxicity 88, 90. 
Without secondary and subsequent signals, T cells become anergic and more difficult to activate 
in future. Self-peptides are not usually presented with appropriate co-stimulation, thus this multi-
step activation process prevents inappropriate responses to self. 
Upon appropriate activation, T cells will upregulate activation markers such as CD69 and CD137. 
In addition, expression of the inhibitory receptor CTLA-4 is also upregulated on activated T cells. 
CTLA-4 has a higher affinity for the B7 ligands it shares with CD28 and this serves as an immune 





1.8. B cells 
B cells are a class of lymphocyte involved in the humoral arm of the adaptive immune response. 
B cells function as professional APC (as discussed in section 1.7.3) with cytokine secretion 
capabilities, but their primary role is the expression/secretion of immunoglobulin (Ig) proteins 
(antibodies). 
 
1.8.1. B-cell development 
B cells originate from common lymphoid progenitors in the bone marrow, and their development 
into mature functional cells occurs in several stages 115. RAG-1 and RAG-2 initiate the 
recombination of the Ig heavy-chain (HC) VDJ gene segments in pro-B cells. Pro-B cells 
represent the earliest committed stage of B-cell development, which occurs in an IL-7 dependent 
manner 116. This is followed by recombination of the light chain (LC) VJ genes in pre-B cells. 
Binding of µHC proteins with the λ5 and VpreB surrogate LCc proteins leads to surface 
expression of the pre-B cell receptor (pre-BCR) on large pre-B cells. The pre-BCR initiates 
proliferation, maturation and survival signals via Igα and Igβ signaling subunits. Down-regulation 
of pre-BCR expression permits entry into the resting small pre B-cell stage. Resting small pre-B 
cells cease cell cycle progression and begin the recombination process again, leading to 
rearrangement of the LC proteins. LC proteins associate with µHC proteins to form the mature B-
cell receptor (BCR). This is expressed on immature B cells as stable IgM and alternative splicing 
permits co-production of IgD. Acquisition of a functional BCR comprising a HC and LC 
combination distinguishes immature B cells from their pre-B cell precursors 117. 
 
1.8.2. B-cell selection and transition 
Immature B cells first undergo selection in the bone marrow (central tolerance) and subsequently 
exit into the periphery where they sustain additional selection (peripheral tolerance) prior to 
becoming functional B cells capable of responding to antigen. If the BCR can bind strongly to self-
antigen, then the B-cell will endure one of three fates: receptor editing to produce a non-
autoreactive BCR, anergy to prevent peripheral activation or clonal deletion via apoptosis. This is 
the first key checkpoint in B-cell development 115.  
 
                                                       
c The ‘surrogate’ light chain is an immunoglobulin light chain-like molecule 
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Much of the data reported for human B cell differentiation has been extrapolated from mouse 
studies and the corresponding processes in humans remain incompletely defined 115, 118. As such 
discrepancies in definitions of transitional B cells are often encountered when the literature is 
reviewed as a whole 119. Broadly, it is believed that after selection, as they migrate from the bone 
marrow and enter the periphery, immature B cells undergo three transitional phases: T1, T2 and 
T3. These phases have discrete phenotypes characterised by analysis of cell-surface markers 
such as IgM, IgD, CD5, CD9, CD10, CD19, CD20, CD21, CD24, CD34 and CD38. Recent bone 
marrow emigrants are considered T1 B cells, primarily characterised as CD5HIGH CD10+ CD21LOW 
IgMHIGH. In the spleen, T1 B cells transition to T2 B cells of a CD5HIGHCD10+CD21HIGHIgMHIGH 
phenotype. T2 B cells can either progress to a T3 phase, exhibiting a CD5LOWCD10-
CD21HIGHIgMLOW phenotype (now thought to represent primarily self-reactive anergic B cells), or 
eventually differentiate into naïve follicular (FO) B cells or marginal-zone (MZ) B cells. This fate is 
dependent on self antigen-mediated activation of the BCR, Notch2, the receptor for B cell-
activating factor (BAFFR) and the canonical nuclear factor-κB (NFκB) pathway, as well as signals 
involved in the migration and anatomical retention of MZ B cells 119. MZ B cells migrate to a new 
location in the spleen, where they are physically retained. A newly differentiated MZ B-cell also 
acquires the ability to self-renew, with an unlimited lifespan 120. 
 
1.8.3. B-cell activation 
Immunocompetent naïve FO B cells re-circulate through the lymphatic system and peripheral 
tissues until they encounter an antigen and are activated. B-cell activation requires two distinct 
signals. The first activation signal occurs when antigen is bound to the BCR. The second 
activation signal occurs via either thymus-dependent or thymus-independent mechanisms (T-
dependent and T-independent respectively) 121, 122. Most B-cell responses to antigen are T-
dependent and require the close interaction of B cells with CD4+ T cells specific for the same 
antigen. The antigen is internalised by B-cell receptor-mediated endocytosis, digested, complexed 
with MHC-II molecules on the B-cell surface and subsequently presented to T cells, inducing their 
activation. The activated T cells then provide a second activation signal to the B cell, which can 
occur through a variety of proteins such as CD40L. Alternatively, there are a few types of antigens 
that can directly provide the co-stimulatory signal for B cells (T-independent), including some 
bacterial cell wall components such as LPS, or antigens containing highly repetitious elements 
such as bacterial flagellin. Once activated, B cells proliferate and form specialized structures 
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called germinal centres (GC) where they differentiate into memory B cells or plasma B cells. 
Following differentiation into plasma cells, additional T-cell derived signals result in somatic 
hypermutation, which can for example, switch the class of antibody produced by the B-cell from 
IgM to IgG. Additionally, the B cells undergo affinity maturation, producing antibodies with 
increased affinity for antigen. With repeated exposure to the same antigen, B cells will produce 
antibodies of several log-fold greater affinity than in a primary response 115. Once released into 
the blood and lymph, these antibodies bind and opsonise target antigens, initiating their 
neutralization or destruction via ADCC (discussed in section 1.4.3) and complement-dependent 










1.8.4. Immunoglobulin  
The fundamental ‘Y’-shaped structure of an antibody Ig molecule can be divided into three 
sections: two arm-like antigen-binding fragment (FAb) regions and a stem-like fragment 
crystallisable (Fc) region. The FAb contains a variable domain (Fv) incorporating 
complementarity-determining regions (CDRs) that bind to cognate antigens 124. The Fc fragment 








































single Ig molecule comprises two identical copies of an inner heavy chain, and two identical 
copies of an outer light chain. Heavy chains are composed of two successive regions: variable 
(VH) and constant (CH). There are five classes of Ig - IgA, IgD, IgE, IgG and IgM; distinguished by 
the type of heavy chain they contain (α-chains, δ-chains, ε-chains, γ-chains and µ-chains 
respectively). The α, δ and γ heavy chains have a constant region composed of three tandem Ig 
domains (denoted CH1, CH2, CH3) and a hinge segment for added flexibility; while ε and µ heavy 
chains have a constant region composed of four domains (denoted CH1, CH2, CH3, CH4). 
Polypeptide variation in the heavy chains allows each immunoglobulin class to function in a 
different type of immune response or during a different stage of immune defence. The amino acid 
sequences that confer these functional differences are located mainly within the Fc region. Some 
immunoglobulins are able to form multimers through linkage of their Fc domains via a J chain. 
IgM for example is a pentamer of five identical Ig monomers and therefore has a high valency due 
to the number of arms available to bind antigen.  
 
Light chains can be classified as either kappa (κ) or lambda (λ) based on small differences in 
polypeptide sequence. A given Ig has either κ light chains or λ light chains, never one of each. No 
functional difference has been found between antibodies having κ or λ light chains, and either 
type of light chain may be found in any of the five major classes of Ig. Light chains are composed 
of two successive regions: variable (VL) and constant (CL) 124.  
 
1.8.5. IgG 
IgG is the most abundant protein in human serum and a major focus in this study. IgG can be 
further divided into subclasses 1, 2, 3 or 4 (denoted IgG1, IgG2, IgG3 or IgG4). Although closely 
related glycoproteins, the major differences between the subclasses are the length of the hinge 
region, amino acid composition, and the numbers of disulfide bridges between the two heavy 
chains, all of which have implications for FcγR binding, effector functions, and pharmacokinetic 
properties. For example, compared to IgG2, IgG1 has two fewer inter-heavy chain di-sulfide bonds 
and an extra 3 aa residues most proximal to the hinge region in the CH2 domain of the Fc portion.  
 
The Fc portion contains a largely overlapping binding site for FcγRIIIa receptors on innate effector 
cells. The aforementioned substitutions here are responsible for a subtle but important change of 
quaternary structure in the Fc, resulting in a more exposed FcγRIIIa binding-site in IgG1. Thus, in 
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contrast to IgG1, IgG2 mAbs are devoid or severely limited in their ability to induce NK cell-











1.8.5.1. IgG in cancer 
Natural IgG recognises defined cell surface structures, predominantly oligosaccharides, which are 
expressed in larger quantities in a tissue-specific manner during fetal differentiation but are also 
expressed on tumour cells. Tumour-reactive natural IgG can be found in a small percentage of 
healthy blood donors 126 and increased concentrations have also been detected in the peripheral 
blood of acute lymphoblastic leukaemia (ALL) patients 127. Natural IgG may not only have a direct 
cytotoxic effect on intact tumour cells, but also a bystander effect during a humoral anti-tumour 
response as they can recognize modified cell surface structures arising during the necrotic 
processes that accompany tumourigenesis. Natural IgG can also help to attract other immune 
cells to sites of inflammation, particularly those bearing CD16 receptors that can potentiate the 
destruction of cancer cells via ADCC or antibody dependent cellular phagocytosis (ADCP): NK 
cells, monocytes, macrophages, neutrophils, eosinophils and DC 128. 
In addition, IgG1 and IgG3 are potent activators of the classical complement pathway. The binding 
of two or more IgG molecules to the surface of tumour cells leads to high-affinity binding of C1q to 
the Fc domain, followed by activation of C1r enzymatic activity and subsequent activation of 
downstream complement proteins. The result of this cascade is the formation of pores facilitated 
by the membrane attack complex (MAC) on the tumour-cell surface, resulting in tumour-cell lysis. 
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The production of the highly chemotactic complement molecules C3a and C5a also leads to the 
recruitment and activation of immune effector cells, such as macrophages, neutrophils, basophils, 
mast cells and eosinophils 129. 
 
1.9. Tumour evasion of immune cell recognition 
Despite the growing knowledge of both TA and immune cell interactions in cancer, tumours can 
utilize a variety of mechanisms to evade the immune system. Immune cells are frequently 
suppressed in cancer patients, the mechanisms of which can be categorised as follows: 
 
1.9.1. Modified expression of ligands on tumour cells 
Evidence for downregulation of the stress molecule major histocompatibility complex class I 
chain-related peptide A (MICA) by tumour cells has been reported. MICA is one of the ligands for 
the NKG2D receptor expressed on NK cells, thus downregulation markedly reduces tumour 
susceptibility to NK-cell mediated lysis 130. It has also been shown that the expression of Fas 
ligand (FASL/CD95L) on tumours can induce apoptosis of intratumoural T cells 131; and that 
tumour cells expressing programmed cell death ligand-1 also known as B7 homolog-1 (PD-
L1/B7.H1) can downregulate active tumour immunity in vivo by limiting antigen-specific T-cell 
proliferation 132. 
 
1.9.2. Secretion of inhibitory ligands by tumour cells 
Secretion of inhibitory ligands like MICA as an exosome (cell derived vesicles 133) or soluble 
ligand (sMICA) effectively engages the NK-cell activating receptor NKG2D away from the tumour 
cell, preventing target cell recognition or causing “mis-firing” 113, 134, 135. Meanwhile, other studies 
demonstrate that the tumour release of immunosuppressive cytokines such as transforming 
growth factor beta (TGFβ) downregulate tumour directed NK-cell cytotoxicity in cancer patients 
135, 136 and that supernatants derived from in vitro cultures of tumour cells adversely affect T-cell 
activation/proliferation by inhibiting transcription factors such as NF-κβ 137.  
 
1.9.3. Altered expression of “self” 
The well-documented disappearance or reduction in the expression of TA and downregulation of 
MHC and other molecules associated with processing and presentation can alter the quantity and 
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profile of MHC-I epitopes presented at the cell surface, and has major implications for CTL 
antigen recognition (comprehensively reviewed by Garrido et al, 2010). While complete loss of 
MHC expression would render tumour cells susceptible to NK-cell mediated lysis, intermediate 
levels have been shown to confer resistance to T-cell and NK-cell killing, supporting the notion 
that thresholds of expression are required for lymphocyte activation. Proteins involved with 
antigen processing and loading share a degree of co-regulation with MHC; thus, changes in MHC 
expression are often accompanied by altered expression of antigen presentation pathway co-
factors such as TAP and β2m 138. Conversely, MHC-I upregulation has been described in some 
tumour types, mechanistically providing a strong inhibition signal for NK cells 139. 
 
A major challenge in cancer therapy is to design means to either prevent these impairment 
mechanisms or find ways to circumvent them. Thus harnessing the immune system for 
therapeutic benefit in cancer has been an attractive long-term goal in oncology. 
 
1.10. Harnessing the power of immune effector cells: immunotherapy 
Improved understanding of TA, the means by which tumours avoid immune detection and the role 
of the immune system have led to the identification of novel therapeutic targets in cancer. 
Immunotherapy is designed to take advantage of the unique properties of the immune system: 
specificity, adaptability, and memory; to destroy tumours and maintain remission. The significant 
breakthroughs are detailed as follows: 
 
1.10.1. Therapeutic antibodies 
In 1975, Kohler and Milstein developed ground-breaking monoclonal antibody (mAb) technology 
that provided the possibility of creating antibodies as a class of therapeutics. Antibodies can be 
purified from the serum of immunised animals, where the antigen of interest stimulates B cells to 
produce a diverse range of antibodies specific to that antigen. The large numbers of antibodies 
produced have different specificities and epitope affinities and are known as polyclonal 
antibodies. Kohler and Milstein were able to fuse immortal heteromyleoma cells with B cells, using 
polyethylene glycol (PEG) to break down cell membranes and allow mixing of the genetic material 
from both cell types. The result was a hybridoma - an immortal cell line with the ability to produce 
antibodies. As the hybridoma was a product of the fusion of one heteromyeloma cell with one B-
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cell, the culture supernatant only contained antibodies to one specific epitope, which, when 
purified, were called monoclonal antibodies 140. 
 
1.10.1.1. Anti-TA monoclonal antibodies 
Anti-TA mAbs are a principal focus in this study and represent an attractive “off the shelf” therapy 
in cancer. Anti-TA mAbs have maintained their popularity and success due to an increased 
understanding of anti-tumour immunity and intense pharmaceutical company investment 
(estimated to be in the order of £100 billion over the next four years) 141, 142. Antibodies remain the 
fastest growing class of biotherapeutics. Currently, there are over 70 mAbs approved for clinical 
use; targeting various TA and antigens in other therapeutic areas such as infection, autoimmunity, 
allergy, inflammation and cardiovascular disease. Notably, expiration of patents on mAb products 
has allowed for the generation of biosimilars - near identical copies of original mAbs synthesised 
by different companies. Approved biosimilars are often produced and sold at substantially 
reduced cost compared to their reference products 143. In 2017, 50 mAbs entered clinical trial, of 
which 28 had a primary indication for cancer therapy 144. The cancer therapeutic mAbs that are 
approved for clinical use by the United States Food and Drug Administration (FDA) are listed in 






















Keytruda	 Pembrolizumab	 PD1	 Humanized	
IgG4	
Refractory	melanoma	


















































Campath	 Alemtuzumab	 CD52	 Human	IgGl	
B-cell	chronic	lymphocytic	
leukaemia	
Avastin	 Bevacizumab	 VEGF	 Humanized	IgGl	
CRC,	NSCLC-squamous,	
renal	cancer	




















Perjeta	 Pertuzumab	 HER2	 Humanized	IgGl	 Her2+	breast	cancer	




Herceptin	 Trastuzumab	 HER2	 Humanized	IgGl	 Her2+	breast	cancer	
Lartruvo	 Olaratumab	 PDGFRa	 Human	IgGl	 Soft	tissue	sarcoma	
Unituxin	 Dinituximab	 GD2	 Chimeric	
IgGl	
Neuroblastoma	









These mAbs can be characterised as murine, chimeric, humanised or human, qualified by the 
extent of human sequences present within the mAb, as illustrated in Figure 1.8. Murine mAbs are 
derived entirely from mouse sources. Chimeric mAbs are constructed with VH and VL regions 
derived from a mouse source and constant regions derived from a human source. Humanized 
mAbs are derived predominantly from a human source except for their CDRs, which are murine. 
Human mAbs are derived entirely from human sources 145. 
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There are a number of ways to achieve mAb chimerism and humanization. The use of mice 
genetically engineered to carry humanised Ig genes or engrafted with a human immune system is 
a means to obtain and immortalise clones that produce either fully human Ig or Ig variable 
domains associated with customised human-like constant regions 146. Mouse free processes have 
also been sought that allow the insertion or substitution of portions of the Ig molecule such as 
CDRs into a human scaffold. These systems take advantage of the fact that mAb production can 
be achieved using recombinant DNA to create constructs for expression in mammalian cell 
culture systems 147. In addition, these mAbs can be any of the IgG1, IgG2, IgG3 or IgG4 subclasses 










1.10.1.2. Immune checkpoint inhibitors 
Immune checkpoints refer to any of the ligand:receptor interactions involved in maintaining self-
tolerance and modulating the amplitude and duration of peripheral immune responses in order to 
minimize collateral damage; particularly in the context of TA-specific T cells. A strong body of 
evidence suggests that tumours can manipulate these pathways as a means to resist immune cell 
control, which gave rise to a class of therapeutics designed to inhibit these ligand:receptor 
interactions. The first to achieve FDA approval was based on the research initiated by Leach et al 
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148. The anti-CTLA-4 mAb: ipilimumab (Yervoy®) prevents the down-modulation of T-cell 
activation 149. Another well-studied immune checkpoint interaction, highlighting the broad and 
diverse targeting opportunities for these inhibitors; is between the receptor programmed cell death 
protein 1 (PD1) and the PD-L1 ligand frequently expressed on tumour cells. The major role of 
PD1 is to limit the activity of T cells in peripheral tissues during inflammatory responses. Phase I 
and II clinical trials of anti-PD1 mAbs are currently ongoing 150, 151.  
 
1.10.1.3. Bi-specific antibodies 
Bi-specific T-cell engagers or BiTEs are recombinant fusion proteins comprising two single chain 
mAbs with different specificities that can target two antigens simultaneously; typically a TA and an 
activating moiety present on effector cells, such as CD3. BiTE constructs have been shown to 
induce strong proliferation and activation of T cells independent of MHC-restriction. A CD3/CD19 
BiTE called blinatumomab has demonstrated potent anti-leukaemia and anti-lymphoma activity at 
low doses 152, prompting the clinical trial of other BiTE combinations such as CD33/CD3 for AML 
153 and EGFR/CD3 for solid tumours 154.   
 
1.10.1.4. Antibody-drug conjugates 
An antibody-drug conjugate (ADC) is composed of an antibody (typically a TA-specific mAb), a 
biologically active cytotoxic drug and a linker that attaches the two. The toxic payload is delivered 
directly into the tumour cell when the antibody is absorbed via receptor-mediated endocytosis, 
then trafficked to and degraded in the lysosome. Many payloads have been attached to mAbs, 
including radioisotopes, protein toxins, laser-activated nanoparticles and small molecule drugs, 
via chemical motifs such as disulfide bonds, non-cleavable thioethers and, more commonly, 
cleavable peptides 155. The ADC inotuzumab ozogamicin (INO) comprises an anti-CD22 mAb 
conjugated to the cytotoxic agent N-acetyl-γ-calicheamicin via an acetyl butyrate linker. In a 
phase II clinical trial, INO demonstrated significant efficacy against CD22+ refractory and relapsed 
ALL. A 57% overall response rate (ORR) was observed in a cohort of 49 patients treated with INO 
as a single agent 156. To date, over 30 INO clinical trials have been initiated, 13 of which are 




1.10.2. Adoptive T-cell therapy 
In adoptive cell therapy (ACT), T cells isolated from patient PBMC or TILs isolated from primary 
tumours are expanded in vitro, (with or without genetic engineering to augment function) and then 
re-infused into the patient in order to enhance anti-tumour responses. An early study by 
Rosenberg and colleagues was the first demonstration that ACT using autologous TILs could 
mediate objective regression of cancer in patients with metastatic melanoma. Patients with 
metastatic melanoma were treated with ex-vivo expanded TILs and IL2. In patients who had not 
previously been treated with IL2, 60% (9 of 15) showed cancer regression. 40% (2 of 5) of 
patients in whom previous IL2 therapy had failed also showed regression. This was sustained for 
up to 13 months 158. In another recent phase II study, ACT using EBV-specific CTL in combination 
with chemotherapy showed promising results, with a 2-year OS of 62.9% 159. 
 
1.10.3. DC vaccines  
Accumulating preclinical evidence suggests that numeric or functional defects in specific DC 
subsets can facilitate tumour growth, tumour progression and chemoresistance 78. Corroborating 
this notion, elevated levels of tumour infiltrating mDC have been associated with improved clinical 
outcomes in cohorts of patients affected by a variety of solid tumours, whereas the accumulation 
of intra-tumoural tolerogenic DC has been indicated as a poor prognostic factor in multiple clinical 
settings 160. Thus, for the last 20 years, strategies have been devised for harnessing the 
immunotherapeutic potential of DC in the treatment of malignant conditions, which, based on the 
underlying mechanistic principle, can be categorised into four major groups 78: 
 
1. In vivo DC loading with TA 161 
2. DC-derived exosomes 162 
3. Reinfusion of B7.IL-12 transduced DC 163  
4. Reinfusion of ex vivo TA loaded DC:  
• Via exposure of iDC to autologous cancer cell lysates 164, 165 
• Via incubation of iDC with recombinant TA 166 
• Via transfection of DC with TA-coding RNA 167 or TA expression vectors 168 




The apogee of these efforts was reached in 2010, when the FDA approved use of Sipuleucel-T 
(Provenge®) in patients with asymptomatic or minimally symptomatic metastatic castration-
refractory prostate cancer. Provenge® is a DC-enriched autologous cell preparation expanded ex 
vivo in the presence of a prostate acid phosphatase/granulocyte macrophage colony-stimulating 
factor (PAP/GMCSF) fusion protein 170. 
 
1.10.4. Enhancing the antigen presenting potential of tumour cells 
Acute myeloid leukaemia (AML) cells express high levels of MHC-II (and in some cases MHC-I) 
but lack CD80, the co-stimulatory molecule that provides the essential second signal required for 
lymphocyte activation, making them poor APC. In addition, the preponderance of AML is 
associated with impaired NK cell activity 171, 172. In 2009, Ingram et al showed that lenti-viral 
transduction of AML cells to express CD80 in conjunction with the stimulatory cytokine IL2 
promoted in vitro NK-cell activation, NK-cell cytolytic activity and increased CD8+ CTL frequency 
and function 172, 173 which importantly showed cytotoxic activity towards autologous unmodified 
AML cells 173. The immunotherapeutic potential of CD80/IL2 transduced AML cells is currently 
being evaluated in a phase I clinical trial at King’s College Hospital. 
 
Treatment of AML cells with TLR agonists such as the synthetic TLR7/TLR8 ligand R-848 
(Resiquimod) promotes increased MHC expression and thus the antigen presentation potential of 
AML cells. R-848 treatment also increased AML cell production of IL-6, IL1β and TNFα; cytokines 
known to induce DC maturation; and induced CD80 upregulation by APC 174 while the 
pharmacological agent 5-aza-2’-deoxycytidine (decitabine) has been shown to upregulate CD80 
in cancer cells directly and stimulate tumour-specific T-cell responses 175. 
 
1.10.5. Chimeric antigen receptor-mediated therapy 
Chimeric antigen receptor (CAR)-redirected T cells (colloquially referred to as CARs) are the 
result of genetic modification of T cells to stably express artificial surface immune receptors, 
conferring novel antigen specificities. Early versions fused single-chain variable fragments (scFv) 
derived from monoclonal antibodies, to the CD3-zeta transmembrane and endodomain. The 
introduction of 2nd and 3rd generation CAR T cells, incorporating co-stimulatory signalling 
elements in their transmembrane portions, have shown considerable promise and many CAR T-
cell clinical trials are currently ongoing in both haematological and solid malignancies 176. CAR-
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mediated immunotherapy has a number of advantages over some of the aforementioned 
immunotherapy approaches insofar as:  
 
1. CARs recognize native, unprocessed antigens, thus bypassing autologous HLA 
restriction and its regulation. 
2. Although CARs are mainly expressed on autologous patient-derived T cells they are not 
limited to T cells. Indeed, several groups have already successfully retargeted monocytes 
177, γδ T cells 178 and NK cells 179 amongst others. 
3. In contrast to conventional αβ TCR, CARs can recognize non-protein targets such as 
carbohydrates and glycolipids 176. 
 
Recently, Zah and colleagues presented work using a novel bi-specific CAR. This was the first 
demonstration that a bi-specific CAR could prevent antigen escape in an in vivo xenograft model 
180. Furthermore, 2015 saw the world first use of a “universal” CAR T-cell redirected to CD19 
(uCART19) in an 11-month-old girl with high-risk CD19+ ALL. The uCART19 were manufactured 
from a third-party healthy donor and genome edited using transcription activator-like effector 
nucleases (TALEN™) to simultaneously inactivate two genes. The knockout of the TCRα gene 
eliminated TCR expression and abrogated the potential for donor-mediated graft-versus-host 
disease (GvHD) while knockout of the CD52 gene made the donor T cells resistant to the 
lymphodepleting agent alemtuzumab, commonly used in the conditioning regimen for bone 
marrow transplantation. Infusion of the uCART19s induced molecular remission where all other 
treatments had failed 181 and have since been used in a second infant ALL case 182. This novel 
strategy, using a frozen preparation of mismatched donor T cells represents another ‘off the shelf’ 
therapy, and provides a considerable reduction in production cost when compared to autologous 
patient-derived preparations. Despite the exciting promise of CAR T cells, this therapy is only at 
the experimental stage. Notably a different CAR would be required for different target epitopes 
and the cost for a single infusion of CAR T cells is estimated to exceed that of the annual cost of 
an equivalent mAb therapy. CAR T cells continue to show poor efficacy in the control of solid 
tumours. Additionally, a major limitation in the use of CAR T-cell therapy is its potential to induce 
cytokine storm (CS), the rapid and massive release of cytokines from CAR T cells into the 
periphery. Although manageable and reversible with the administration of steroids and IL-receptor 
antagonists, in some cases the precipitous drops in blood pressure, swelling and high fevers that 
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result from CS can lead to life threatening multiple organ failure. More research is needed before 
CAR T-cell therapy becomes a routine option in cancer treatment 183.  
 
1.11. EGFR+ cancers 
EGFR (also known as ErbB-1 or HER1) is a tyrosine kinase receptor of the HER family, affecting 
cell adhesion, cell survival and cell proliferation. The binding of EGFR specific endogenous 
ligands such as epidermal growth factor (EGF) or transforming growth factor alpha (TGFα) 
induces receptor dimerisation, transphosphorylation of the kinase domains with subsequent 
activation of two major signalling cascades: Ras/Raf/MEK/MAPK and PI3K/Akt/mTOR. These 
pathways trigger numerous oncogenic processes such as cell survival, proliferation, 
angiogenesis, tumourigenesis and inhibition of apoptosis 184. The overexpression of EGFR is 
correlated to poor prognosis and has been characterised in 80-100% of head and neck squamous 
cell carcinomas (HNSCC) 185, 40-80% of non small cell lung carcinomas (NSCLC) 186 and 50-80% 
of colorectal carcinomas (CRC) 187. 
 
In CRC, a modest increase in average survival can be achieved with current chemo-therapeutic 
strategies, yielding 10-12 months with single agent 5-Fluorouracil and increasing to 16-20 months 
upon addition of oxaliplatin and irinotecan when compared to 6 months with palliative care alone. 
When administered as a first line treatment, combination chemotherapy can substantially improve 
response rates from 31% to 56%, median PFS from 6.5 to 9 months and median OS from 14.5 to 
21.4 months 188, 189, 190, 191, 192, 193, 194, 195, 196, 197. Although encouraging, much remains to be 
achieved in CRC therapy. 
 
1.11.1. Anti-EGFR mAbs in the treatment of EGFR+ cancer 
The expression of EGFR on malignant cells can reach 2x106 million receptors per cell, compared 
to 40,000-100,000 receptors on normal cells 198. This significant difference makes targeted EGFR 
therapies potentially very effective and less toxic than traditional chemotherapy. The mAbs 
panitumumAb and cetuximAb bind to the extracellular domain of the human EGFR with 
approximately 5 to 10 fold higher affinity than its natural ligands. They block ligand binding, 
resulting in inhibition of receptor function and blocking of downstream survival signals; and can 
also induce the internalisation and downregulation of EGFR 199. However, the benefit of anti-
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EGFR mAbs can be bypassed by gain-of-function mutations in Kirsten rat sarcoma viral 
oncogene homolog (KRAS), a signalling molecule downstream of EGFR 200, 201, 202, 203. In patients 
with KRAS-mutant tumours, the proliferative signal is constitutively active and therefore 
unaffected by receptor blockade 204. 
While panitumumAb is human IgG2 class, cetuximab is a chimeric antibody of IgG1 class, with 
demonstrable improvements over panitumumab in terms of NK-cell recruitment for ADCC 205. 
Cetuximab (marketed by Merck, trade name Erbitux®) is still the only targeted agent that has 
been approved for the treatment of HNSCC by the regulatory agencies of the US and Europe. In 
addition cetuximab is approved for use in metastatic NSCLC, KRAS wild type (WT) CRC in 
combination with chemotherapy, and as a 3rd and 4th line single agent therapy in CRC patients 
who are intolerant to irinotecan or who have failed oxaliplatin- and irinotecan-based therapy 199.  
 
1.11.2. MAbs: why the lack of therapeutic efficacy? 
For dose escalation studies and early phase clinical trials, new drugs are typically tested alone, 
with efficacy compared to the standard level of care. Upon reaching phase II, immunotherapies 
can be combined with conventional radiotherapy/chemotherapy as per standard clinical 
conditions. As a single agent, TA-targeted mAbs such as cetuximab offer only modest response 
rates. A study by Pessino et al treated 39 chemotherapy naïve CRC patients with cetuximab as a 
first line monotherapy. According to WHO definitions, one patient showed a complete response, 
with no detectable cancer after a median 8-weeks treatment and three showed a partial response 
(≥ 50% reduction in measurable tumour). This represented an ORR of 10% 206 with a 
HNSCC/NSCLC study showing that the response rate rises only moderately to 15% upon 
combination of cetuximab with cisplatin-based chemotherapy 207. Indeed, as of November 2015, 
the NHS removed cetuximab from its list of funding approved 3rd and 4th line single agents 208. 
 
Although predicting clinical efficacy is multifactorial and may not be explicable by one factor per 
se, the CD16 polymorphism, described in section 1.4.3, has been implicated in influencing the 
clinical outcome of mAb therapy. Mechanistically, this polymorphism modulates the affinity of 
CD16 for IgG1 antibodies, consequently affecting the potency of ADCC 209. The F/F allelic variant 
of CD16 has been correlated with poor clinical responses to cetuximAb, the rationale being that 
the lower affinity conferred by this genotype may reduce the clearance of antigen:antibody 
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immune complexes (ICs) 210. The efficacy of cetuximAb is therefore limited by patient genotype, 
but could still be useful in a personalised medicine setting with pre-selection of patients 
predisposed to respond. Notably, the finding of a link between Fc receptor affinity and ADCC 
efficiency is important because it leads to the prediction that enhancements of mAb affinity for Fc 
receptors may result in significant therapeutic benefit. 
 
1.12. Anti-EGFR mAb enhancements: glyco-engineering  
Standard mAbs can be further optimised for greater therapeutic potential. One approach to 
increase the binding between Fc receptors and mAbs is to manipulate protein glycosylation, 
which is known to affect protein-protein interactions. Pioneering work demonstrated that 
antibodies lacking fucose residues in their Fc domain show greatly increased affinity for CD16, 
ultimately resulting in ADCC amplification 211, 212, 213.  
 
1.12.1. Protein glycosylation 
Glycosylation is an enzymatic modification that results in the addition of sugar moieties to specific 
amino acids. It is a critical function of the biosynthetic-secretory pathway in the ER and Golgi 
apparatus and approximately half of all proteins expressed in a cell undergo glycosylation - 
including ligands, surface receptors and secreted proteins. Protein glycosylation exerts multiple 
functions within the cell that are not necessarily dependent on the detailed 3-dimensional 
structure of the glycan, but rather their bulk. Glycans can alter the behaviour of proteins, for 
example by covering antigenic sites; protecting them from proteolysis; or making them more 
soluble, simply because they are large and hydrophilic 214. 
 
The molecular events of glycosylation include ligation of monosaccharides, transfer of sugars 
between substrates and the trimming of sugars from the glycan structure. Unlike other cell 
processes such as transcription or translation, glycosylation is non-templated, and as such it is 
possible that not all of these steps occur during every glycosylation event. The pathway relies on 
a host of enzymes such as glycosyltransferases (Gtf) and glycosidases that respectively add or 
remove sugars in a stepwise fashion, to generate the glycoproteins. Each glycosidase shows 
specificity for removing a particular sugar e.g., mannosidase. Since enzyme activity varies by cell 
type and intracellular compartment, a single cell can provide heterogeneous glycosylation 
patterns that differ by up to 30%. Almost every aspect of this process can be modified, including: 
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the site of glycosidic linkage, glycan composition; glycan length (short- or long-chain) and glycan 
structure (branched or unbranched chains). Therefore, glycosylation increases the diversity of the 
proteome to a level unmatched by any other post-translational modification (be it phosphorylation, 
ubiquitination, nitrosylation, methylation, acetylation, lipidation and proteolysis) 215.  
Five classes of glycans are produced, which are classified as follows based on the nature of the 












The most common class and therefore the emphasis of this study, is N-linked; which accounts for 
90% of glycosylation and can occur both co-translationally (where the glycan is attached to the 
nascent protein during translation and transport into the ER) and as a post-translational 
modification 216. 
 
N-glycosylation can be categorised into three initial stages - precursor glycan assembly; 
attachment; and subsequent trimming - which occur identically for all N-glycosylated proteins. 
The diversity previously described manifests during the final stage - maturation in the Golgi 
complex. Oligosaccharides attached to proteins via N-glycosidic linkages are derived from a 14-
sugar precursor molecule comprised of N-acetylglucosamine (GlcNAc), mannose (Man) and 
glucose (Glc). These sugars are added consecutively via a polyisoprenoid lipid carrier called 
dolichol, which is embedded in the ER membrane 217, 218. Glycans are covalently bound to the 
carboxamido nitrogen on asparagine (Asn or N) residues, from which the “N” nomenclature is 
derived. Notably, not all Asn residues with consensus sequence are glycosylated. Protein 
synthesis occurs in the direction N- to C-terminus and the growing polypeptide is transported into 
the ER in the same orientation that it is synthesised. Since protein folding occurs soon after ER 
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entry, the consensus sequences for glycan transfer become less accessible, thus more N-
terminal than C-terminal Asn residues are glycosylated.  
The oligosaccharides are then trimmed via glycosidase hydrolysis, until correctly folded. In higher 
eukaryotes, the glycan structure for all properly folded glycoproteins that proceed to the Golgi is 
Man6-5GlcNAc2 219. In the Golgi, the enzymes that mediate glycan processing are segregated 
into distinct cisternae to ensure that glycosylation occurs in a step-wise fashion. Further step-wise 
sugar addition and removal yields a common core oligosaccharide, to which multiple Gtfs add 
different sugars to generate two other forms - highly variable complex oligosaccharides and high 
mannose oligosaccharides. The crystal structure of IgG1 and the common core oligosaccharide 



























6-deoxy-L-galactose (fucose) is a common component of many N-linked glycans produced in 
mammalian cells 124. Fucose is added to the core glycan structure of IgG in the late stages of 
glycan biosynthesis by Golgi-resident fucosyltransferase (FuT) enzymes. A total of 13 FuT have 
been identified in the human genome, which catalyse the transfer of a fucose residue from 
Guanosine 5′-diphospho-β-L-fucose to an acceptor substrate; however, FuT8 is the only FuT that 
transfers fucose via an α1,6-linkage to the innermost N-acetylglucosamine on N-linked glycans for 
core fucosylation 216. The position of the fucose residue on N-linked glycans is illustrated in Figure 
1.9. 
 
1.12.3. Glyco-engineering and afucosylation 
It is long established that core fucosylation of IgG-Fc affects binding to FcγRIIIa; where non-
fucosylated antibodies bind to FcγRIIIa with significantly higher affinity (5-50 fold), translating into 
a significantly greater magnitude of ADCC and phagocytosis of targets by these antibodies 220, 221.  
GlycoMab technology, created by Glycart Biotechnology and acquired by Roche, was developed 
for the glyco-engineering (GE) of human proteins to express complex N-glycosylation 
modifications 222. Glycart first utilised their technology in Chinese hamster ovary (CHO) cells. 
Umana et al transfected CHO cells to produce: i) an anti-neuroblastoma chimeric IgG1 mAb 
called chCE7 and ii) tetracycline-regulated expression of (1,4)-N-acetylglucosaminyltransferase III 
(GnTIII). GnTIII catalyzes the formation of a bisecting GlcNAc by attaching a GlcNAc to the β-
linked mannose of the trimannosyl core of N-glycans (position illustrated in Figure 1.9). It was 
shown that overexpression of GnTIII in CHO cells was able to reduce Fc core fucosylation and 
inhibit further processing due to substrate competition and steric hindrance. Roche also evaluated 
the overexpression of a series of Golgi resident enzymes in combination with GnTIII and showed 
that overexpression of GnTIII and Golgi α-mannosidase II resulted in the highest level of bisecting 
and afucosylated glycans on IgG antibodies 221, 223. 
 
Glycoprotein identification and quantitation was performed before and after enzymatic cleavage 
using mass spectrometry (which required protein enrichment, multidimensional separation by 
liquid chromatography, tandem MALDI-TOF mass spectrometry and subsequent bioinformatics 
analysis). Approximately 70% of chCE7 Fc regions bore bisecting and afucosylated glycans after 
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glyco-engineering, and importantly, the process of glyco-engineering did not alter the binding 
affinity of chCE7 for human neuroblastoma cells when compared to non-GE and parental mAb 221. 
This technology was used to create the GE-mAbs imgatuzumab and GA101GE. Their WT 
equivalents were created in the same model, but with the administration of tetracycline to inhibit 
GnTIII function (thereby removing inhibition of FuT8); or in unmodified CHO cells 212, 221. 
 
1.12.4. Other methods of glyco-engineering 
CHO Lec13 cells are deficient in endogenous GDP-mannose 4,6-dehydratase (GMD), an enzyme 
responsible for catalysing de novo GDP-fucose biosynthesis. As a result CHO Lec13 are naturally 
defective in GDP-fucose formation 61. Shields et al exploited this property of Lec13 cells for the 
production of afucosylated antibodies 220. However subsequent studies showed that single clones 
isolated from Lec13 cells displayed a wide range of fucosylation; with the majority producing 50–
70% fucosylated antibody under confluent culture conditions 224. 
Another strategy to produce afucosylated antibodies involves inactivating the FuT8 gene. 
Yamane-Ohnuki et al targeted the FuT8 gene in an anti-CD20 antibody-producing CHO DG44 cell 
line, using sequential homologous recombination 225. Both FuT8 alleles were knocked out from 
the FuT8 genomic region in the resultant cell line. FuT8-/- CHO were shown to express completely 
afucosylated antibodies, and elicited a two-fold increase in ADCC compared to the same antibody 
produced in parental cells. FuT8-/- CHO also demonstrated similar growth kinetics and 
productivity compared to the parental cell line when cultures were scaled up to 1L bioreactors 225. 
FuT8 gene has also been targeted for inactivation using the zinc finger nucleases 226 or small 
interfering RNA (siRNA) 227. Respectively, this led to the production of 100% and 60% 
afucosylated antibodies.  
 
1.12.5. The impact of afucosylation on FcγRs 
Defucosylated forms of human IgG are observed as a natural component of normal human serum 
228, as such there is little concern regarding their intrinsic immunogenicity and the control of core 
fucosylation of therapeutic mAbs is now widely recognised as being of great importance regarding 
Fcγ receptor biology. The family of Fcγ receptors are broadly characterized into three groups: 
FcγRI (CD64), FcγRII (CD32) and CD16. Differences exist between the groups of receptors, 
particularly in their structure, function, and affinity for IgG. CD64, CD32a and CD16 are ITAM 
containing activating receptors that induce effector activities in innate cells such as macrophages 
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and NK cells. CD32b harbours an ITIM thus fundamentally acts as an inhibitory receptor 229. 
Signalling through CD32b induces inhibitory signals that decrease the activation:inhibition (A:I) 
ratio and bring the cells further from the threshold level required for activation 230.  
 
Importantly, the oligosaccharide structure of Fcγ receptors is also found to contribute to the 
binding of afucosylated antibody 212. The structural basis for the high ADCC observed with 
afucosylated mAbs is that the fucose located at the core Asn297 on IgG1 Fc blocks the interaction 
of the carbohydrate located at Asn162 on FcγRIIIa 213. Afucosylated mAbs thus exhibit higher 
affinity selectively for FcγRIIIa (and the FcγRIIIb expressed exclusively on neutrophils 230) since 
the other Fcγ receptors are not glycosylated at that location 212, 213. Detailed X-ray crystallography 
studies of the Fc:FcγRIIIa complex confirmed this model. Ferrara et al showed that an increased 
number of newly formed hydrogen bonds and van der Waals contacts coupled with a unique type 
of carbohydrate:carbohydrate interaction likely contribute to the increased binding affinity 
observed between afucosylated Fc and the Asn162 on FcγRIIIa 212. Fc galactosylation and 
sialylation also modulate IgG1 interaction with FcγRIIIa, but to a significantly lesser extent than 
afucosylation 231. 
The binding of human IgG1 antibodies to C1q and CD64 does not change irrespective of the core 
fucosylation, although afucosylated human IgG1 shows a slight increase in binding for FcγRIIa 
and FcγRIIb 220, 231. 
 
1.12.6. The benefits of glyco-engineering: GA201GE (Imgatuzumab) 
Importantly, glyco-engineering improves the therapeutic potential of mAbs in both low (158F) and 
high (158V) affinity variants of CD16 205, 232. Gerdes et al measured killing of the EGFR+ human 
tumour cell line A431 by variants of the human NK cell line NK-92 expressing either the V158 
(high affinity) or F158 (low affinity) CD16 genotype in the presence of cetuximAb or the novel 
humanised IgG1 glyco-engineered mAb imgatuzumab (also known as RG7160). With high affinity 
CD16 expressing NK-92 at an effector to target (E:T) ratio of 3:1, imgatuzumab was 
approximately 2-fold more efficacious at inducing ADCC than the same concentration of 
cetuximAb. This increased dramatically to 35-fold when low affinity CD16 expressing NK-92 cells 
were used. Notably, in the presence of physiologic concentrations of competing nonspecific total 
human IgG, imgatuzumab continued to promote substantial ADCC-mediated killing, whereas the 
ADCC activity of cetuximAb was virtually abolished. Superior imgatuzumab activity was also 
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demonstrated for survival in a KRAS mutant mouse xenograft model. Furthermore, GE-mAbs 
exhibit enhanced ability to induce monocyte/macrophage mediated phagocytosis and cytotoxicity 
233. Thus, to summarise, novel drugs such as imgatuzumab are efficacious, irrespective of patient 
genotype and additionally irrespective of KRAS status, and as such would not require selection of 
patients who are most likely to benefit 205. 
 
1.12.7. Imgatuzumab in clinical trials 
For ADCC-based immunotherapy to be effective, it is essential that pivotal immune effector cells 
are present and have sufficient functional capacity; however, chemotherapy induced leukopenia 
may negatively impact on the immunotherapeutic efficacy of mAbs. Understanding whether 
ADCC-eliciting antibodies retain effectiveness when combined with chemotherapy is a vital 
requirement in the development of novel therapeutic strategies against cancer. The importance of 
which is illustrated by recent findings calling into question the clinical efficacy of cetuximab when 
combined with oxaliplatin-based chemotherapy 195. Therefore an examination of the use of 
imgatuzumab in cancer patients formed the basis of a clinical trial collaboration between King’s 
College London and Roche Glycart AG. The analytical service conducted at King’s involved in 
vitro studies of NK-cell cytotoxic responses in metastatic CRC, HNSCC and non-small cell lung 
cancer (NSCLC) patients. Early trial objectives included: 
 
• Generation of a longitudinal serum cytokine profile throughout the course of treatment 
using a multiplex immunodetection assay (LUMINEX – Invitrogen, Paisley UK)  
• Monitoring of patient immune cell populations to include enumeration of T cells (with 
CD4+/CD8+ subsets), B cells and NK cells 
• Detailed examination of patient NK cell phenotype 
• Assessment of patient CD16 genotype 
• Analysis of cytotoxic capacity of patient NK cells against EGFR+ and EGFR- tumour cell 
lines 
 
1.12.7.1. Ethical approval 
The clinical studies were conducted in accordance with Good Clinical Practice guidelines and the 
Declaration of Helsinki. All patients provided written consent, and local independent ethics 
committee approval was obtained (comments detailed in Roche-Glycart investigator brochures: 
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WP21748, BO21495, BP22350, BP22349, BP25438 and summarised by Paz-Ares et al, 2011 
234). Information sheets provided to patients for informed consent included details of sample 
frequency, sample storage and sample access. In addition information sheets detailed the use of 
samples for in vitro immunophenotyping and in vitro functional assessments, with potential 
assessment of the development of adaptive immune responses in patients of suitable HLA type 
(comments detailed in Roche-Glycart investigator brochures). 
 
1.12.8. In vitro assessment of imgatuzumab 
As a major trial objective, the potential of mAbs to elicit NK-cell mediated ADCC in vitro was 
assessed via a degranulation assay. Lysosomal-associated membrane protein I (LAMP-I more 
commonly referred to as CD107a) is a vesicle-associated protein that is transiently displayed on 
the surface of an NK cell when it degranulates, thus serving as a measure of NK-cell cytotoxic 
capacity 235. The assay was conducted as follows: in the presence or absence of therapeutic 
mAbs, patient peripheral blood mononuclear cells (PBMC) were co-incubated with two tumour 
target cell lines - A431 or K562. A431 cells were derived from the vulval carcinoma of an 85-year-
old female and express a very high level of EGFR 236, thus serving as a realistic model for the 
tumour type of trial participants and a means to assess CD16-dependent responses. K562 is an 
undifferentiated erythroleukaemic, BCR:ABL fusion gene positive (Philadelphia+) cell line that was 
derived from a 53-year-old female CML patient in blast crisis 237. Importantly, K562 cells are 
devoid of MHC-I and thus serve as a classical target for CD16-independent NK cell killing. K562 
served as a positive control for NK-cell cytotoxicity and flow cytometry was used to detect and 
quantify CD107a+ positive NK cells as a measure of degranulation and, by inference, cytotoxicity. 
One of the earliest trial protocols involved assessment of metastatic CRC patient PBMC before, 
during and after oxaliplatin/irinotecan-based chemotherapy. It was found that patient NK cell 
frequencies were preserved and NK cells retained their CD16 expression and ability to mount an 
imgatuzumab-mediated ADCC response; regardless of their therapeutic stage (no statistical 
differences compared to age-matched healthy controls), as illustrated in Figure 1.10. These 
results, published by Oppeneheim et al, were a promising indication that immunotherapeutic 
approaches exploiting ADCC in cancer patients may be viable, despite the lymphopenia induced 
by chemotherapy 238. Phase I and II clinical trials were subsequently undertaken to assess the 
combination of imgatuzumab with chemotherapy in multiple tumour types, often compared to 













Adapted	 from	Oppenheim	et	al	2014	 238.	 (A)	 Frequency	 in	 lymphocytes	 (B)	 absolute	 counts	of	CD3-CD56/CD16+	NK	









1.13. Experimental assessment of NK:DC:T-cell crosstalk 
In the context of cancer immunotherapy, an adaptive T-cell mediated immune response is 
advantageous because of specificity for TA and the persistent memory that is essential for long-
term immunosurveillance. It is therefore important to evaluate whether ADCC mediated by NK 
cells and induced by mAbs such as imgatuzumab has the potential to promote adaptive immunity. 
Co-incubation of tumour target cells, NK cells and DC in the presence of TA-directed mAbs is a 
means of building upon the CD107a assay discussed in section 1.12.4 and assessing NK:DC 
crosstalk, antigen cross presentation and T-cell immunity in vitro. In 2002, Dhodhapkar et al 
reported that antisyndecan-I mAb coating of myeloma cells promoted cross presentation of TA to 
T cells by DC, in a series of in vitro co-culture experiments 239. In 2011, the group led by Robert L 
Ferris, extended these studies to the EGFR and ADCC setting by incubating the EGFR+HLA-
A*02- HNSCC cell line PCI-15B (Tu) with cetuximab, NK cells and HLA-A*02+ DC. In addition to 
showing that NK cells activated by ADCC induced DC maturation, they assessed the IFNγ 
production of EGFR specific HLA-A*02 restricted CD8+ T cells exposed to DC that had been co-
cultured with NK cells and tumour cells. They established that NK-cell killing mediated by 
cetuximab promoted cross presentation of EGFR peptides by DC 96. The Ferris group is, to date, 
the only group to present evidence that cetuximab mediated ADCC activation of NK cells 
promotes DC cross-presentation of antigens to T cells. They also noted that the frequency of 
EGFR specific T cells was significantly increased in cetuximab treated versus cetuximab naïve 
patients. This is important for two reasons: first it suggests that associated enhancement of 
adaptive immunity with mAb treatment may contribute to a clinical response. Second it confirms 
the clinical response by providing evidence for detectible EGFR-specific T cells, in agreement 
with a previous study by Schuler et al (2011) 240. 
 
1.13.1. T-cell immunity: intra- and inter-molecular epitope spreading 
Typically, a T-cell response to an antigenic protein is focused on one or two epitopes within the 
protein, which are termed dominant. Immunodominance occurs in part because of the individual 
HLA-type peptide binding preferences detailed in section 1.7.4, but also because of any marked 
bias in the processing or presentation of a protein. If, for example, the conformation or tertiary 
structure of an antigen dictates that some parts of the protein are more easily accessible than 
others, then these parts will be preferentially targeted for antigen processing. The diversification 
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of epitope specificity from the initial focused dominant epitope to subdominant epitopes within the 
protein was first described in an autoimmunity setting by Lehman et al as an example of intra-
molecular epitope spreading; and can occur for the same reasons as dominant epitopes 241, 242. 
Interestingly, intra-epitope spreading has been seen in cases of clinical responders to peptide 
vaccines in clinical trials involving patients with melanoma 243. 
Furthermore, when the targeting of a TA such as EGFR induces NK cell-mediated lysis of tumour 
cells, other antigens such as carcino-embryonic antigen (CEA), present in lysis particulates are 
also phagocytosed by DC and presented to T cells. This is known as inter-epitope spreading. The 
EGFR targeting experiments by the Ferris group showed that the DC matured by anti-EGFR 
mAb-activated NK cells not only enhance cross-presentation to EGFR specific CD8+ T cells but 
also cross-present another antigen, melanoma antigen III (MAGE-3) to CD8+ T cells in HNSCC 



























































































1.14. CD20+ cancers 
CD20 is selectively expressed on the surface of both normal and malignant B cells, but absent on 
plasma B cells. Although much has been learned about its structure, its function is still poorly 
characterised and its natural ligand unknown. CD20 is a small transmembrane protein with 
multiple hydrophobic regions that confer the remarkable ability to pass through the cell membrane 
four times. The N- and C-termini located in the cytoplasm are serine and threonine rich, housing 
multiple consensus sequences for phosphorylation. Only a small portion of the molecule is 
exposed at the cell surface and it is currently suggested that CD20 regulates transmembrane 
Ca2+ conductance and initiates intracellular signals that modulate cell growth and differentiation 
250. 
 
The distinct stages of B-cell development have been associated with B-cell malignancies. 
Chromosomal translocations and gene mutations are frequently involved in these neoplasms, and 
additional genetic aberrations such as hyperploidy and aneuploidy are also important contributors 
to the disease phenotypes. B-cell acute lymphocytic leukaemias (B-ALLs) arising from pre-B cells 
usually involve the BCR–ABL translocation or mutations affecting one or more of the following 
genes: runt-related transcription factor 1 (RUNX1), pre-B cell leukaemia homeobox 1 (PBX1), 
mixed-lineage leukaemia (MLL), protein tyrosine phosphatase non-receptor type 11 (PTPN11) 
and RAS. These transforming events do not affect resting small pre-B cells which undergo light-
chain gene rearrangement, but rather the rapidly proliferating large pre-B cellsd. 
The diversity of GC-derived lymphomas parallels the diversity of this dynamic compartment. 
Follicular lymphoma, diffuse large B cell lymphoma (DLBCL) and Burkitt's lymphoma are all 
derived from GC B cells. Multiple myeloma (MM) is a GC-derived plasma cell malignancy that is 
dependent on stromal cell contact and cytokines such as IL-6. Thus MM persists in the bone 
marrow. In some types of B-cell malignancy there is evidence that continual BCR signalling is 
required for malignant-cell survival and progression 251, 252. 
                                                       
d Several types of lymphoma arise from differentiated subsets of mature B cells in the secondary lymphoid organs. B-cell 
chronic lymphocytic leukaemia (B-CLL) is an indolent malignancy and an unmutated type of B-CLL is derived from mature 
CD5-positive B cells. Mantle cell lymphomas (MCL) arise from differentiated subsets of mature B cells in the secondary 
lymphoid organs. Splenic marginal zone lymphoma (SMZL) and mucosa-associated lymphoid tissue (MALT) lymphoma 




1.14.1. Anti-CD20 mAbs in the treatment of CD20+ cancers 
Since expression of the CD20 glycoprotein is tightly restricted to the surface of B-cells it is 
therefore a favoured target for therapy in malignant lymphoma and other B-cell malignancies 253. 
In 1997, the anti-CD20 IgG-I chimeric mAb rituximab was approved for use in non-Hodgkin 
lymphoma (NHL) and demonstrated promising clinical activity. However, early trials in chronic 
lymphocytic leukaemia (CLL) showed only a modest 12% ORR with rituximAb as a single agent. 
This ORR dramatically increased to 95% with rituximab in combination with standard fludarabine 
and cyclophosphamide chemotherapy, findings that eventually revolutionised CLL treatment 254. 
Despite these impressive statistics, some CLL patients fail to respond to rituximab therapy, and 
relapse rates are high in those who do initially respond to treatment 253. The F/F allelic variant of 
CD16 has been correlated with poor clinical responses to rituximAb 255, thus, strategies to 
enhance efficacy of anti-CD20 mAb therapy have been sought. 
 
1.14.2. Anti-CD20 mAb enhancements: Obinutuzumab (GA101GE) 
Obinutuzumab (GA101GE) is a glyco-engineered anti-CD20 mAb with superior efficacy to 
rituximab in terms of CD16 affinity and NK-cell mediated ADCC 232, 253, that has recently received 
US approval as a first line CLL treatment in combination with the chemotherapeutic agent 
chlorambucil 233. Anti-CD20 mAbs have been classified into two subtypes based on antigen-
binding properties and mechanism of action. Type I mAbs like rituximab elicit CDC activation and 
redistribute CD20 into membrane lipid rafts. Type II mAbs like obinutuzumab do not stabilise 
CD20 redistribution, and have minimal CDC potential. However, they exhibit direct tumoural 
effects and increased ADCC. GA101GE was approved for use by the European Medical 
Association (EMA) based on the results of the CLL11 clinical trial (reported by Goede et al) 256. 
The study was designed to compare the efficacy of GA101GE plus chlorambucil to rituximab plus 
chlorambucil or chlorambucil alone in CLL patients with significant co-morbidities. Although both 
mAbs showed significant increases in PFS and OS, the inclusion of GA101GE yielded a 
significant increase in PFS when compared to rituximab 256. Notably however, despite promising 
preclinical activity; subsequent studies in DLBCL patients did not support the findings of the 
CLL11 study 257, 258. Vitolo et al reported that there were no significant differences in PFS for 
patients administered GA101GE plus cyclophosphamide, doxorubicin, vincristine, and prednisone 
(G-CHOP) or rituximab plus CHOP (R-CHOP). This was despite patients receiving GA101GE at 
higher doses than rituximab (1000mg and 375mg/m2 respectively - i.v. every 21 days for 8 
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cycles), and receiving two additional infusions of GA101GE on days 8 and 15 of cycle 1, that were 
not included in the rituximab treatment arm 258, 259. This disparity provides further rationale for 
investigating the underlying immune cell mechanisms involved in sustained tumour clearance in a 
wide variety of CD20+ tumour types. 
 














































































1.15. Hypothesis, specific aims and experimental model 
Previous studies have shown therapeutic mAbs that mediate ADCC can also promote the NK:DC 
cross-talk that stimulates TA-specific CD8+ T cell immunity 97, 263. GE mAbs have been developed 
that exhibit enhanced ADCC compared with conventional therapeutic mAbs 205, 232. In this study, 
the potential for GE mAbs to promote anti-tumour adaptive cellular immunity was assessed and 
compared with conventional therapeutic mAbs. 
 
1.15.1. Hypothesis 
GE-mAbs induce NK-cell activity that promotes DC to phagocytose TA, undergo maturation and 
cross present TA to TA-specific CD8+ T cells. 
 
1.15.2. Study aims 
The hypothesis was tested by addressing the following research questions: 
 
1. Does GE-mAb-mediated ADCC induce NK-cell activation and function associated with 
promoting adaptive cellular immunity?  
2. Are GE-mAbs able to induce DC phagocytosis of TA and promote DC maturation?  
3. Do GE-mAbs promote DC cross presentation of TA to TA-specific CD8+ T cells?  
 
1.15.3. Experimental model 
Interactions between tumour cells and highly purified (>90%) NK cells, DC and CD8+ T cells in the 
presence of unmodified or GE-mAbs were assessed using the in vitro co-culture model illustrated 
in Figure 1.12. To study cross presentation, HLA-A*02- tumour cells were used with HLA-A*02+ 
NK cells, DC and CD8+ T cells. NK-cell mediated lysis of tumour cells will release particulate 
antigen for uptake by DC and presentation of HLA-A*02-restricted peptides to HLA-A*02+ TA-
specific CD8+ T cells. The HLA mismatch between tumour cells and CD8+ T cells allows for the 
assessment of cross presentation of TA by DC to HLA-A*02 restricted T cells because the HLA-















Chapter 2. Materials and Methods 
 
The products and reagents used in this study are detailed in Table 2.1 with supplier information 
indicated. When combinations of reagents were used to make a solution (w/v or v/v), the 
composition has been described and an abbreviated name for the composition is used thereafter. 
 
2.1. Products and reagents 
2.1.1. Media, buffers and solutions 
Complete DMEM: comprised Dulbecco’s Modified Eagle Medium supplemented with 10% heat 
inactivated foetal bovine serum (FBS), 100IU/ml penicillin and 100mg/ml streptomycin (PS).  
Complete RPMI: comprised Roswell Park Memorial Institute1640 (RPMI) Medium supplemented 
with 10% heat inactivated FBS and PS. 
Complete RPMI and complete DMEM were 0.22µM filtered before use. 
Cytokines: were reconstituted according to manufacturer instructions, diluted to working 
concentrations and frozen at -20°C in single use aliquots. 
DAPI solution: comprised PBS+ supplemented with 0.25µg/ml 4’,6-diamidino-2-phenylindole, 
dihydrochloride (DAPI). 
DC Differentiation Medium I (DCD1): comprised complete RPMI supplemented with 1000IU/ml 
IL-4 and 1000IU/ml GMCSF. 
DC Differentiation Medium II (DCD2): comprised CellGro DC Medium supplemented with 1% 
“Off The Clot” human AB serum (hAB); 10ng/ml IL-4 and 800IU/ml GMCSF. 
DC Differentiation Medium III (DCD3): comprised CellGro supplemented with 1% hAB; 10ng/ml 
IL-4 and 1600IU/ml GMCSF. DCD2/D3 were as described by Wolfl and Greenberg (2014) 264. 
DC Maturation Medium I (DCM1): comprised complete RPMI supplemented with 10ng/ml IL-1β; 
1000IU/ml IL-6; 1µg/ml PGE2 and 10ng/ml TNFα. Adapted from protocols stipulated by Dauer et 
al 265. 
DC Maturation Medium II (DCM2): comprised complete RPMI supplemented with 25ng/ml IL-1β; 
25ng/ml Poly I:C; 5500IU/ml TNFα; 1000IU/ml IFNγ and 3000IU/ml IFNα as described by López-
Albaitero et al 266. 
DC Maturation Medium III (DCM3): comprised CellGro supplemented with 1% hAB; 10ng/ml LPS 
and 100IU/ml IFNγ as described by Wolfl and Greenberg (2014) 264. 
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Fluorescence Activated Cell Sorting (FACS) Buffer: comprised PBS+ supplemented with 2.5% 
FBS and 0.1% (w/v) sodium azide (NaN3). 
Lysogen broth (LB) agar plates: comprised 20g/L LB agar in dH2O, supplemented with 30µg/ml 
kanamycin. 
LB Medium: comprised 15g/L LB agar, 10g/L sodium chloride (NaCL2), 5g/L yeast and 10g/L 
tryptone in deionised water (dH2O). 
Magnetic Activated Cell Sorting (MACS) Buffer: comprised PBS+, 2mM 
ethylenediaminetetraacetic acid (EDTA) and 0.5% bovine serum albumin (BSA) was kindly 
donated by King’s College London (KCL - London, UK) tissue bank staff. 
NK-cell Recovery Medium (NKRM): comprised complete RPMI supplemented with 50IU/ml IL-2 
PBS+ and PBS-: Phosphate Buffered Saline with or without 1mM calcium chloride (CaCl2) and 
magnesium chloride (MgCl2) supplementation. 
Peptides: were reconstituted in dimethyl sulfoxide (DMSO) to a stock concentration of 20mg/ml. 
Stock and working dilutions were frozen at -20°C in single use aliquots. 
pHrodo Red Succinimydyl Ester (pHrodo-SE): was reconstituted in DMSO to a stock 
concentration of 1mg/ml and frozen at -20°C in single use aliquots. 
T-cell Recovery Medium (TcRM): comprised CellGro supplemented with 5% hAB; 5ng/ml IL-7. 
T-cell Stimulation Medium - Day Zero (TcSM0): comprised CellGro supplemented with 5% hAB 
and 30ng/ml IL-21.  
T-cell Stimulation Medium - I (TcSM1): comprised CellGro supplemented with 5% hAB and 
5ng/ml IL-7 and IL-15. 
T-cell Stimulation Medium - II (TcSM2): comprised CellGro supplemented with 5% hAB and 
10ng/ml IL-7 and IL-15. 
TcRM, TcSM0, TcSM1 and TcSM2 were as described by Wolfl and Greenberg (2014) 264 
T-cell Stimulation Medium - III (TcSM3): comprised X-Vivo15 medium supplemented with 
5ng/ml IL7 
T-cell Stimulation Medium - III (TcSM4): comprised X-Vivo15 medium supplemented with 
10ng/ml IL-2 and IL7 
Triton Solution (0.1%): comprised PBS+ supplemented with 0.1% Triton X-100. 






	 Product	 Catalogue	No.	 Supplier	
	 	 	 	
Reagents	 “Off	the	Clot”	Human	AB	serum	 ACCM-112-HIS	 SeraLab,	UK	
	 10x	Tris-Acetate-EDTA	(TAE)	Buffer	 T9650	 Sigma-Aldrich	-	Dorset,	UK	
	 6x	Loading	Dye	 R0611		 ThermoFisher	-	Paisley,	UK	
	 Agarose	Powder	 A5304	 Sigma-Aldrich	-	Dorset,	UK	
	 BD	Cytofix	 554655	 BD	Biosciences	-	Oxford,	UK	
	 BD	Cytoperm	 554723	 BD	Biosciences	-	Oxford,	UK	
	 Brefeldin	 B5936	 Sigma-Aldrich	-	Dorset,	UK	
	 CellGro	DC	Medium	 0020801-0500	 CellGenix	-	Germany	
	 CompBeadPLUS	 560497	 BD	Biosciences	-	Oxford,	UK	
	 CST	Beads	 642412	 BD	Biosciences	-	Oxford,	UK	
	 DAPI	 40835	 CellSignallingTechnology	-	UK	
	 Dulbecco’s	Modified	Eagle	Medium	 D5796	 Sigma-Aldrich	-	Dorset,	UK	
	 Dulbecco’s	Phosphate	Buffered	Saline	withCa/Mg	 D8662	 Sigma-Aldrich	-	Dorset,	UK	
	 Dulbecco’s	Phosphate	Buffered	Saline	withoutCa/Mg	 D8537	 Sigma-Aldrich	-	Dorset,	UK	
	 Ethidium	Bromide	 E1510	 Sigma-Aldrich	-	Dorset,	UK	
	 Ficoll-Paque	PLUS	 17-1440-03	 GE	Healthcare	-	UK	
	 Goat	Anti-Rabbit	AF647	2°	 ab150083	 AbCam	-	Cambridge,	UK	
	 Heat	Inactivated	Foetal	Bovine	Serum	(FBS)	 10500-064	 Gibco,	London,	UK	
	 Ionomycin	 I0634	 Sigma-Aldrich	-	Dorset,	UK	
	 Kanamycin	 K1377	 Sigma-Aldrich	-	Dorset,	UK	
	 LB	Agar	 A5306	 Sigma-Aldrich	-	Dorset,	UK	
	 Leukocyte	Activation	Cocktail	(LAC)	 550583	 BD	Biosciences	-	Oxford,	UK	
	 Lipopolysaccharide	(LPS)	 L4391-1MG	 Sigma-Aldrich	-	Dorset,	UK	
	 Monensin	 M5273	 Sigma-Aldrich	-	Dorset,	UK	
	 Mounting	Medium	 345789	 Merck	Millipore	-	UK	
	 Nuclease	Free	Water	 AM9938	 ThermoFisher	-	Paisley,	UK	
	 O’gene	Ruler	DNA	ladder	 SM0333	 ThermoFisher	-	Paisley,	UK	
	 Penicillin-Streptomycin	 P4333	 Sigma-Aldrich	-	Dorset,	UK	
	 PGE2	 TOCRIS	2296	 R&D,	London,	UK	
	 pHrodo	Red	Succinimidyl	Ester	 P36600	 ThermoFisher	-	Paisley,	UK	
	 Plasmocin	 ant-mpt	 Source	Bioscience	-	UK	
	 PMA	 P8139	 Sigma-Aldrich	-	Dorset,	UK	
	 Polyinosinic:polycytidylic	acid	(Poly:IC)	 P9582	 Sigma-Aldrich	-	Dorset,	UK	
	 Puromycin	 sc-108071	 SantaCruz	Bio	-	Germany	
	 Rabbit	Anti-MelanA	1°	 ab51061	 AbCam	-	Cambridge,	UK	
	 Roswell	Park	Memorial	Institute1640	Medium	(RPMI)	 R8758	 Sigma-Aldrich	-	Dorset,	UK	
	
Super	 Optimal	 Broth	 with	 Catabolite	
Repression	(SOC)	
15544-034		 ThermoFisher	-	Paisley,	UK	
	 Synth-a-Freeze	Cryopreservation	Medium	 A12542-01	 Gibco,	London,	UK	
	 TaqMan	Genotyping	MasterMix	 4371353	 ThermoFisher	-	Paisley,	UK	
	 Total	Immunoglobulin	G	(IgG)	 I4506	 Sigma-Aldrich	-	Dorset,	UK	
	 Trypan	Blue	 T8154	 Sigma-Aldrich	-	Dorset,	UK	
	 Trypsin-EDTA	10x	Solution	 T4174	 Sigma-Aldrich	-	Dorset,	UK	
	 UltraComp	antibody	capture	beads	 01-2222-42	 eBioscience	-	Wycombe,	UK	
	 X-Vivo	15	Medium	 LZBE04-418F	 Lonza,	UK	
	 Yeast	 288620	 BD	Biosciences	-	Oxford,	UK	









	 Dead	Cell	Removal	kit	 130-090-101	 Miltenyi	Biotec	-	Surrey,	UK	
	 DNA	Blood	Mini	Kit	 51104	 Qiagen	-	Manchester,	UK	
	 DNA	Maxi-Prep	Kit	 12662	 	
	 EZ-PCR	Mycoplasma	Test	Kit	 20-700-20	 Biological	Industries,	Israel	
	 FITC	Annexin	V	Apoptosis	Detection	Kit	with	PI	 640914	 BioLegend	-	London,	UK	
	 Human	CD45RO+	Cell	Isolation	Kit	 130-046-001	 Miltenyi	Biotec	-	Surrey,	UK	
	 Human	CD57+	Cell	Isolation	Kit	 130-092-073	 Miltenyi	Biotec	-	Surrey,	UK	
	 Human	CD8+	T-cell	Isolation	Kit	 130-094-156	 Miltenyi	Biotec	-	Surrey,	UK	
	 Human	Monocyte	Isolation	Kit	II	 130-091-153	 Miltenyi	Biotec	-	Surrey,	UK	
	 Human	NK-cell	Isolation	Kit	 130-092-657	 Miltenyi	Biotec	-	Surrey,	UK	
	 K2	Transfection	Kit	 T060-8.0	 Biontex	-	Munich,	Germany	
	 TaqMan	SNP	Genotyping	Assay:	rs396991	 4351379	 Thermofisher	-	Paisley,	UK	







monoclonal	 GA101-WT	 	 Basel,	Switzerland	
antibodies	 Imgatuzumab	(GA201GE)	 	 	
	 Obinutuzumab	(GA101GE)	 	 	
	 Panitumumab	 	 	











conjugated	 CD11c	FITC	 301604	 BioLegend	-	London,	UK	
antibodies	 CD11c	PerCP/Cy5.5	 301624	 BioLegend	-	London,	UK	
(mouse	anti-human)	 CD137	APC	 309810	 BioLegend	-	London,	UK	
	 CD14	PB	 301828	 BioLegend	-	London,	UK	
	 CD16	APC-H7	 560195	 BD	Biosciences	-	Oxford,	UK	
	 CD19	PB	 302232	 BioLegend	-	London,	UK	
	 CD20	PB	 302328	 BioLegend	-	London,	UK	
	 CD20	PE	 302305	 BioLegend	-	London,	UK	
	 CD3	PE/Cy7	 317334	 BioLegend	-	London,	UK	
	 CD4	APC	 317416	 BioLegend	-	London,	UK	
	 CD56	PB	 304629	 BioLegend	-	London,	UK	
	 CD56	PE	 318306	 BioLegend	-	London,	UK	
	 CD69	FITC	 310904	 BioLegend	-	London,	UK	
	 CD71	APC/Cy7	 334110	 BioLegend	-	London,	UK	
	 CD8	PerCP/Cy5.5	 344710	 BioLegend	-	London,	UK	
	 CD80	PE	 305208	 BioLegend	-	London,	UK	
	 CD83	PECy7	 305326	 BioLegend	-	London,	UK	
	 CD86	APC	 305412	 BioLegend	-	London,	UK	
	 EGFR	PE	 352903	 BioLegend	-	London,	UK	
	 HLA-A2	PE	 343306	 BioLegend	-	London,	UK	
	 HLA-DR	FITC	 307604	 BioLegend	-	London,	UK	
	 IFNγ	FITC	 506518	 BD	Biosciences	-	Oxford,	UK	
	 TNFα	AF700	 56-7349-42	 eBioscience	-	Wycombe,	UK	









	 Live/Dead	Zombie	Violet	 423113	 BioLegend	-	London,	UK	









	 CMV	Pentamer-PE	 F008-2B-G	 ProImmune	-	Oxford,	UK	
	 EGFR	Pentamers-PE	 F2A-G	CUSTOM	 ProImmune	-	Oxford,	UK	
	 Flu	Pentamer-PE	 F007-2A-G	 ProImmune	-	Oxford,	UK	
	 MelanA	Dextramer-PE	 WB2162-PE	 Immudex	-	Denmark	









	 CMV	Peptide	 aa	sequence*	 ProImmune	-	Oxford,	UK	
	 EGFR	Peptides	 	 ProImmune	-	Oxford,	UK	
	 Flu	Peptide	 	 ProImmune	-	Oxford,	UK	
	 MelanA	Peptide	 	 ProImmune	-	Oxford,	UK	









(recombinant	human)	 IFNα	 300-02A	 Peprotech,	London	UK	
	 IFNγ	 300-02	 Peprotech,	London	UK	
	 IL-1β	 200-01B	 Peprotech,	London	UK	
	 IL-2	 200-02	 Peprotech,	London	UK	
	 IL-4	 200-04	 Peprotech,	London	UK	
	 IL-6	 200-06	 Peprotech,	London	UK	
	 IL-7	 200-07	 Peprotech,	London	UK	
	 IL-15	 200-15	 Peprotech,	London	UK	
	 IL-21	 200-21	 Peprotech,	London	UK	
	 TNFα	 130-094-017	 Miltenyi	Biotech	-	Surrey,	UK	









	 H1299	(WT	and	EGFRLOW/MEDIUM/HIGH)	 -	 Donated	
	 JY	 -	 Donated	
	 K562	 CCL-243	 ATCC/LGC	-	Teddington,	UK	
	 SK-MEL-30	 ACC-151	 DSMZ	-	Germany	
	 T2	 -	 Donated	









	 75cm2	Tissue	Culture	Treated	Flask	 315361	 Greiner	Bio	-	Stonehouse,	UK	
	 96-well	V-bottomed	Plates	 651101	 Greiner	Bio	-	Stonehouse,	UK	
	 LD	MACS	Column	 130-042-901	 Miltenyi	Biotech	-	Surrey,	UK	
	 LS	MACS	Column	 130-042-401	 Miltenyi	Biotech	-	Surrey,	UK	
	 MicroAmp	Fast	Plates	 4346907	 ThermoFisher	-	Paisley,	UK	
	 MicroAmp	Optical	Adhesive	Film	 4360954	 ThermoFisher	-	Paisley,	UK	




1°	 Primary	antibody	 FITC	 Fluorescein	isothiocyanate	
2°	 Secondary	antibody	 GMCSF	 Granulocyte	macrophage	colony-stimulating	factor	
AF	 Alexa	fluor	 H7	 Cyanine7	analogue	
APC	 Allophycocyanin	 IF	 Interferon	
BV421	 Brilliant	violet	421	 IL	 Interleukin	
Ca/Mg	 Calcium/Magnesium	 PB	 Pacific	blue	
CD	 Cluster	of	differentiation	 PE	 R-phycoerythrin	
Cy7	 Cyanine	7	 PerCP/Cy5.5	 Peridinin-chlorophyll/cyanine	5.5	
DAPI	 4',6-diamidino-2-phenylindole	 TNF	 Tumour	necrosis	factor	







2.1.2. Therapeutic mAbs 
The mAbs and stock concentrations detailed in Table 2.2 were provided by Roche Glycart (Basel, 
Switzerland). Concentrations were determined by measuring absorbance at 280nm (A280) on a 
NanoDrop spectrophotometer (ThermoFisher) utilising calculated antibody-specific extinction 

















10mg/ml	 10.34	 5.16	 1.02	 Amgen	Inc	
Cetuximab	
(Erbitux®)	










10mg/ml	 10.04	 5.00	 1.04	 Hoffmann-La	
Roche	










2.2. Cell lines 
All cell lines were handled aseptically in containment level two microbiological safety cabinets and 
grown in standard vented 75cm2 tissue culture treated flasks. Cells were incubated at 37°C in 5% 
carbon dioxide (CO2). Supplier details can be found in Table 2.1 and specific cell culture 
requirements are described below. 
 
2.2.1. A431 
A431 cells were derived from the vulval carcinoma of an 85-year-old female 236. The cells 
expressed very high levels of EGFR (confirmed by flow cytometry, see Figure 3.2). Cells were 
maintained in either complete DMEM or complete RPMI, with a minimum of 2 passages per week 
when cells reached approximately 80% confluence. As an adherent cell line, A431 required 
trypsinisation to obtain a cell suspension. Briefly, A431 cells were washed twice in PBS- and 
incubated with 5ml trypsinisation buffer for 10-15 minutes at 37°C; with regular checks to 
determine adherent status. When all cells were in suspension, trypsinisation buffer was 
neutralised with an equal volume of complete RPMI, centrifuged at 300gmax for 5 minutes and 
resuspended in appropriate medium to be counted and reseeded at desired concentration. 
 
2.2.2. H1299 
H1299 cells were derived from the NSCLC lymph node metastasis of a 43 year old male patient 
269 and were confirmed as expressing HLA-A*02 by flow cytometry. As an adherent cell line, 
H1299 required trypsinisation to obtain a cell suspension, as described for A431. H1299 cells that 
had been transfected to express various levels of EGFR were kindly provided by Professor 




JY is an Epstein–Barr virus (EBV) transformed B cell lymphoblastoid cell line, first characterised 
by Terhorst et al as expressing CD20, HLA-A*02:01 and class-II HLA-DR 270 and known to form 
aggregates in suspension culture. JY cells were kindly donated by Dr Linda Barber (KCL - 
London, UK) and maintained in suspension culture in complete RPMI, with a minimum of 2 
passages per week at a cell density approximately 10 times greater than initial seeding density (or 
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when medium was spent). Before use in assays, dead cells were removed from JY cultures as 
described in section 2.18. 
 
2.2.4. K562 
K562 is an undifferentiated human erythroleukaemic, BCR:ABL fusion gene positive 
(Philadelphia+) cell line, derived from a 53-year-old female chronic myeloid leukaemia (CML) 
patient in blast crisis 237. Importantly, the cells are devoid of MHC-I and thus served as a classical 
target for NK cells. It is well established that K562 cells are highly sensitive to NK-cell killing 271. 
K562 were maintained in suspension culture in complete RPMI, with a minimum of 2 passages 
per week at a cell density approximately 10 times greater than initial seeding density (or when 
medium was spent). 
 
2.2.5. SK-MEL-30 
SK-MEL-30 is a melanoma cell line reported to exhibit medium to high levels of the MelanA 
transcript and protein 272, and additionally characterised by Letsch et al as expressing HLA-A*02 
273 (MelanA protein and HLA-A*02 expression was confirmed by flow cytometry). Cells were 
maintained in complete RPMI, with a minimum of 2 passages per week when cells reached 
approximately 80% confluence. As an adherent cell line, SK-MEL-30 required trypsinisation to 
obtain a cell suspension, as described for A431. 
 
2.2.6. T2 
T2 cells were derived from the EBV transformed B-cell lymphoblastoid cell line 721.174 274, 275. 
The cells are deficient in TAP and therefore unable to transport endogenous processed peptides 
generated in the cytosol to the site of MHC-I loading in the ER. Consequently T2 MHC-I cannot 
present peptides derived from cytosolic antigens and therefore MHC-I is not stably expressed at 
the cell surface. The HLA-A*02:01 molecules expressed by T2 cells can be stabilised by culture 
with exogenous provision of HLA-A*02:01 restricted peptide, and is used as an assay to assess 
peptide binding. T2 cells were kindly donated by Dr Linda Barber (KCL - London, UK) and 
maintained in suspension culture in complete RPMI, with a minimum of 2 passages per week at a 





2.3. Mycoplasma testing 
Cell lines were tested monthly for mycoplasma contamination or more frequently when necessary. 
The procedure involved polymerase chain reaction (PCR) amplification of genus and species-
specific mycoplasmal 16S ribosomal RNA sequences naturally present in high copy numbers in 
contaminated cultures 276. The PCR reaction was set up according to the protocol provided within 
the EZ-PCR Mycoplasma Test Kit (Biological Industries, Israel). Briefly, 5mls of supernatant was 
removed from confluent cell cultures and centrifuged at 300gmax for 5 minutes to pellet any cellular 
debris. 1ml of the resulting supernatant was transferred to a sterile 1.5ml capped microfuge tube 
and centrifuged at 16,500gmax for 10 minutes, to sediment mycoplasma. After carefully decanting 
the supernatant, the micro-pellet was resuspended in 25µl of the Sample Buffer Solution provided 
and heated to 95°C for 3 minutes. Reaction mixtures were then prepared in PCR tubes according 
to Table 2.2 and the PCR was performed in a Veriti® Thermal Cycler (Applied Biosystems - 
Paisley, UK) according to the conditions detailed in Table 2.3. Substituting the sample with either 










Reaction Mix 5 
Test Sample 2.5 




Temperature (°C) Time (seconds) Cycles 
94 30 1 
94 30 
35 60 120 
72 60 
94 30 1 
60 120 1 
72 300 1 
4 ∞ ∞ 
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2.4. Agarose gel electrophoresis 
Electrophoresis was used to separate PCR amplified products in an agarose gel for determination 
of molecular weight by subsequent comparison to a standardized DNA ladder. The agarose gel 
was made by adding agarose powder to 1x Tris Acetate-EDTA (TAE) buffer at 2% w/v. The 
agarose was carefully dissolved in a microwave with intermittent power and stirred until 
transparent and free of bubbles. After cooling to a temperature of approximately 50°C, 6µl of 
ethidium bromide (10mg/ml stock) was added per 100ml of solution. The gel was then poured into 
a casting tray with a comb inserted to create wells, and left to solidify for approximately 30 
minutes. With comb removed, the gel and casting tray were placed into a gel rig and completely 
immersed in 1x TAE buffer. 10µl of O’Gene Ruler DNA Ladder (New England Biolabs, USA) was 
added to the first and last wells to enable fragment size determination and subsequently, the gel 
was loaded with a mixture containing 10µl of the PCR product and 2µl of 6x loading dye. A steady 
current of 100 volts was then applied to the gel for 1 hour. To enable fragment band comparison, 
the gel was carefully removed from the rig and casting tray and placed upon an ultra violet (UV) 
light box (UVP GelDoc-IT, UVP, Cambridge, UK). The gel was then photographed using the 
associated Polaroid camera. Mycoplasma contamination in samples was indicated by the 
presence of a PCR product with the same molecular weight as the positive control. 
 
2.5. Elimination of mycoplasma from cell cultures  
Cultures identified as positive for mycoplasma contamination and easily replaceable were 
immediately discarded. When cultures were irreplaceable, cells underwent a decontamination 
treatment regimen using the bactericidal agent PlasmocinTM and a protocol adapted from Uphoff 
et al, 2012 277. Cells were cultured in a standard 75cm3 tissue culture treated flask in complete 
RPMI supplemented with 25µg/ml PlasmocinTM. Cells were seeded to reach 90% confluence 
within 2-3 days, with fresh treatment medium added at each passage. After a minimum of 14 
days, treatment was removed and cells were cultured in RPMI supplemented with 10% (v/v) 
0.22uM filtered, heat inactivated FBS without P/S. After at least 7 days growth in the absence of 
antibiotics, confluent culture supernatant was re-tested for mycoplasma contamination as 




2.6. Peripheral blood mononuclear cells 
Peripheral blood leukophoresis, obtained as described by Dietz et al 278 was purchased from 
National Health Service Blood and Transplant (NHS-BT) in the form of anonymised leukocyte 
reduction chambers (hereafter referred to as leukocyte cones). Cells were recovered aseptically 
in a laminar hood (class II microbiological safety cabinets), as described by Néron et al 279 and 
peripheral blood mononuclear cells (PBMC) were isolated from the leukophoresis product by 
Ficoll-Paque density gradient centrifugation. Leukocyte cones were swabbed with 70% ethanol 
and contents were drained into sterile 50ml tubes. Cones were flushed with 20ml PBS+, the eluate 
made to 35ml final volume with PBS+ to give an approximate 1:3 dilution of the leukophoresis 
product, and then gently inverted to mix. A sterile 50ml tube containing 15ml of Ficoll-Paque 
(previously warmed to room temperature) was prepared and the diluted leukophoresis product 
was carefully layered onto the gradient. Tubes were centrifuged at 1000gmax with rapid 
acceleration and slow deceleration (no brake applied) for 20 minutes at room temperature (RT). 
Upon completion of centrifugation cycle, the clearly visible white PBMC layer (resembling a thick 
carpet of cells) was collected into a new sterile 50ml tube, topped up to 50ml with PBS+ and 
washed twice, first at 250gmax for 10 minutes at RT and subsequently at 200gmax for 10 minutes at 
RT to facilitate platelet removal. Cells were resuspended in RPMI supplemented with P/S, and 
live cells counted via trypan blue exclusion. 105 live cells were removed to screen for expression 
of HLA-A*02 as described in section 2.18. Remaining cells were pelleted and cryopreserved in 
1ml chilled synth-a-freeze freezing medium per 5x107 live PBMC, with 1ml aliquoted to labelled 
cryovials and stored in a -80°C freezer within a chilled Nalgene (Nunc International, Hereford, UK) 
temperature controlled freezing vessel containing isopropanol. After 24 hours, the frozen vials 
were transferred to -196°C gaseous phase liquid nitrogen storage in our cryostore facility. Cells 
were retrieved from the cryostore on dry ice, thawed quickly at 37°C and added to prospective 
assay medium, drop-wise initially then at a quicker rate for counting and washing immediately 
prior to use. 
 
2.7. Cell isolations 
2.7.1. NK cells 
The human NK-cell population was isolated from PBMC by negative selection via Miltenyi 
magnetic activated cell sorting (MACS) according to the protocol supplied within the NK-cell 
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Isolation Kit. Briefly, after collection of PBMC by centrifugation at 300gmax for 5 minutes, the cell 
pellet was resuspended in MACS buffer (40µl per 107 cells) and a cocktail of biotin-conjugated 
mAbs were added to label all non-NK cells (10µl per 107 cells). After a 5 minute incubation at 4°C, 
microbeads conjugated to anti-biotin mAbs were added (20µl per 107 cells) and incubated for a 
further 10 minutes at 4°C. This solution was made up to 1ml with MACS buffer and applied to a 
pre-washed LS MACS column. Non-NK cells were retained on the column and the eluted fraction, 
containing the negatively selected NK cells, was collected. Eluted NK cells were counted and 105 
apportioned for isolated NK “time zero” phenotyping and purity assessment. The remainder were 
centrifuged at 300gmax for 5 minutes and resuspended at a concentration of 106 NK cells per ml in 
NKRM. NK cells were recovered for a minimum of 4 hours before use in subsequent processes. 
 
2.7.2. Monocytes 
2.7.2.1. Monocytes: MACS 
The human monocyte population was isolated from PBMC by negative selection via Miltenyi 
MACS, according to the protocol supplied within Monocyte Isolation Kit II. Briefly, after collection 
of PBMC by centrifugation at 300gmax for 5 minutes, the cell pellet was resuspended in MACS 
buffer (30µl per 107 cells). An FcR blocking reagent was added and then a cocktail of biotin-
conjugated mAbs to label all non-monocytes (both 10µl per 107 cells). After a 10 minute 
incubation at 4°C, microbeads conjugated to anti-biotin mAbs were added (20µl per 107 cells) and 
incubated for a further 15 minutes at 4°C. Cells were then washed once in 2mls of MACS buffer; 
the pellet was resuspended in 1ml MACS buffer and then applied to a pre-washed LS MACS 
column. Non-monocytes were retained on the column and the eluted fraction, containing the 
negatively selected monocytes, was collected on ice. Eluted monocytes were counted and 105 
apportioned for isolated monocyte phenotyping and purity assessment. The remainder were 
centrifuged at 300gmax for 5 minutes and resuspended in appropriate media for subsequent 
processes. 
 
2.7.2.2. Monocytes: plastic adherence 
PBMC were plastic adhered in tissue culture treated 6-well plates for two hours. The cells were 
suspended in 2ml RPMI at concentrations of 1.18x106-1.98x106 cells per cm2. This cell seeding 
range was determined during several years of research and development for the Rayne Cell 
Therapy Suite (RCTS) adaptation of the Northwest Biotherapeutics DCVax®-L protocol 
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(unpublished commercial data). After 2 hours, non-adherent cells were gently washed thrice with 
1ml of warm complete RPMI and either discarded in the case of isolated monocytes or frozen for 
later use as a source of NK cells. The remaining adherent monocytes were resuspended in 
appropriate media for subsequent processes. 
 
2.7.3. CD8+ T cells 
The human CD8+ T-cell population was isolated from PBMC by negative selection via Miltenyi 
MACS according to the protocol supplied within the CD8+ T-cell Isolation Kit. Briefly, after 
collection of PBMC by centrifugation at 300gmax for 5 minutes, the cell pellet was resuspended in 
MACS buffer (40µl per 107 cells) and a cocktail of biotin-conjugated mAbs were added to label all 
non-CD8+ T cells (10µl per 107 cells). After a 5 minute incubation at 4°C, microbeads conjugated 
to anti-biotin mAbs were added (20µl per 107 cells) and incubated for a further 10 minutes at 4°C. 
This solution was made up to 1ml with MACS buffer and applied to a pre-washed LS MACS 
column. Non-CD8+ T cells were retained on the column and the eluted fraction, containing the, 
negatively selected CD8+ T cells, was collected. Eluted CD8+ T cells were counted and 105 
apportioned to assess purity. The remainder were centrifuged at 300gmax for 5 minutes and 
resuspended in appropriate medium for subsequent processes. 
 
2.7.4. Naïve CD8+ T cells 
To purify a human naïve T-cell population, CD8+ T cells were first isolated from PBMC by 
negative selection as described above, then subsequently depleted of CD45RO+ and CD57+ T 
cells via Miltenyi MACS positive selection. CD8+ T cells that express CD57 and/or CD45RO were 
thus removed from the isolated CD8+ T-cell population to leave the naïve population. The 
procedure was performed as follows: after CD8+ T-cell isolation, cells were counted and collected 
by centrifugation at 300gmax for 5 minutes. The cell pellet was resuspended in MACS buffer (40µl 
per 107 cells) and a cocktail of microbead-conjugated mAbs were added to label CD57+ and 
CD45RO+ cells (20µl each per 107 cells). After a 15 minute incubation at 4°C the solution was 
made up to 1ml with MACS buffer and applied to a pre-washed LD MACS column. CD57+ and 
CD45RO+ cells were retained on the column and the eluted fraction, containing the negatively 
selected naïve T-cells, was collected. The eluted naïve T cells were counted and 105 apportioned 
to assess purity. The remainder were centrifuged at 300gmax for 5 minutes and resuspended at a 
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concentration of 3x106 naïve T cells per ml in TcRM. Naïve T cells were recovered overnight 
before use in subsequent processes. 
 
2.7.5. Dead cell removal 
In the culture of adherent cell lines, dead cells are identified as those that float and therefore were 
easily removed with PBS- washes prior to trypsinisation. As this was not possible with suspension 
cells, dead cells were removed via Miltenyi MACS according to the protocol supplied within the 
Dead Cell Removal Kit. Briefly, after collection of cells by centrifugation at 300gmax for 5 minutes, 
the cell pellet was directly resuspended in dead cell removal microbeads (100µl per 107 cells). 
After a 15-minute incubation at RT, the solution was made up to 1ml with dead-cell binding buffer 
and applied to a pre-washed LS MACS column. Dead cells were retained on the column and the 
eluted fraction, containing negatively selected viable cells, was collected. Eluted viable cells were 
counted using the trypan blue exclusion method to determine viability, then subsequently 
centrifuged at 300gmax for 5 minutes and resuspended in appropriate medium for subsequent 
processes. 
 
2.8. MoDC preparation 
The protocol for generation of moDC underwent a series of refinements. The final optimised 
procedure is described below. For standard “slow” DC preparation in 6-well plates, 5x106 isolated 
monocytes were incubated in 2ml DCD1 medium. After 3 days, a further 2ml of DCD1 was added. 
After 6 days of differentiation, iDCs were either harvested or matured for use in subsequent 
processes. Harvesting was performed by vigorous trituration, first in incubation media and then 
with cold PBS to remove any remaining adherent cells. Cells were counted, 105 cells were 
allocated for time zero phenotyping as described in section 2.18, and remaining cells were 
washed in complete RPMI and resuspended in relevant medium for subsequent processes. 
Maturation was induced by addition of DCM1 or DCM2 media for a further two days. At day 8, 
mDC were harvested as previously described for iDC. For ‘fast’ DC, the duration of monocyte 
differentiation ranged from 1-3 days in total to yield iDC and the subsequent maturation step 




2.9. In vitro expansion of antigen specific CD8+ T cells 
The HLA-A*02:01 restricted peptides and their concentrations used for in vitro stimulation of T 




Antigen	 Peptide	Designation	 aa	Sequence	 Concentration	(μg/ml)	
CD20	 CD20188-196	 SLFLGILSV	 10	
CMV	pp65	Protein	 CMVpp65495-504	 NLVPMVATV	 50	
EGFR	 EGFR479-488	 KLFGTSGQKT	 10	
	 EGFR1138-1147	 YLNTVQPTCV	 5	
Influenza	A	Matrix	Protein-I	 Flu-A58-66	 GILGFVFTL	 50	





2.9.1. In vitro expansion of HLA-A*02:01-restricted antigen-specific CD8+ T cells from the 
naïve repertoire in healthy donors  
Several protocols have been described for in vitro expansion of antigen specific CD8+ T cells from 
the naïve population. All involve the following steps: selection of APC; APC antigen loading; 
selection, prime and re-stimulation of responder T cells; and screening for antigen specificity. The 
protocols vary greatly in terms of media, cytokine use, cell ratios and duration of stimulation (as 

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Purified CD8+ naïve T cells from HLA-A*02+ healthy donors were stimulated with autologous, 
peptide-pulsed DC. iDC were incubated for 16 hours in DCM3 supplemented with peptides at 2.5 
µg/ml (v/v). The peptide pulsed DC were then washed once with CellGro and resuspended at a 
concentration of 5x105/ml in TcSM0. Recovered CD8+ naive T cells were resuspended in TcSM0 at 
a concentration of 2x106. Equal volumes of the T-cell and DC suspensions were combined to give 
a final T-cell:DC ratio of 4:1 and 2ml of this suspension was added to multiple wells of a 24-well 
plate on day zero and incubated. On day 3, 500µl of TcSM1 was added to each well. On day 6, T 
cells were harvested by gentle trituration, leaving behind the majority of adherent DC. Contents 
were transferred to 12 well plates, where a further 1ml of TcSM1 was added. On day 8, wells were 
again harvested as described on day 6. Contents were transferred to 6-well plates where a further 
2ml of TcSM2 was added. Peptide-stimulated T cells were harvested on days 10-12 and screened 
for antigen specificity via MHC-multimer staining (as described in section 2.18.3) prior to 
cryopreservation. Frozen antigen specific T cells were thawed and added directly to co-culture 
assays as required. 
 
2.9.2. In vitro expansion of HLA-A*02:01-restricted CD8+ T cells from cancer patients 
A single in vitro stimulation was employed, using a protocol adapted from the study by Andrade 
Filho et al 282, because cell numbers from patient samples were limited. Thawed patient cells were 
allocated at 2x106 PBMC per well (24 well plate) for each condition, in the presence of IL7 at a 
final concentration of 10ng/ml. Peptides were added to respective wells at a final concentration of 
5-10µg/ml. IL-2 was added to a final concentration of 25U/ml on days 3 and 6. On day 10, 
cultures were harvested and screened for antigen specificity. 
For samples with very low cell numbers, a pool of peptides was used in a single culture instead of 
multiple cultures testing individual peptides. When pools were used, peptide concentrations were 
adjusted so that high affinity binders were present at lower concentrations than low affinity binders 
to ensure that all peptides were present at equivalent densities.  
 
2.9.3. HLA-A*02:01 peptide binding assay using T2 cells 
In order to assess the relative binding capacity of peptides to HLA-A*02:01, 5x105 T2 cells were 
cultured for 18 hours in complete RPMI with various concentrations of the peptides (0.1 - 20 
µg/ml). T2 cells were then screened for surface expression of HLA-A*02 by flow cytometry as 
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described (section 2.18.1). The HLA-A*02 binding scores were calculated using median 
fluorescence intensity (MFI) as follows: 
	 𝑇2 𝐵𝑖𝑛𝑑𝑖𝑛𝑔 𝑆𝑐𝑜𝑟𝑒 =  𝑀𝐹𝐼 [𝑇2 + 𝑃𝑒𝑝𝑡𝑖𝑑𝑒]𝑀𝐹𝐼 𝑇2 𝐴𝑙𝑜𝑛𝑒  
	
The T2 binding scores were used to adjust the concentration of individual peptides so that all 
peptides were likely to be presented by HLA-A*02 at equivalent densities when peptide pools 
were used to stimulate T cells. 
 
2.10. Genomic DNA extraction 
Total genomic DNA was extracted from either whole blood (WB) or PBMC samples using the 
QIAamp DNA Blood Mini Kit (Qiagen - Manchester, UK) according to the manufacturer’s protocol. 
Briefly, 200µl of whole blood or PBMC suspension containing 106-107 cells was lysed in the 
presence of a protease to release the cell contents and remove protein contamination. The DNA 
was then bound to the silica membrane of the mini column via centrifugation in the presence of 
the organic solvent ethanol and high concentrations of chaotropic salt. The salt dehydrates the 
negatively charged DNA and decreases the negative surface charge density of the silica, thereby 
permitting binding by reducing electrostatic repulsion. Remaining contaminants and enzyme 
inhibitors were removed via two wash steps and the DNA was then eluted in a low salt TE buffer. 
The process of solid phase DNA extraction has been described in detail by Vandeventer et al 
(2012) 283. 
 
2.11. DNA quantification and purity assessment 
DNA concentration and purity was assessed using a NanoDrop spectrophotometer (Thermo 
Scientific, UK). DNA absorbs UV light at 260 and 280 nanometres (nm), while proteins containing 
aromatic amino acids absorb UV light at 280 nm. Pure DNA has an A260/A280 ratio of 1.8 or 
greater indicating that the preparation is relatively free from protein contamination. DNA that is 
contaminated with protein has an A260/A280 ratio lower than 1.8. At a concentration of 1mg/ml 
and with a 1cm path length, double stranded DNA (dsDNA) has an absorption at 260nm of 50 




2.12. CD16 genotyping 
A real-time PCR based approach was employed for CD16 genotyping. The assay utilised allele 
specific probes that have a fluorophore and a quencher linked to the 5’ and 3’ ends respectively. 
When the probe is intact, the quencher remains in close proximity to the fluorophore, eliminating 
its signal. However, when the probe binds to DNA it is degraded by the 5’-nuclease activity of Taq 
polymerase, thereby separating the fluorophore from the quencher molecule and generating a 
detectable signal 284. The assay was conducted according to the protocol supplied with the 
TaqMan SNP Genotyping Assay C__25815666_10 corresponding to SNP id: rs396991 
(Invitrogen - Paisley, UK). Briefly, genomic DNA was isolated as described in section 2.10 and 
diluted to a concentration of 0.555µg/ml. Reaction mixtures were then prepared in fast PCR 
reaction plates according to Table 2.7 The PCR was performed using a StepOnePlusTM real-time-
PCR unit (Applied Biosystems - Paisley, UK) according to the thermal cycling conditions detailed 
in Table 2.8. Substituting the test sample with molecular biology grade water served as a negative 
“no target” control (ran in triplicate) and samples of known genotype were included as positive 






Reagent Volume (µl) 
Genotyping Mix 0.5 
TaqMan Master Mix 5 
Test Sample 4.5* 








Temperature (°C) Time (seconds) Cycles 









Donor	 HLA-A*02	Status	 CD16	Genotype	 	 Donor	 HLA-A*02	Status	 CD16	Genotype	
LC44	 Negative	 V/F	 	 LC98	 POSITIVE	 F/F	
LC45	 POSITIVE	 F/F	 	 LC99	 Negative	 F/F	
LC46	 Negative	 F/F	 	 LC100	 POSITIVE	 V/F	
LC47	 Negative	 V/V	 	 LC101	 Negative	 F/F	
LC48	 Negative	 V/F	 	 LC102	 POSITIVE	 V/F	
LC49	 Negative	 V/V	 	 LC103	 POSITIVE	 V/F	
LC53	 Negative	 F/F	 	 LC104	 Negative	 V/F	
LC54	 POSITIVE	 V/V	 	 LC105	 POSITIVE	 V/F	
LC55	 POSITIVE	 V/V	 	 LC116	 POSITIVE	 V/F	
LC56	 Negative	 F/F	 	 LC117	 POSITIVE	 V/F	
LC60	 Negative	 F/F	 	 LC118	 POSITIVE	 F/F	
LC63	 Negative	 V/F	 	 LC119	 Negative	 F/F	
LC64	 Negative	 V/F	 	 LC120	 POSITIVE	 F/F	
LC65	 POSITIVE	 V/F	 	 LC121	 Negative	 F/F	
LC67	 POSITIVE	 V/F	 	 LC122	 Negative	 F/F	
LC94	 Negative	 V/F	 	 LC123	 POSITIVE	 F/F	
LC96	 POSITIVE	 F/F	 	 LC124	 Negative	 V/F	
LC97	 POSITIVE	 F/F	 	 	 Total	Donors	 35	
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2.13. Plasmid expression vectors 
Variants of the A431 and H1299 cell lines expressing MelanA protein (hereafter referred to as 
A431MelanA and H1299MelanA) were produced by transfection with a plasmid expression vector 
encoding MelanA. The plasmid comprised the full length MelanA gene fused to green 
fluorescence protein (GFP) gene via a short, inert DNA sequence encoding a self-cleaving 
peptide known as a P2A (described in detail by Kim et al, 2011 285). In addition to the 
MelanA/GFP fusion gene insert, the plasmid also contained a cytomegalovirus (CMV) promoter 
for driving expression MelanA/GFP, a puromycin resistance gene placed downstream of an 
internal ribosome entry site (IRES) and a prokaryotic kanamycin resistance gene. The “MelanA” 
plasmid, descriptively named CMV-MelanA.P2A.eGFP-IRES-Puro was 6515 nucleotide base 
pairs (bp) in length and produced A431MelanA and H1299MelanA transfected cells. Expression of the 
puromycin resistance gene was used to select transfected cells. GFP expression by transfected 
cells was used as an indirect measure of likely expression of MelanA. A “Control” plasmid with an 
insert containing the P2A and GFP DNA sequences but no MelanA gene was also synthesised 
(6164 bp in length) and designated CMV-P2A.eGFP-IRES-Puro; producing A431CTRL and 
H1299CTRL transfected cells. Dr David Darling and Dr Richard Beswick (KCL - London, UK) kindly 
helped with advice for vector design and codon optimisation. Insert DNA was synthesised and 
cloned into the NcoI/XbaI restriction sites of the ready-made OG317 vector by Oxford Genetics 
(Oxford, UK). The DNA sequences of the plasmid expression vectors can be found in the 























2.14. E. coli transformation and maxi-prep 
E. coli C2988J DH5α cells were purchased from New England Biolabs (NEB - Hitchin, UK) and 
stored at -80°C. The CaCl2 treatment of these bacterial cells produces competent cells that will 
uptake DNA after a heat shock 286. To transform a 50µl suspension of C2988J, cells were thawed 
on ice in a sterile 1.5ml capped microfuge tube and inoculated with 200pg of plasmid DNA. After a 
30 minute incubation on ice, the mixture was heated for 1 minute at 42°C to disrupt the bacterial 
cell membrane, allowing the DNA to enter. The mixture was then placed back on ice. After a 
minimum of 1 minute, to allow for retention of the plasmids inside the bacteria, 950µl of super 
optimal broth with catabolite repression (SOC) medium was added to the transformed bacteria. 
The tube was then placed horizontally in a shaking incubator (Cole-Parmer, UK) for 1 hour at 
37°C and 225 revolutions per minute (rpm). Each transformation mixture was then centrifuged at 
500gmax. The pellet was resuspend in residual SOC medium and this volume was spread on pre-
warmed LB agar plates, then incubated overnight at 37°C. 
The following day, 1-3 well-spaced single, kanamycin resistant bacterial colonies were selected 
for expansion in sterile 500ml flasks containing 200ml LB medium supplemented with 30µg/ml 
kanamycin. Flasks were placed in a shaking incubator overnight at 37°C and 225rpm. Plasmid 
DNA was isolated using the QIAamp HiSpeed Plasmid Maxi Kit with a protocol similar to the 
genomic DNA extraction described in section 2.10 but scaled up for a larger column. Plasmid 
DNA was subsequently quantified and purity checked as described section 2.11. 
 
2.15. Tumour cell transfection 
Transfection is the process by which genetic material is introduced into cells 287. Tumour cells 
were transfected with plasmid DNA using the Biontex K2 transfection system according to the 
manufacturer’s protocol. Briefly, A431 or H1299 cells were seeded in complete RPMI in multiple 
wells of a 6-well plate. Cells were monitored until an optimum confluence of 70-80% was 
achieved with the cells in exponential growth phase (typically seen the day after seeding). Media 
was then removed and replaced with 2ml of complete RPMI supplemented with 9µl/ml K2 
multiplier reagent for a minimum of 2 hours pre-transfection. Plasmid DNA and K2 transfection 
reagent were combined for 20 minutes in serum/antibiotic free RPMI at a ratio of 0.5µg/µl 
respectively in order to form lipid complexes. This “lipoplex” mixture was then applied to the pre-
treated cells and gently swilled. After 24 hours, transfection medium was replaced with fresh 
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complete RPMI. After 48 hours, cells were either exposed to puromycin or harvested for 
subsequent processes. Puromycin was administered in complete RPMI at a pre-determined killing 
concentration for each cell line, enabling enrichment of transfected puromycin resistant cells and 
removal of untransfected cells. Harvested cells were sorted by FACS based on GFPHIGH 
expression and subsequently screened for intracellular expression of MelanA or used in co-
culture assays. 
 
2.16. Co-culture assays 
Final optimised procedures are described below with any refinements detailed in the results 
section. All assays were conducted in V-bottomed plates in complete RPMI with a 200µl total 
volume. Cultures were incubated at 37°C in 5% CO2.  
 
2.16.1. NK-cell activation 
This assay was designed to measure ADCC activation of NK cells in the presence of therapeutic 
mAbs and as such comprised two cell types, tumour cells and NK cells as illustrated in Figure 3.1. 
Recovered NK cells (2.5x104) were incubated with viable tumour cells at a 1:1 ratio in the 
presence or absence of mAbs at various concentrations. NK cells alone for the duration of the 
assay served as a negative control and 10ng/ml PMA with 1µg/ml ionomycin (PMA/Ionomycin) 
was used to activate NK cells for a positive control. After 6-18 hours of co-culture, cells were 
washed with 200µl PBS+, pelleted by centrifugation at 300gmax for 5 minutes and phenotyped as 
described in section 2.18.  
 
When intracellular cytokine staining (ICS) was performed, CD107a antibody was added for the 
duration of the incubation at 5µl per well. After one hour, the protein transport inhibitor brefeldin A 
(BFA) was added to a final concentration of 10µg/ml and incubated for a further 5 hours. BFA 
blocked intracellular protein transport such that cytokines accumulated in the rough ER to a level 
detectable by intracellular staining, as described by Nylander and Kalies 288. NK cells alone for the 
duration of the assay served as a negative control and NK cells activated with 1µl/well leukocyte 
activation cocktail (LAC) were used as a positive control. LAC contains the phorbol ester phorbol 
12-myristate 13-acetate (PMA), a calcium ionophore (Ionomycin) and the protein transport 




2.16.2. Tumour cell apoptosis 
This assay was designed to measure the induction of tumour cell apoptosis and as such 
comprised two cell types, tumour cells and NK cells as illustrated in Figure 3.1. Recovered NK 
cells (2.5x104) were incubated with either mAbs alone at various concentrations or at a 1:1 ratio 
with viable JY cells plus mAbs at various concentrations. Some assays were performed in the 
presence of physiologic concentrations of total IgG (5µg/ml). JY cells alone for the duration of the 
assay served as a negative control and a (v/v) combination of Actinomycin D (10µM), 
Camptothecin (2µM), Cycloheximide (0.1mM), Dexamethasone (10µM) and Etoposide (0.1mM) 
were used to induce JY apoptosis for a positive control (provided in the CalTag apoptosis Inducer 
set). After incubation intervals of 3, 6 and 9 hours, cells were pelleted by centrifugation at 300gmax 
for 5 minutes and phenotyped as described in section 2.18.4. 
 
2.16.3. NK:DC crosstalk 
This assay was designed to measure the effect of ADCC activated NK cells on iDC and thus 
comprised three cell types, tumour cells, NK cells and iDC as illustrated in Figure 4.5. Recovered 
NK cells were incubated with autologous iDC and allogeneic tumour cell lines at a 1:1:1 ratio in 
the presence or absence of mAbs at various concentrations. ‘iDC alone’ and ‘iDC with tumour 
cells plus mAb’ for the duration of the assay served as negative controls. DC matured with DCM1 
medium served as a positive control. After co-culture durations of 18-48 hours, cells were 
phenotyped as described in section 2.18. 
 
2.16.4. T-cell activation: cross presentation of tumour antigen to CD8+ T cells 
This assay was designed to generate tumour antigen by ADCC activated NK-cell lysis of tumour 
cells and assess cross presentation by DC to TA-specific T cells, based on measurement of T-cell 
activation. The assay utilised HLA-A*02- A431MelanA as the tumour antigen source and autologous 
HLA-A*02+ recovered NK cells, DC and MelanAT cells, incubated at 1:1:1:4 ratio for 18 hours, as 
depicted in Figure 5.7. MelanAT cells alone for the duration of the assay served as an unstimulated 
negative control. MelanAT cells incubated with EGFR peptide pulsed DC served as an irrelevant 
stimulus negative control. MelanAT cells incubated with MelanADC, SK-MEL-30 or PMA/Ionomycin 




2.17. Phagocytosis assay 
This assay was designed to assess the uptake by DC of tumour-cell derived particulate antigen 
generated by apoptosis of tumour cells. The assay exploited the properties of pHrodo-SE, a pH-
sensitive fluorescent dye that enables detection of engulfed apoptotic cells due to increased post-
phagocytic light emission 289. 
 
2.17.1. Labelling of apoptotic tumour cells with pHrodo-SE 
After removal of dead cells, viable JY were resuspended at 106 cells/ml in either complete RPMI 
or complete RPMI supplemented with 10µg/ml GA101-GE to induce apoptosis. After 16 hours, 
cells were washed twice with PBS-, pelleted by centrifugation at 300gmax for 5 minutes and 
resuspended in PBS- at 106 cells/ml. pHrodo-SE was added to a final concentration of 1µg/ml. 
After incubation for 30 minutes in the dark at RT cells were washed twice with complete RPMI 
and resuspended at 0.5x106 cells/ml in complete RPMI. 
 
2.17.2. Uptake of tumour cell particulate by DC 
Harvested iDC were resuspended at 0.5x106 cells/ml in complete RPMI and incubated with 
pHrodo-SE labelled viable or apoptotic JY cells at 1:1 ratio for 1, 2 or 3 hours in a 96 well V-
bottomed plate in a 200µl total volume and protected from light. After incubation, cells were 
washed and resuspended in 100µl FACS buffer with 5µl of CD11c FITC added to each well to 
label DC. After incubation for 30 minutes at 4°C, cells were washed with PBS+, pelleted by 
centrifugation at 300gmax for 5 minutes and resuspended in 125µl PBS+.  
 
2.17.3. Slide preparation 
The cell suspension was applied to the chamber of an assembled cell concentrator (Thermofisher 
Scientific - Basingstoke, UK), illustrated in Figure 2.2. The concentrator was placed in the Statspin 
Cytofuge® II (Beckman Coulter - High Wycombe, UK) and centrifuged at 55gmax for 5 minutes 290. 
The supernatant was then aspirated and after washing gently with 200µl PBS+, cells were fixed to 
the slide by adding 200µl of 3% formaldehyde solution to the central chamber at RT, protected 
from light. After 15 minutes, formaldehyde was aspirated, the slide was washed gently with 200µl 
PBS+ and the cells were then permeabilised with 0.1% triton solution. After 5 minutes, the triton 
was aspirated, cells were washed and 150µl of DAPI solution was added to the central chamber 
at RT, protected from light. After a further 5 minutes, slides were washed with 200µl PBS+ and 
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coverslips were applied with mounting media. The labelled slides were immediately refrigerated 
and visualised by microscopy within 72 hours. 
 
The Statspin Cytofuge® II, cell concentrators, mounting media, triton and DAPI solutions were 







2.17.4. Fluorescent microscopy  
Internalisation of tumour-cell particulate was visualised using the Nikon A1R confocal microscope 
at the KCL Nikon Imaging Centre (NIC – London, UK). All images were captured at 60x 
magnification (oil immersion objective) with a display resolution of 1024 pixels or greater, and 
where 10 or more DC occupied the focal plane. Three images were taken per slide. Files were 
saved in nd2 format and analysis performed using the NIS elements viewer, version 4.0 (Nikon 
Instruments - Europe) and ImageJ (National Institutes of Health - Maryland, USA). The 
percentage of DC showing phagocytic activity was calculated as follows: 
 Number of DC containing ≥ 1 phagocyte(s)Total number of DC in focal plane  x 100 
 









2.18. Phenotyping of cells 
Phenotyping was typically performed in a 96 well V-bottomed plate protected from light, using 
2.5x104-1x106 cells labelled with fluorochrome-conjugated antibodies at titrated or manufacturer-
recommended concentrations. Phenotyping antibody cocktails are detailed in Table 2.10 and 
labelling protocols are described below. 
 
2.18.1. Cell surface staining 
Cells were washed in 200µl PBS+ to remove serum, pelleted by centrifugation at 300gmax for 5 
minutes and stained with a fixable viability dye (diluted in 100µl PBS+) for 20 minutes at 4°C. 
Without washing, cells were then counter stained with a phenotyping antibody cocktail at 4°C. 
After a further 30 minutes, cells were pelleted by centrifugation at 300gmax for 5 minutes, washed 
in 200µl PBS+. and pelleted. Cells were resuspended in 100-300µl PBS+ and transferred to round-
bottom 12x75mm polystyrene test tubes for immediate analysis by flow cytometry. If analysed at a 
later time, cells were fixed in 100-300µl 1% PFA and refrigerated at 4°C. Fixed cells were 
analysed within 72 hours. 
 
2.18.2. Intracellular staining 
If required, cells were first stained for surface markers (as described above), then washed and 
fixed in 100µl BD cytofix solution at 4°C. After 20 minutes, 100µl PBS+ was added before 
centrifugation at 300gmax for 5 minutes. Cell pellets were resuspended in 100µl of 1x BD cytoperm 
solution at 4°C. After 20 minutes, 100µl 1x BD cytoperm solution was added before centrifugation 
at 300gmax for 5 minutes. Cell pellets were then resuspended in either an intracellular cytokine 
staining (ICS) antibody cocktail or with primary then secondary antibody cocktails, for 30 minutes 
at 4°C. Cells were subsequently washed in 200µl PBS+, resuspended in either PBS+ or 1% PFA 
and transferred to tubes for analysis. 
 
2.18.3. MHC multimer staining 
Cells were incubated at RT with 10µl of pentamer in 50µl FACS buffer. After 10 minutes, cells 
were centrifuged at 300gmax for 5 minutes, washed with 200µl PBS+ and surface staining 







                                                       
e Volumes per test were determined by titration  
f Live/Dead viability dye diluted 1:1000 in PBS. 100µl of this solution added to cells. 
g Intracellular cytokines screened after fixative/permeation step. Detailed in section 2.18.2. 




	 	 	 	







	 	 	 	
	 	 	 	
NK-cell	activation	ICSg	 IFNγ	FITC	 4S.B3	 5	
	 TNFα	AF700	 MAb11	 5	
	 CD107a	APC	 H4A3	 5	
	 CD16	APC-H7	 3G8	 0.5	
	 CD3	PB	 UCHT1	 2	
	 Live/Dead	Aqua	 -	 0.1	
	 CD56	PE	 HCD56	 2	
	 	 	 	
	 	 	 	






	 	 	 	
	 	 	 	
T-cell	activation		 CD69	FITC	 L78	 5	
	 CD8	PerCP/Cy5.5	 RPAT8	 5	
	 CD137	APC	 4B4-1	 5	
	 CD71	APC-Cy7	 CY1G4	 5	
	 Live/Dead	Violet	 -	 0.1	
	 Multimer	PE	 -	 10	
	 CD3	PECy7	 SK7	 5	
	 	 	 	
	 	 	 	
T-cell	activation	ICS		 IFNγ	FITC	 4S.B3	 5	
	 CD8	PerCP/Cy5.5	 RPAT8	 5	
	 Live/Dead	Violet	 -	 0.1	
	 Multimer	PE	 -	 10	
	 CD3	PECy7	 SK7	 5	
	 	 	 	
	 	 	 	
Apoptosis	 CD20	PB	 2H7	 5	
	 Annexin	V	FITC	 -	 5	
	 PI	 -	 10	
	 Binding	Buffer	 -	 80	
	 	 	 	








	 2°	-	Goat	anti	Rabbit	AF647	 -	 0.2h	
	 	 	 	
	 	 	 	
Other	phenotyping	 HLA-A*02	PE	 BB7.2	 5	
	 EGFR	PE	 AY13	 5	
	 CD20	PE	 2H7	 5	
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2.18.4. Apoptosis assay staining 
Pelleted cells were resuspended at RT in 100µl of apoptosis phenotyping antibody cocktail. 
Experimental samples were numbered in the order they were to be analysed by flow cytometry, 
stained chronologically at one-minute intervals and immediately transferred to tubes. When all 20 
samples had been stained, analysis was performed chronologically at one-minute intervals. This 
ensured that each sample was exposed to propidium iodide (PI) for the same length of time (20 
minutes).  
 
2.19. Flow cytometry 
Flow cytometry was used to assess and quantify expression of cell surface and intracellular 
markers. Flow cytometry was also used to sort and retrieve cells, based on marker expression. 
Analysis was performed using either a BD FACSCantoII™, BD LSRFortessa™ or BD FACSAria™ 
flow cytometer with associated FACSDiva™ software, version 6.0 or above (BD Biosciences, 
Oxford, UK). 
 
2.19.1. Instrument setup 
Mahnke and Roederer (2007) provide comprehensive guidance on cytometry instrument set-up 
and experimental validation, which was followed closely 292. Cytometer Setup and Tracking beads 
(CST - BD Biosciences, UK) were run once a week to monitor instrument performance. 
Automated compensation was conducted using either UltraComp or CompBeadPLUS antibody 
capture beads with the purpose of establishing corrections for the spectral overlaps in 
fluorochrome combinations. The compensation beads were labelled with the same fluorochrome-
conjugated antibody used for experimental samples. The positive signal for the compensation 
sample was always at least as bright as the corresponding signal for the fluorochrome in the test 
sample. At least 10,000 live cells were acquired for phenotyping. Raw data files were exported 
and analysed using FlowJo cytometric analytical software (TreeStar Inc. Ashland, OR), version 
9.6.4 or above. 
 
2.19.2. Controls for analysis 
In a widely cited article, Maecker and Trotter (2006) detail considerations for the control of 
background fluorescence in flow cytometry 293. They present a set of recommendations that 
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enable users to develop optimized cell labelling protocols that minimize background and 
maximize the ability to reliably distinguish between positive and negative cell populations. Of their 
crucial criteria, foremost was the inclusion of viability dyes, which are essential for removing dead 
cells that will non-specifically uptake antibodies and auto-fluoresce. 
 
They suggest that fluorescence minus-one (FMO) controls are more relevant than isotype 
controls for gating cells in the context of data spread due to the multiple fluorochromes in a 
phenotyping panel 293. FMOs are samples that are stained with all antibody conjugates present in 
test samples, except one. The channel of the omitted antibody is the one for which the FMO 
provides a gating control (as illustrated in figures 3.6, 3.7 and 4.8). 
 
Maecker and Trotter were careful to state that the best control for a marker stimulated in vitro is 
an unstimulated control sample, stained with the same antibodies as the test sample. They 
emphasised that an unstimulated control is far more relevant and appropriate than an isotype or 
FMO control and advised that measurements of positivity or upregulation should always be 
relative to these. Their recommendations were echoed and adopted by McLaughlin et al, who 
sought to formulate consensus guidelines for FACS analysis of clinical samples across multiple 
instruments 294. As such, FMOs were included in all preliminary studies and viability dyes and 
unstimulated or unactivated reference samples were included in all experiments. 
 
2.20. Statistical analysis 
A professional statistician, Dr Alessandra Bisquera (KCL - London, UK) was consulted regarding 
statistical analysis. All data were analysed and plotted using GraphPad Prism® software, version 
5 (GraphPad Software - California, USA). No assumptions were made about the distribution of 
data. Significance was calculated using the non-parametric Wilcoxon signed-rank test when 
considering two paired parameters. For comparison of three or more paired parameters, overall 
significance was first evaluated via Friedman’s analysis of variance (ANOVA) with Dunn’s multiple 
comparison post-hoc 295. As is appropriate for data that is ranked and non-Gaussian, data are 





Chapter 3. Results I: Glyco-engineered monoclonal antibodies 
induce NK-cell activation and function associated with 
promoting adaptive cellular immunity 
 
3.1. Introduction 
Previous studies have reported that GE-mAbs possess enhanced ability to induce ADCC. Gerdes 
et al (2013) showed that imgatuzumab exhibits superior in vitro ADCC activity compared to 
cetuximab. The increased ADDC translated into superior in vivo anti-tumour activity that was 
evaluated using a human tumour xenograft mouse model 205. Similarly, Mössner et al (2010) 
showed that GA101GE has augmented in vitro ADCC activity relative to rituximab 232. These 
studies suggest that GE-mAbs may be more effective than antibodies with already proven clinical 
benefit.  
 
A property of GE-mAbs that has not yet been assessed is their ability to promote anti-tumour 
cellular immunity.  To this end, the first stage of this study aimed to determine whether GE-mAbs 
activate NK cells and induce functions necessary for stimulation of adaptive immunity. This 
required establishing the two-cell in vitro co-culture model depicted in Figure 3.1. The model was 
designed with potential to add other cell types in mind, so that subsequent analyses could be 
undertaken to assess the ability of GE-mAb-activated NK cells to promote DC maturation and 
cross presentation of antigen to TA-specific CD8+ T cells. The previous in vitro studies of GE-mAb 
ADCC activity were performed using the human NK-cell line NK-92 205 or human PBMC 232 as 
effectors, with a primary focus on measurement of tumour cell death. No evaluation of NK-cell 
activation or function, other than lytic activity, was performed. In this study, purified primary NK 
cells from healthy donors were used and a flow-cytometry based readout developed to assess 
NK-cell activity based on expression of the activation marker CD69, downregulation of CD16, 
degranulation (CD107a) and production of TNFα and IFNγ. This combination of markers has 
previously been used by the Ferris laboratory to study activation of NK cells by cetuximab and 




The objective of the studies described in this chapter was to assess whether GE-mAbs induce 
activation of NK cells and functions required for promotion of adaptive cellular immunity. Previous 
studies of GE-mAbs have compared their efficacy with clinically utilised mAbs at equivalent 
concentrations, with the rationale that a more efficacious drug could potentially replace the current 
standard of care 205, 232, 238, 263, 297. In keeping with this precedent, imgatuzumab was compared 
with the clinically utilised anti-EGFR mAb cetuximab at equivalent concentrations, and GA101GE 
was compared with the clinically utilised anti-CD20 mAb rituximab. These comparator mAbs, 
however, have different epitope specificities to the GE-mAbs. Therefore, to assess any impact of 
the GE modification per se on efficacy, GA101GE was compared to the unmodified counterpart 






3.2. In vitro assessment of NK-cell activation: co-culture components 
with anti-EGFR mAbs 
3.2.1. EGFR+ tumour cell line: A431 
EGFR is typically overexpressed in solid tumours of epithelial origin. The A431 cell line was 
chosen for use in the EGFR in vitro model due to pathophysiological similarities with epithelial 
carcinomas and because other groups have previously reported successful use of A431 cells to 
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study anti-EGFR mAbs 205, 238. Surface expression of EGFR by A431 cells was confirmed by flow 









3.2.2. NK cells 
NK cells were isolated from healthy donor PBMC by negative selection using antibody conjugated 
magnetic microbeads. Previous studies have used CD16 as a biomarker for potential clinical 
response to therapeutic mAbs and correlated CD16 genotype with prognosis 209 210, 255. Therefore, 
PBMC from 35 healthy donors were screened for the FCRγIIIa polymorphism (V158F) that yields 
the low (F/F) and high (V/V) affinity variants of CD16, in order to correlate CD16 genotype with 





Genotype Frequency (%) 
V/V (High) 11.1 
V/F 41.7 










3.2.3. NK-cell phenotyping and gating strategy 
The NK-cell phenotyping panel was designed to achieve clear segregation of NK cells within a 
mixed population and to include markers for phenotypic identification of NK cells and 
measurement of NK-cell activation. Markers of NK-cell activation were selected based on use in 
previously published studies. The most frequent indicators of NK-cell activation used are 
upregulated expression of the secreted cytokines IFNγ and TNFα, and the surface markers CD69 
and CD107a 71, 172, and reduced surface expression of CD16 298. 
 
The sequential NK-cell gating strategy is illustrated in Figure 3.3. After exclusion of doublets, 
debris and dead cells, lymphocytes were separated into quadrants containing permutations of 













































The co-culture model was ultimately to be used for assessment of NK:DC crosstalk. Therefore, 
NK cells were purified from PBMC via Miltenyi MACS because it was important that no other 
effector lymphocytes were present. Negative selection was chosen to minimise any engagement 
of NK-cell surface receptors that could lead to NK-cell activation. For ten independent 
experiments, the average NK-cell isolation purity was 97.1% +/- 1.1% standard deviation (sd). 











Purified NK cells were stimulated for 6 hours with PMA/Ionomycin to demonstrate that they were 
capable of activation and function. The most informative NK-cell markers are summarised in 
Table 3.2. The markers NKp44, NKG2D and HLA-DR were also evaluated, but showed only 
modest modulation after stimulation. This was consistent with previously published work 299 and 




























Figure 3.5 depicts the expression of these activation markers on unstimulated NK cells (panel A) 
and stimulated NK cells (panel B), with a histogram overlay for comparison of fluorescence (panel 
C). As described in section 2.19, FMO controls were used to define background fluorescence for 
each of the NK-cell activation markers and the FMO gating strategy is illustrated in Figures 3.6 








NK	cells	were	gated	 to	determine	 the	baseline	percentage	of	 cells	expressing	activation	markers;	 these	gates	were	























































PE	 -	 CD56	 CD56	
PE/Cy7	 -	 CD3	 CD3	
APC-H7	 -	 -	 CD16	
FITC	 -	 CD69	 CD69	
Aqua	 -	 Live/Dead	 Live/Dead	
A	

























PE	 -	 CD56	 CD56	
PE/Cy7	 -	 CD3	 CD3	
APC-H7	 -	 CD16	 CD16	
FITC	 -	 -	 CD69	













fluorochrome-conjugated	 antibodies	 except	 IFNγ-FITC	 (panel	 A),	 TNFα-AF700	 (panel	 B)	 or	 CD107a-APC	 (panel	 C).	
Gating	boundaries	were	determined	for	FMO	stained	NK	cells	(dotted	blue	line).	Unstained	NK-cell	gating	boundaries	
are	also	shown	(dotted	pink	line).	Representative	example	of	n=2	independent	experiments.	 	

























PE	 -	 CD56	 CD56	
PB	 -	 CD3	 CD3	
APC-H7	 -	 CD16	 CD16	
FITC	 -	 -	 IFNγ	
AF700	 -	 TNFα	 TNFα	
APC	 -	 CD107a	 CD107a	
Aqua	 -	 Live/Dead	 Live/Dead	
A	


































PE	 -	 CD56	 CD56	
PB	 -	 CD3	 CD3	
APC-H7	 -	 CD16	 CD16	
FITC	 -	 IFNγ	 IFNγ	
AF700	 -	 -	 TNFα	
APC	 -	 CD107a	 CD107a	
Aqua	 -	 Live/Dead	 Live/Dead	
B	





















PE	 -	 CD56	 CD56	
PB	 -	 CD3	 CD3	
APC-H7	 -	 CD16	 CD16	
FITC	 -	 IFNγ	 IFNγ	
AF700	 -	 TNFα	 TNFα	
APC	 -	 -	 CD107a	




3.3. In vitro assessment of NK-cell activation: preliminary co-cultures 
with anti-EGFR mAbs 
To assess ADCC-mediated activation, NK cells were incubated with A431 tumour target cells at 
1:1 ratio, with or without anti-EGFR mAbs at 10µg/ml. Preliminary co-cultures were performed for 
48 hours and utilised NK cells immediately after MACS isolation. The cell ratio, assay duration 
and mAb concentrations were based on studies previously reported by the Ferris laboratory 97, 240. 
Cell numbers were based on those used for the clinical trial in vitro studies of patient samples, 
discussed in section 1.12.4 and these studies had also used mAbs at a concentration of 10µg/ml. 
Notably each of the cell types used in the co-cultures had individual preparation requirements. 





Condition Preparation Notes Medium 
NK-cell MACS negatively selected NK cells (Straight ex vivo - NO recovery) - 
A431 tumour cell Seeded night before assay DMEM (with 2% hAB) a 
Assay details 96-well flat bottom RPMI (with 2% hAB) a 
Assay duration 48 hours b 
Cell ratio | Cell number  (1:1 ratio) b | 105 of each cell type c 








3.3.1. Positive and negative controls for assessment of NK-cell activation 
NK cells stimulated with PMA/Ionomycin were used as a positive control for NK-cell activation 
compared to freshly isolated NK cells; and are referred to in figures as [NK POSITIVE CONTROL] 
and [NK TIME ZERO] respectively. As a negative control, NK cells alone for the duration of the 
assay were included to assess the level of spontaneous NK-cell activation; referred to in figures 




3.3.2. Preliminary results showed high levels of spontaneous NK-cell activation 
Results presented in Figure 3.8 show that all NK cells in the negative control exhibited substantial 
downregulation of CD16 and upregulated expression of CD69 compared to NK cells at time zero, 
indicative of spontaneous activation. When the two-cell co-culture was conducted in the presence 
of imgatuzumab (10µg/ml), the modulation of NK-cell activation markers did not surpass the high 










3.4. In vitro assessment of NK-cell activation: optimisation of co-
cultures with anti-EGFR mAbs to reduce spontaneous NK-cell 
activation 
A series of assay refinements were undertaken to reduce spontaneous activation of NK cells. 
Optimisation of the two-cell co-culture was undertaken in conjunction with the three-cell co-culture 
optimisation described in Chapter 4 (section 4.6). The refinements relevant to NK-cell activation 








3.4.1. NK-cell recovery prior to co-culture 
There is a precedent in published literature to use NK cells after a period of recovery in low dose 
IL-2. This has been shown to improve NK-cell viability and also to induce uniformly 
higher expression levels of CD56 and CD16 when compared to non-recovered NK cells 
(comprehensively examined by Bryceson et al, 2006) 302. In light of this, an NK-cell recovery 
period was introduced, comprising 16-hour incubation in complete RPMI supplemented with 
50U/ml IL-2. The decision to recover the NK cells and the IL-2 concentration was also based on 
our previous experience of analysing samples from clinical trial patients that showed recovery of 
viable NK cells for use in functional assays was improved by incubation of thawed PBMC in 
50U/ml IL-2 for 16 hours prior to assay. Recovering NK cells prior to use in co-culture achieved a 
reduction in spontaneous NK-cell activation as illustrated in Figure 3.9.  
 
3.4.2. Media standardisation and removal of human AB serum 
Although inclusion of 2% v/v hAB serum was the initial choice to avoid xenoactivation of effector 
cells, it came to light that hAB serum contains a high concentration of TGFβ (personal 
communication from Professor Giovanna Lombardi, KCL); an immunosuppressive cytokine 
known to negatively affect NK-cell function 136. Additionally, it was observed that A431 cells 
contracted in size and lost their typical uniform monolayer when grown in DMEM supplemented 
with 2% hAB serum. Therefore, the media used in all cell preparations was standardised so that 
cells were not subjected to the shock and potential stimulatory effects of a media change when 
combined for co-culture. The in vitro maintenance of the A431 cell line and recovery of NK cells 
were all performed in complete RPMI (with relevant supplementation) and this media 
standardisation achieved a reduction in spontaneous NK-cell activation as illustrated in Figure 
3.9. 
 
3.4.3. Shorter co-culture durations and reduction of cell numbers 
The 48-hour co-culture duration was reduced to 18 hours for assessment of surface activation 
markers and 6 hours for assessment of functional activation markers. The shorter intervals were 
sufficient to detect NK-cell activation with a lower level of spontaneous activation, as illustrated in 
Figure 3.9 A, in addition to a reduction in NK-cell death (3.9 B). Cell numbers were decreased 
from 105 of each type to 2.5x104 of each type while the co-culture volume, mAb concentration and 
1:1 cell ratio were maintained. The lower cell numbers allowed for more economical use of limited 
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donor material, without undue compromise to the flow cytometry results obtained (data from a 
minimum of 10,000 events was always collected). The cumulative effect of refinements detailed in 
sections 3.4.1 - 3.4.3 substantially reduced spontaneous NK-cell activation as illustrated in Figure 
































































3.4.4. Imgatuzumab induces activation of NK cells 
Using the optimised two-cell co-culture assay, the abilities of imgatuzumab and cetuximab to 
activate NK cells were assessed. The results are displayed in Figure 3.10 and show the 
expression of the NK-cell activation marker CD69 induced by the anti-EGFR mAbs at a range of 
concentrations between 10µg/ml and 0.1ng/ml, relative to the NK-cell negative control. 
Imgatuzumab was found to induce expression of CD69 by NK cells. Cetuximab also induced NK-
cell activation, consistent with other previously published reports 96, 97, 263. At mAb concentrations 
of 100ng/ml and above, imgatuzumab and cetuximab induced similar levels of CD69 expression 
by NK cells. Notably, imgatuzumab activated NK cells to a greater extent than cetuximab at the 
lower concentrations of 10ng/ml and 1ng/ml. An objective during development and evaluation of 
therapeutic mAbs is to determine the minimum effective dose, often referred to as the minimum 
anticipated biological effect level (MABEL), because use of the lowest efficacious dose may help 







Figure	3.10.	 Imgatuzumab	 induces	 expression	of	 the	activation	marker	CD69	by	NK	 cells	 and	 to	 a	 greater	 extent	
than	cetuximab	at	the	lower	mAb	concentrations	
2.5x104	 recovered	NK	 cells	were	 incubated	 either	 alone	 or	 at	 1:1	 ratio	with	 A431	 tumour	 cells	 in	 the	 presence	 or	
absence	of	mAbs	at	0.1,	1,	10,	100,	1,000	and	10,000ng/ml.	After	18	hours	of	co-culture,	NK	cells	were	screened	for	

































































Condition Preparation Notes Medium a 
NK-cell 
Negatively selected NK cells isolated 
by magnetic cell separation and 
recovered for 16 hours 
NKRM 
A431 tumour cell Seeded 4 hours before assay Complete RPMI 
Assay details 96-well v-bottom Complete RPMI 
Assay duration 18 hours  
Cell ratio | Cell number  (1:1 ratio) | 2.5x104 of each cell type  





3.5. Comparison of NK-cell activation and function induced by the 
anti-EGFR mAbs imgatuzumab or cetuximab 
3.5.1. Imgatuzumab promotes changes in expression of NK-cell surface activation markers 
to a greater extent than cetuximab at low mAb concentrations 
Using the optimised two-cell co-culture conditions summarised in Table 3.4, NK cells isolated 
from 6 healthy donors were incubated with A431 cells in the presence of the anti-EGFR mAbs at 
equivalent concentrations, followed by measurement of expression of the surface activation 
markers CD16 and CD69. These experiments included an important negative control condition of 
NK cells incubated with A431 without mAb to assess the potential for allogeneic activation of NK 
cells by the HLA class I mismatched A431 cells. North et al demonstrated that allogeneic tumour 
cells could activate NK cells. These tumour-activated NK (TANK) cells displayed levels of NCR 
killing akin to those observed with IL2 activated NK cells 299. In light of this, positive activation 
gates were set using the allogeneic control and applied to all other conditions. The only difference 
between the allogeneic control and the test conditions was the presence of mAb, and therefore 
represents a more appropriate negative control than NK cells alone. This gating strategy ensured 
that activation reported was above any potential allogeneic activation (although none was seen in 
experiments reported here). 
 
Results are presented in Figure 3.11. CD16 expression by NK cells was significantly 
downregulated by imgatuzumab, but not by cetuximab. The median frequency of CD16+ NK cells 
was 77.5% for NK cells co-cultured with A431, 75.5% for NK cells co-cultured with A431 plus the 
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negative control IgG2 mAb panitumumab at 1ng/ml and similarly 71.4% for NK cells co-cultured 
with A431 plus cetuximab at 1ng/ml (Figure 3.11 A). In contrast, imgatuzumab at 1ng/ml induced 
a 2.6-fold reduction of CD16+ NK cells to 30.3% (p <0.05). The NK cells that remained CD16+ in 
the co-culture containing imgatuzumab expressed significantly lower levels of CD16 compared to 
expression levels on CD16+ NK cells in the co-culture containing cetuximab (p <0.05) (Figure 3.11 
B).  
 
CD69 expression by NK cells was significantly upregulated by imgatuzumab, but not by 
cetuximab.  The median frequency of CD69+ NK cells was 1.1% for NK cells co-cultured with 
A431, 10.9% for NK cells co-cultured with A431 plus panitumumab at 1ng/ml and 10.5% for NK 
cells co-cultured with A431 plus cetuximab at 1ng/ml (Figure 3.11 C). In contrast, imgatuzumab 
induced a 32-fold increase of CD69+ NK cells to 34.9% (p <0.05). The NK cells that became 
CD69+ in the co-culture containing imgatuzumab expressed a significantly higher intensity of 
CD69 compared to expression levels on CD69+ NK cells in the co-culture containing cetuximab (p 
<0.05) (Figure 3.11 D).  
 
The mAbs were also tested at 10ng/ml and a similar trend was observed for both NK-cell surface 
activation markers (Figure 3.11). Although this was not significant for the frequencies of CD16+ 
and CD69+ NK cells, the NK cells that became CD69+ in the presence of 10ng/ml imgatuzumab 
compared to cetuximab expressed a significantly higher intensity of CD69 (p <0.05). These 
results show that imgatuzumab promoted downregulation of CD16 and increased expression of 
CD69 by NK cells at low mAb concentrations, whereas cetuximab did not consistently activate NK 
cells at low concentrations. The mAbs used in these experiments had been quantified via 
spectrophotometry (Table 2.2, Materials and Methods) to ensure differences observed could be 










































































































































3.5.2. Imgatuzumab promotes changes in expression of NK-cell surface activation markers 
to a greater extent than cetuximab when target cells express low levels of EGFR    
Expression of EGFR by primary tumours is heterogeneous and at lower levels than the A431 cell 
line, which expresses uniformly high levels of EGFR 305. Therefore, it was important to assess the 
impact of EGFR cell surface expression on mAb mediated NK-cell activation. Assays were 
performed using the transfected H1299 cell line from which three ΔEGFR stable sub-lines were 
selected that expressed a range EGFR levels, designated EGFRLOW, EGFRMEDIUM and EGFRHIGH, 
as depicted in Figure 3.12. 6-hour assays were conducted using mAbs at 10ng/ml; probing 
expression of NK-cell surface activation markers CD16 and CD69. The use of isogenic 
transfected cells meant that any variation in induced NK-cell activation was likely the result of 








These experiments included the negative control conditions of NK cells incubated with EGFRLOW, 
EGFRMEDIUM or EGFRHIGH without mAb, to assess the potential for allogeneic activation of NK 
cells by the HLA class I mismatched ΔEGFR cells and the gating strategy ensured that activation 








these experiments, cetuximab exhibited some ability to promote NK-cell activation, but 
imgatuzumab was superior at all target cell EGFR expression levels.  
The median frequency of CD16+ NK cells was 72.6% for NK cells co-cultured with EGFRLOW 
target cells alone and similarly 67.6% for NK cells co-cultured with EGFRLOW plus panitumumab. 
The CD16+ frequency decreased to 47.4% for NK cells co-cultured with EGFRLOW plus cetuximab, 
but decreased furthermore to 28.4% in the presence of imgatuzumab (p <0.05). This represented 
a median 1.5- and 2.6-fold decrease in CD16 expression induced by cetuximab and imgatuzumab 
respectively, relative to the control. Although the same trend was observed using EGFRMEDIUM and 
EGFRHIGH target cells, these results were not significant, as illustrated in Figure 3.13 A. The 
median fold change in activation marker expression compared to control is summarised in Table 
3.5. 
 
The median frequency of CD69+ NK cells was 1.1% when co-cultured with EGFRLOW target cells 
alone and similarly 1% when co-cultured with EGFRLOW plus panitumumab. The CD69+ frequency 
increased to 9.4% for NK cells co-cultured with EGFRLOW plus cetuximab, but increased 
furthermore to 11.6% in the presence of imgatuzumab (p <0.05). This represented a median 8.5 
and 10.5-fold increase in the CD69 expression induced by cetuximab and imgatuzumab 
respectively, relative to the control. Like CD16, this finding was not observed with the use of 
EGFRMEDIUM and EGFRHIGH target cells. There were no statistical differences between the 
cetuximab or imgatuzumab induced CD69+ NK-cell frequencies as illustrated in Figure 3.13 B, nor 
the median fold change as summarised in Table 3.5. 
 
Of note, higher levels of EGFR expression by target cells correlated with greater NK-cell 
activation. For imgatuzumab, the median fold change in CD16+ NK-cell frequency rose from 2.6 to 
5.2 when using EGFRLOW and EGFRHIGH target cells respectively and the median fold change in 
CD69+ NK-cell frequency rose from 10.5 to 15.1 when using EGFRLOW and EGFRHIGH target cells 
respectively. Since the mAb concentration was kept constant across all EGFR intensities it is 
reasonable to assert that the level of NK-cell activation is also dependent on antigen density, a 










































































































































PAN	 CETUX	 IMGAT	 PAN	 CETUX	 IMGAT	 PAN	 CETUX	 IMGAT	
%CD16+	 1.1	 1.5	 2.6*	 1.1	 2.1	 2.6	 0.99	 2.7	 5.2	






It was intended that all experiments conducted with A431 would be reproduced with H1299 cells. 
Unfortunately this was not possible as H1299 clones became infected with mycoplasma and 
attempts to rescue were unsuccessful. 
 
3.5.3. Imgatuzumab promotes NK-cell function to a greater extent than cetuximab 
Comparison of the promotion of NK-cell function by imgatuzumab and cetuximab anti-EGFR 
mAbs was performed using NK cells isolated from 7 healthy donors. Recovered NK cells were 
incubated with A431 cells in the presence of mAbs at 10ng/ml for 6 hours, followed by 
measurement of NK-cell function based on expression of CD107a and production of IFNγ and 
TNFα. These experiments included the condition of NK cells incubated with A431 without mAbs, 
to control for potential allogeneic NK-cell activation. The results are presented in Figure 3.14. For 
all NK-cell function markers, no NK-cell activation was detected in the test condition of NK cells 
incubated with A431 and panitumumab, consistent with the limited ability of the IgG2 mAb to 
recruit NK cells for ADCC (the effector recruitment capabilities of antibody isotypes is reviewed by 
Vidarsson et al 124). Incubation of NK cells with K562 cells increased the frequency of CD107a+, 
IFNγ+, TNFα+ and IFNγ+TNFα+ NK cells to medians of 20.8%, 6.1%, 7.3% and 4.2% respectively, 
consistent with NK-cell activation induced by CD16-independent killing mechanisms. 
 
Comparison of median percentage positive showed that imgatuzumab consistently mediated 
significantly greater NK-cell functional activity than cetuximab (p <0.05). The median CD107a+ 
NK-cell frequency increased significantly from 30.2% in the presence of cetuximAb to 46.8% with 
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imgatuzumab. Similarly, the median IFNγ+ frequency rose significantly from 9.2% to 16.8%, 
TNFα+ from 9.4% to 15% and IFNγ+TNFα+ from 3.1% to 6.3%. The superiority observed with 












































































































































































































3.5.4. Imgatuzumab promotes NK-cell function to a greater extent than cetuximab in the 
context of all CD16 genotypes 
The V158F FCγRIIIa (CD16) polymorphism encoding V/V high affinity homozygotes has 
previously been correlated with improved survival in cetuximab-treated HNSCC patients when 
compared to F/F low affinity homozygotes 97. The NK-cell function experiment described in 
section 1.5.3 included donors with all possible CD16 genotypes. In Figure 3.15, these results 
have been segregated according to donor CD16 genotype (CD16 low affinity (F/F), high affinity 
(V/V) and heterozygote (V/F) donors). At equivalent concentration, imgatuzumab promoted better 
NK-cell functional activity than cetuximab, specifically using NK cells from donors that were 
homozygous for the low affinity CD16 genotype. Unfortunately the cohort of NK-cell donors used 











experiments	 (n=7).	CD16	 low	affinity	 (F/F),	high	affinity	 (V/V)	and	heterozygote	 (V/F)	donors	are	highlighted	 in	 red,	
blue	and	black	respectively.	
 	

























































































































3.6. Comparison of NK-cell activation and function induced by the 
glyco-engineered anti-CD20 mAb GA101GE or unmodified 
equivalent GA101WT 
The ability of a GE-mAb to induce NK-cell activity and function was also assessed for the 
antibody target CD20, which is exploited for the treatment of B-cell malignancies. Both the GE-
modified anti-CD20 drug obinituzumab (GA101GE) and the unmodified wild type counterpart 
GA101WT were available for study, enabling evaluation of the impact of the GE-modification per 
se. In keeping with the precedent to compare efficacy of GE-mAbs to clinically utilised mAbs set 
by previously reported studies 205, 232, 238, 263, 297, the widely used anti-CD20 therapeutic mAb 
rituximab was also studied. 
The material transfer agreement between Roche Glycart and King’s College London for use of 
GA101GE and GA101WT was only obtained towards the end of the research project. Therefore, 
due to limited time, it was not possible to perform all the two-cell in vitro co-culture experiments to 
evaluate NK-cell activity and function that were previously undertaken with the anti-EGFR mAbs. 
 
3.6.1. CD20+ tumour cell line: JY 
The TA CD20 is a surface marker expressed by B cells. The Epstein-Barr virus immortalised 
lymphoblastoid B-cell line JY was used in the CD20 in vitro model. Surface expression of CD20 
by JY cells was confirmed by flow cytometry, with the A431 cell line used as a negative control. 









3.6.2. GA101GE promotes changes in expression of NK-cell surface activation markers to a 
greater extent than GA101WT 
The two-cell, 18-hour co-culture assay was performed to assess NK-cell activation in the 
presence of the anti-CD20 mAbs rituximab, GA101WT and GA101GE, using CD20+ JY tumour 
target cells co-cultured with recovered NK cells isolated from 6 healthy donors. The mAbs were 
tested at concentrations of 10ng/ml and 1ng/ml. Experiments included the negative control 
condition of NK cells incubated with JY only, to assess the potential for allogeneic activation of NK 
cells by the HLA class I mismatched JY cells. Gates set using the JY allogeneic control were 
applied to all other conditions, ensuring that reported activation was above any potential 
allogeneic activation. 
 
Results displayed in Figure 3.17 show that the glyco-engineered mAb GA101GE promoted 
changes in expression of NK-cell surface markers indicative of activation. Moreover, GA101GE 
induced changes to a significantly greater extent than GA101WT at both concentrations tested, 
indicating that the GE modification enhances activity. The median percentage of CD16+ NK cells 
was reduced to 53.3% with GA101GE compared to 73% with GA101WT at 1ng/ml; 2.7% and 
64% respectively at 10ng/ml (p <0.05). Also, the remaining CD16+ NK cells had significantly lower 
levels of CD16 expression with GA101GE compared to GA101WT at both concentrations (p 







significantly increased to 23.2% with GA101GE compared to 6.1% with GA101WT at 1ng/ml; 
42.8% and 22.7% respectively at 10ng/ml. However, the induced CD69+ NK cells attained similar 
levels of expression at both concentrations. Notably the median percentage of CD69+ NK cells 
was significantly higher with 10ng/ml GA101GE (42.8%) compared to 1ng/ml GA101GE (23.2%). 
The increase in mAb concentration correlated with the increase in NK-cell activation, suggesting 
that the level of activation induced by ADCC is also dependent on mAb concentration; supporting 
previous findings by Derer et al 306. Additionally, at the lower concentration of 1ng/ml, a 
significantly greater level of activation was induced with GA101GE compared to GA101WT for 
both activation markers (p <0.05). The mAbs used in these experiments had been quantified by 
spectrophotometry (Table 2.2) to ensure differences observed could be attributed to properties of 
the mAbs, not differences in concentration. Rituximab promoted little or no change in expression 












Figure	 3.17.	 GA101GE	 promotes	 changes	 in	 expression	 of	 NK-cell	 surface	 activation	 markers	 to	 a	 significantly	
greater	extent	than	GA101WT	at	equivalent	concentration	
2.5x104	 recovered	 NK	 cells	 were	 incubated	 at	 1:1	 ratio	with	 JY	 tumour	 target	 cells	 in	 the	 presence	 or	 absence	 of	
rituximab,	 GA101WT	 or	 GA101GE	 (1ng/ml	 and	 10ng/ml).	 Cells	 were	 co-cultured	 for	 18	 hours.	 Graphs	 depict	 CD3-
CD56+CD16+	NK-cell	frequency	(A)	and	MFI	(B)	and	CD3-CD56+CD69+	NK-cell	frequency	(C)	and	MFI	(D),	with	median	











































































































3.6.3. GA101GE promotes NK-cell function to a greater extent than GA101WT 
Comparison of the promotion of NK-cell function by GA101GE and GA101WT anti-CD20 mAbs 
was performed using NK cells isolated from 8 healthy donors. Recovered NK cells were incubated 
with JY cells in the presence of mAbs at 10ng/ml for 6 hours, followed by measurement of NK-cell 
function based on expression of CD107a and production of IFNγ and TNFα. These experiments 
included the condition of NK cells incubated with JY without mAbs, to control for potential 
allogeneic NK-cell activation. 
 
The results presented in Figure 3.18 show that GA101GE consistently mediated significantly 
greater NK-cell functional activity than GA101WT (p <0.05). The median CD107a+ NK-cell 
frequency increased significantly from 20.4% in the presence of GA101WT to 35.5% with 
GA101GE. Similarly, the median IFNγ+ frequency rose significantly from 20.7% to 46.5%, TNFα+ 
from 14.4% to 29.8% and IFNγ+TNFα+ from 15.9% to 32.2%. Rituximab did not promote NK-cell 
function at the concentrations tested. The superiority observed with GA101GE over GA101WT 
was reproducible for NK cells from all donors across all markers of NK-cell function assessed. 
These findings indicate that the GE modification significantly improves the ability of the mAb to 














Figure	 3.18.	 GA101GE	 promotes	 NK-cell	 function	 to	 a	 significantly	 greater	 extent	 than	 GA101WT	 at	 equivalent	
concentration	
2.5x104	 recovered	 NK	 cells	 were	 incubated	 at	 1:1	 ratio	with	 JY	 tumour	 target	 cells	 in	 the	 presence	 or	 absence	 of	
rituximab,	GA101WT	or	GA101GE	 (10ng/ml).	 Cells	were	 co-cultured	 for	 6	 hours	with	 addition	 of	 BFA	 after	 1	 hour.	
























































































































































































































































3.6.4. GA101GE promotes tumour cell apoptosis to a greater extent than GA101WT 
Stimulation of TA-specific CD8+ T cell immunity as a consequence of ADCC activity by mAbs 
requires that they induce apoptotic death of tumour cells, thereby releasing TA for phagocytosis 
by DC.  The next step, therefore, was to assess whether the NK-cell activity induced by GE-mAbs 
resulted in apoptosis of tumour cells.   
 
Apoptotic cells undergo multiple microcellular rearrangements including cellular condensation, 
redistribution of specific organelles into peripheral membrane protrusions or “blebs” and the 
exposure of apoptosis-specific structures on the cell membrane such as, phosphotidyl serine (PS) 
307, 308. AnnexinV is an intracellular protein that binds to PS with high affinity and can be used as a 
sensitive marker to identify early apoptotic cells that possess PS on the cell surface. Early 
apoptotic cells exclude viability dyes such as propidium iodide (PI) whilst the loss of membrane 
integrity observed in late-stage apoptotic and necrotic cells allows passage of these dyes into the 
nucleus where they bind DNA. The combination of a viability dye such as PI and annexin V can 
be used to identify early apoptotic and late apoptotic/necrotic populations. Viable cells are 
considered AnnexinV-PI-; early apoptotic cells are AnnexinV+PI-; and late apoptotic/necrotic cells 
are AnnexinV+PI+. A single observation of double positive cells is not sufficient to conclude 
apoptosis as the mode of cell death, rather, when apoptosis is measured over time or over a 
range of drug killing concentrations, the cells can be tracked through the three stages 308, 309, 310. 
 
Induction of apoptotic cell death was measured in the anti-CD20 mAb setting using the JY tumour 
cell line. The activity of GA101GE was assessed and compared to the unmodified GA101WT to 
evaluate any impact of the GE-modification per se. The anti-CD20 therapeutic mAb rituximab was 
also studied. An assessment of target cell apoptosis induction using the anti-EGFR mAbs could 
not be performed because the EGFR+ tumour cell line A431 is adherent, requiring trypsinisation 
that made the cells permeable to PI. Recovered NK cells from 4-6 healthy donors were incubated 
with JY tumour cells for 3, 6 and 9 hours in the presence of the anti-CD20 mAbs at 10ng/ml, 
100ng/ml and 1000ng/ml. The three-hour assay was also conducted in the presence of 
physiologic concentrations of competing non-specific total human IgG (5mg/ml) as this was used 
for some of the GE-mAb mediated tumour killing assays reported by Gerdes et al 205. 
 
































































































As negative controls, JY cells were incubated alone without mAbs to assess spontaneous 
apoptosis (Figure 3.20A), or in the presence of NK cells (1:1 ratio) without mAbs, to assess 
apoptosis induced by NK-cell allorecognition of JY cells (Figure 3.20B). As a positive control, JY 
cells were exposed to a combination of apoptosis inducing agents - 10µM actinomycin D, 2µM 












Results presented in Figure 3.21 show that the glyco-engineered mAb was able to promote NK-
cell mediated apoptotic tumour cell death. Moreover, GA101GE promoted apoptosis to a greater 
extent than unmodified GA101WT, with significant differences observed using mAbs at a 
concentration of 10ng/ml (Figure 3.21 A) and at the 3-hour incubation time (Figure 3.21 B). Under 



























GA101GE (22.6%) compared to GA101WT (16.1%, p <0.05). GA101GE was 1.4-fold more 
efficacious at inducing apoptosis than GA101WT at the same concentration. Rituximab only 
promoted apoptosis of tumour cells at the higher mAb concentrations (100ng/ml and 1µg/ml) and 














Previous studies have reported that the dimerization of CD20 induced by antibody binding is 
sufficient to induce apoptosis, in the absence of ADCC 297, 311, 312  (reviewed by Deans et al, 2002 
313). Therefore, JY cells were incubated with mAbs at 10ng/ml in the absence of NK cells to 
assess CD20 ligation-mediated apoptosis. JY cells alone served as a negative control to assess 
spontaneous apoptosis. Results are displayed in Figure 3.21 C. Spontaneous apoptosis of JY 
cells occurred with a median of 11% at 3 hours rising to 15% at 6 hours and 17% by 9 hours. The 
presence of mAbs at 10ng/ml did not increase the level of tumour-cell apoptosis significantly 
145 
 
above spontaneous apoptosis; suggesting that at a concentration of 10ng/ml mAbs alone were 
not inducing apoptosis in assays reported in this study. 
 
The significantly enhanced efficacy of GA101GE was maintained when apoptosis of tumour cells 
was assessed in the presence of physiologic concentrations of competing nonspecific total human 
IgG (5mg/ml). The results presented in Figure 3.22 show that presence of competing IgG reduced 
mAb-mediated apoptosis of JY cells, but GA101GE still induced a significantly higher percentage 









rituximab,	 GA101WT	 or	 GA101GE	 (10ng/ml).	 Cells	 were	 incubated	 for	 3	 hours	 without	 (A)	 or	 with	 physiologic	




















































The results presented in this chapter demonstrated that GE mAbs induced the NK-cell activation 
and NK-cell function associated with adaptive cellular immunity. This is the first report to describe 
the cytokine and surface marker phenotype of primary NK cells activated by GE-mAb-mediated 
ADCC. Previous studies have used NK cell lines as effectors 205, and assessed ability to lyse 
tumour cells but did not evaluate NK-cell activation and function associated with promoting anti-
tumour adaptive cellular immunity 205, 232, 297. In keeping with the precedent set by these previous 
studies, GE mAbs were compared to clinically utilised mAbs at equivalent concentrations, and 
shown to promote NK-cell activity to a greater extent at low mAb concentrations. 
 
3.7.1. GE-mAbs induce NK-cell activation and functions associated with stimulation of 
adaptive immunity 
 
Activation of NK cells by GE-mAbs was detected in the context of several different parameters of 
NK-cell activity. ADCC-mediated killing of target cells by NK cells can be inferred by measuring 
downregulation of CD16 that occurs after binding of IgG1 298. The GE-mAbs consistently induced 
downregulation of CD16 on NK cells, indicating the ability to promote NK-cell killing of tumour 
cells. GE-mAbs also induced increased cell surface expression of CD69. CD69 is an early 
activation marker that is now considered to be a NCR, following observations that it can initiate 
lytic activity 314.  
 
Assessment of NK-cell activity by measurement of the functional parameters CD107a, IFNγ and 
TNFα also showed the GE-mAbs induced functional activity. CD107a is expressed on lysosomal 
intra-cellular membranes. Presence on the cell surface is indicative of degranulation, and thus 
represents another measure of NK-cell killing activity. Evidence of enhanced production of 
cytokines in the presence of GE-mAbs is important because cytokines promote activity of other 
immune cells, such as DC 74, 301. Assessment of the ability of GE-mAbs to promote DC function 
will be described in the next chapter. Notably, the GE-mAbs increased the frequency of 
polyfunctional NK cells producing both IFNγ and TNFα. Effector cells that produce multiple 
cytokines are associated with more effective immune responses than single cytokine producers 




3.7.2. Imgatuzumab significantly enhances NK-cell activation compared to cetuximab 
When compared with cetuximab, imgatuzumab was found to promote modulation of CD16 and 
CD69, to a significantly greater extent than cetuximab; including when tumour antigen expression 
was low. The finding that a imgatuzumab has significantly better ability to promote NK-cell killing 
at lower antigen densities is important because heterogeneity of tumour antigen expression is 
observed, and studies have cited low antigen expression and downregulation of tumour antigen 
post treatment as reasons for lack of mAb efficacy 305, 317. The augmented performance of a GE-
mAb at low antigen density does, however, warrant caution. In the case of TA such as EGFR, a 
protein expressed at low levels on healthy cells and abnormally high levels on tumour cells, a GE-
mAb may have the potential to cause killing of normal healthy cells. This so called ‘on-target’ but 
‘off-tumour’ reactivity could have life threatening consequences. 
 
Imgatuzumab-activated NK cells upregulated CD107, IFNγ and TNFα to a significantly greater 
extent than cetuximab-activated NK cells. The rationale for glyco-engineering a therapeutic IgG1 
mAb is to circumvent the impact of CD16 genotype on functional efficacy. Although the number of 
donors was insufficient for statistical analysis of each CD16 genotype, imgatuzumab promoted 
superior NK-cell functional activity compared to cetuximab across all functional activation markers 
and for all donors, irrespective of genotype and importantly in the most challenging setting of low 
affinity. Extending the study to include sufficient donors for statistical analysis of each CD16 
genotype is a future consideration. 
 
Statistically significant differences between imgatuzumab and cetuximab were observed at low 
concentrations (1ng/ml and 10ng/ml), and often when imgatuzumab showed activity but 
cetuximab was close to background. These results support the findings of Gerdes et al, who 
measured cell cytotoxicity by quantifying lactose dehydrogenase activity released from 
damaged/dying cells 205 and observed that imgatuzumab exhibited superior in vitro ADCC when 
compared with cetuximab. Gerdes et al titrated mAbs from 1µg/ml to 0.01ng/ml in a number of 
their experiments with A431 or A549 adenocarcinoma cells 205 and 10ng/ml was often the earliest 




In this study, NK-cell activity was indistinguishable at higher mAb concentrations. This 
observation suggests that GE mAbs may have better potential for activity within the tumour milieu 
where mAb concentrations are likely to be much lower than circulating levels in plasma 318, 319, 320. 
Pharmacokinetic studies of patients treated with GE and non-GE mAbs have reported the mean 
peak plasma concentration post single-dose infusion to be around 10µg/ml (personal 
communication from Roche-Glycart and cited elsewhere for cetuximab as ~200ng/ml based on 
standard 400mg/m2 321). By inference, the 1-10ng/ml concentration at which NK-cell activation 
efficacy differed between the imgatuzumab and cetuximab may approximate to the physiologically 
relevant concentration of mAb within tumour lesions. 
 
Undertaking a functional comparison between imgatuzumab and cetuximab calls for caution 
before drawing any conclusions. The binding site of imgatuzumab differs from cetuximab (see 
Table 1.2). Consequently, the superiority of imgatuzumab could also be due to fundamental 
differences in its interactions with the binding site on the EGFR ECD, such as binding orientation 
and membrane proximity. Rigorous comparison, with the objective to identify which variation is 
responsible for which experimental effect would require step-wise assessment, that is, the use of 
GE-cetuximab, such as that created by Yi et al 322 for direct comparison with non-GE cetuximab; 
and the use of GE and non-GE imgatuzumab to evaluate the contribution of glyco-engineering, 
then comparison of equivalent mAb forms to evaluate the benefit of the binding epitope. 
 
Gerdes et al determined the mAb concentration that inhibited the binding of EGF to EGFR by half 
(IC50) for cetuximab and imgatuzumab and both mAbs inhibited EGF binding with an IC50 of 
~0.33nmol/L 205. Treating at equivalent EGF-binding concentrations such as IC50, or at equivalent 
binding affinity are further strategies to normalise each of the mAbs used in this study and should 
be considered in future. 
 
3.7.3. GA101GE induces NK-cell activation to a greater extent than GA101WT 
The epitope limitations mentioned for the anti-EGFR mAb comparisons also apply to the 
comparison of rituximab and GA101GE in the anti-CD20 mAb context; although the inclusion of 
GA101WT has addressed this. Roche Glycart have previously reported that their WT- and GE-
mAbs showed identical antigen binding and pharmacokinetic (PK) properties to their parental 
mAbs; and reason that this is because there are no potential N-linked glycosylation sites within 
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their variable regions 205, 221. This finding that the altered FcγR binding affinity in afucosylated 
mAbs does not alter PK compared to fucosylated mAbs is supported by at least one other study 
323, using FuT8-KO glyco-engineering. Therefore comparing GA101WT and GA101GE allowed 
conclusions to be drawn on the effect of glyco-engineering per se, because these mAbs bind 
identical antigen epitopes. 
 
GA101GE was found to promote the modulation of CD16, CD69, CD107, IFNγ and TNFα to a 
significantly greater extent than GA101WT. Thus, under the conditions described in this study, 
glyco-engineering can enhance NK-cell activation, which has the potential to benefit individuals of 
both low (158F) and high (158V) affinity CD16 genotype 205, 232. 
 
3.7.4. GA101GE promotes apoptotic tumour-cell death to a significantly greater extent than 
GA101WT 
Given one objective of this study was to assess whether GE-mAbs are able to induce adaptive 
immunity, a key assessment of the NK-cell activity promoted by GE-mAbs was measurement of 
the tumour cell apoptosis induced. Blebbing associated with apoptosis is a potent ‘eat me’ signal 
for DC that facilitates cell clearance and crucially could provide DC with tumour antigen for 
presentation to T cells 70.  
 
It is well established that destruction of tumour cells by apoptosis is essential for tumour-cell 
phagocytosis by DC, and that tumour particulate with a higher percentage of apoptotic material is 
preferentially phagocytosed compared to necrotic remnants with a lower proportion of apoptotic 
material 70, 106, 324, 325, 326. The GE-mAb-mediated apoptosis of tumour cells therefore generates 
apoptotic tumour particulate that could potentially be ingested by DC.  
When compared at equivalent concentration, GA101GE was shown to promote a significantly 
higher frequency of NK-cell mediated apoptosis of tumour cells in the same timeframe as 
GA101WT. This effect was maintained in the presence of physiologic concentrations of non-
specific total IgG. Faster induction of apoptosis is important for two reasons. First, the length of 
time that the immune synapse between an NK-cell and its target remains stable can potentially be 
as short as 45 minutes before the NK-cell disassociates to continue serial killing 327. Second, DC 
actively ingest exogenous material, a process which has been shown to occur within 6 minutes for 
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some phagocytes 328. Therefore, by inference, GE-mAbs might augment DC phagocytosis of 
tumour particulate compared to unmodified mAbs.  
 
The choice to use the EGFR+ A431 cell line was justified by its use in previous studies as 
representative of epithelial carcinomas 205, 238. Significant differences between imgatuzumab and 
cetuximab were also seen with an alternative EGFR+ cell line H1299, providing some evidence for 
wider applicability. However, because of the delay in receiving the anti-CD20 mAbs, these 
experiments were conducted with only one CD20+ cell line, JY. Interpretation of results using JY 
may be problematic for the following reasons: 
 
1. JY cells characterised by RNA-seq analysis have been reported to express murine leukaemia 
virus (MuLV) antigens, which Lin et al suggested are potentially immunogenic and a source of 
experimental variation 329. The authors were however careful to indicate that the cells they tested 
were donated 20 years prior to their analysis, undergoing multiple rounds of freeze thawing. They 
analysed a further 3 CD20+ cell lines subsequently purchased from ATCC and compared them in 
parallel to their donated stocks. The purchased cells were MuLV- negative, therefore implicating 
laboratory contamination as the most likely mechanism of infection 329. Although NK cells did not 
appear alloreactive to JY cells in this study, this is nevertheless a cautionary note on fully 
characterising investigative cell lines; which, other than screening for surface expression of the 
antigen of interest and HLA-type, was not done in this study. 
 
2. In addition, JY cells may represent an aggressive subtype of DLBCL-like EBV-driven 
lymphoproliferative disease, in which rituximab has limited efficacy (personal communication with 
Professor Christopher Fegan, Cardiff University). This may explain why experimental results with 
rituximab and JY were essentially negative or close to background. The demonstration that 
GA101GE-induced NK-cell activation exceeded both GA101WT and rituximab in many JY 
experiments suggests that GA101GE has potential to be efficacious even in a wider variety of B-
cell malignancies including those that are rituximab refractory. Notably this in vitro result 
contradicts the initial clinical observations of the GOYA DLBCL study described in section 1.14.2, 
which saw no statistical differences in the efficacy of GA101GE compared to rituximab 258. This 
discord suggests that JY cells may not be suitable for in vitro CD20+ tumour modelling, possibly 
because their uniformly high CD20 expression does not reflect the heterogeneity of CD20 
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expression between and within different lymphoma subtypes as determined by flow cytometry 330, 
thus cannot predict the heterogeneity of a clinical response. Interestingly, subsequent reanalysis 
of GOYA study data by the original investigators identified a new molecular subgroup of DLBCL 
referred to as "strong- germinal center B-cell" (GCB) in almost 25% of patients. This distinct 
subgroup was identifiable by gene expression profiling and characterised by mutations that are 
also commonly identified in FO-lymphoma patients. Strikingly, in the strong-GCB subgroup, 
treatment with G-CHOP conferred substantial clinical benefit over R-CHOP, with PFS of 88% and 
66% respectively 331. Thus the retrospective GOYA data analysis showed some agreement with 
the in vitro results obtained for JY in this study, but mostly served to highlight and reiterate that JY 
cells may represent a distinct rituximab refractory niche. It would be invaluable if PFS in the 
strong-GCB subgroup could be further categorised or correlated with other prognostic markers 
such as CD20 expression. This may help to identify panels of representative cell lines upon which 
pre-clinical work could be modelled. 
 
3. Furthermore, although the GA101GE results detailed in this chapter were significant, related 
studies of anti-CD20 targeted therapies have presented data with more widely used CD20+ cell 
lines such as Daudi 317, 332 and Raji 232, 253, 297, 317 (both derived from Burkitt’s lymphoma). Ideally, 
both established cell lines and recently harvested primary tumour cells should be used to 
reproduce these experiments, to enable comparisons with previous work and to demonstrate 
wider applicability and clinical relevance. 
 





Chapter 4. Results II: Glyco-engineered monoclonal antibodies 




Results presented in the previous chapter demonstrated that GE-mAbs are able to induce the NK-
cell functions required for stimulation of adaptive cellular immunity. In this chapter, analysis of the 
cross-talk of GE-mAb-activated NK cells with DC is described.  
 
The next steps required for priming of TA-specific CD8+ T cells are that tumour particulate 
generated by apoptotic tumour cell death induced by GE-mAbs is phagocytosed by DC and that 
NK-cell activity induces maturation of DC. Tumour particulate taken up by DC is processed to 
generate TA for cross-presentation to CD8+ T cells. DC maturation is characterised by the 
upregulation of co-stimulatory molecules which provide the essential second signal for activation, 
differentiation and proliferation of CD8+ T cells. The GE-mAb-activated NK cells were shown to 
produce IFNγ and TNFα that could potentially induce DC maturation. Furthermore, results 
presented in Figures 3.14 and 3.18 showed that GE-mAbs promote production of IFNγ and TNFα 
by NK cells to a significantly greater extent than non-GE mAbs at equivalent concentrations. 
Therefore, by inference, GE-mAbs may induce DC maturation more than unmodified mAbs.  
 
Visualisation by in vitro fluorescence microscopy of the ability of GE-mAbs to enhance 
monocyte/macrophage and neutrophil-mediated phagocytosis of tumour cells has been reported 
previously 233, 333. Using a similar approach, GE-mAb-dependent phagocytosis by DC was 
evaluated.   
 
The Ferris laboratory has shown that cetuximab-activated NK cells induce DC maturation 96, 97, 263. 
In this study, the ability of GE-mAb-activated NK cells to induce maturation of iDC was explored. 
Comparisons with clinically utilised mAbs at equivalent concentrations were performed, in keeping 
with the precedent to compare efficacy of GE-mAbs to current standard of care set by previously 
reported studies 205, 232, 238, 263, 297. To assess any impact of the GE modification per se on efficacy, 
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where possible GA101GE was compared to the unmodified counterpart GA101WT that is 
otherwise identical.   
 
The objectives of the studies described in this chapter were to assess whether tumour particulate 




4.2. Phagocytosis of tumour particulate by DC 
The phagocytosis of tumour-derived material was examined by co-culture of iDC with apoptotic 
tumour cells. Phagocytosis of tumour particulate by DC was assessed in the context of the anti-
CD20 mAb in vitro co-culture model using JY tumour cells that are grown in suspension. 
Experiments in the context of anti-EGFR mAbs were not performed because the trypsinisation 
required for the adherent tumour cell line A431 before co-culture caused some background 
apoptosis, likely due to the increased permeability of A431 cell membranes after this process. 
 
Detection of DC phagocytosis in vitro requires high concentrations of apoptotic material. The 
enhanced ability of GA101GE to induce apoptosis compared to GA101WT was only evident at a 
concentration of 10ng/ml, however less than 45% of tumour cells underwent apoptosis at these 
low concentrations (Figure 3.21 A and B) and the amount of material generated with 10ng/ml 
GA101GE was insufficient to detect phagocytosis of apoptotic tumour particulate by DC above 
background in this studyi. At the high mAb concentrations required to induce sufficient apoptosis 
of tumour cells for detection, it has been reported previously that anti-CD20 mAb alone induces 
high levels of tumour-cell apoptosis due to dimerization of CD20 stimulating apoptosis, in the 
absence of ADCC 297, 311, 312  (reviewed by Deans et al, 2002 313). The phenomenon of CD20 
ligation-mediated apoptosis by mAb alone was exploited to assess whether phagocytosis of 
tumour particulate by DC could occur in the in vitro co-culture model used in this study.  
 
                                                       
i Triplicates screened: 
n=3 independent experiments with GA101GE at 10ng/ml 
n=2 independent experiments with rituximab at 10ng/ml 
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4.2.1. Assay conditions for assessment of phagocytosis 
The assay used was based on a protocol described by Miksa et al (2009) that exploited the 
properties of pHrodoRed-SE to label cells after apoptosis induction. This pH-sensitive dye 
fluoresces with brighter intensity in acidic environments such as in the DC phagosome and 
enabled detection of engulfed material due to increased post-phagocytic light emission 289. Miksa 
and colleagues induced apoptosis in thymocytes by pre-treating with dexamethasone, labelled the 
apoptotic cells with pHrodoRed-SE and subsequently monitored phagocytosis of the thymocytes 
by monocytes using microscopy. In this study, JY tumour cells were pre-treated with 10µg/ml 
GA101GE for 16 hours to induce high levels of apoptosis, then labelled with pHrodoRed-SE prior 
to addition of iDC for 1-3 hours at 1:1 ratio, followed by counterstaining and visualisation by 
microscopy. 
 
4.2.2. Microscopy: phagocytosis visualisation strategy 
The visualisation strategy employed gave the clearest discrimination of phagocytosed particles. 
The top three panels in Figure 4.1 display iDC labelled with CD11c FITC (green), JY tumour 
particulate labelled with pHrodoRed-SE (red) and a merged image of the same area (left to right). 
The merged image in the bottom right panel incorporated the DAPI nuclear stain (blue) to identify 
intact DC. The enlarged slices view illustrates discrimination of tumour particulate that had been 
engulfed by the DC, with phagocytosis indicated by co-localisation and yellowing, compared to a 
situation where tumour particulate is attached to a DC, but not inside the cell. Figures 4.2 and 4.3 






































4.2.3. Tumour particulate produced by GA101GE treatment is phagocytosed by DC  
Using the visualisation strategy detailed in section 4.2.2, the percentage of pHrodoRed+ DC was 
measured and the results are displayed in Figure 4.4. The assays were performed using iDC from 
four different healthy donors and each condition was tested in triplicate. For two of the donors, 
slides were also prepared at time zero for each condition to confirm that the process of slide 
preparation per se did not produce false positives. No pHrodoRed+ DC were observed at time 
zero. A low percentage of pHrodoRed+ DC was observed after culture with untreated JY cells, 
rising from a median of 0.7% at 1 hour, to 0.9% at 2 hours, and 1.6% at 3 hours. This was 
possibly due to the death of some JY cells as a result of manipulation during assay set up, and 
subsequent phagocytosis by DC. The median percentage of pHrodoRed+ DC in GA101GE pre-
treated JY cells was 12.9%, 15.1% and 14.5% at 1, 2 and 3 hours respectively. The difference 
compared to untreated control JY cells was significant after a 2-hour incubation (*p <0.05) and 
trends were evident at 1 and 3 hours. The results obtained demonstrate that tumour particulate 
generated by GA101GE-mediated apoptosis was phagocytosed by DC. This indicates that a pre-
requisite step for assessment of TA processing by DC and cross presentation to T cells does 














4.3. In vitro assessment of DC maturation 
The ability of GE-mAb-activated NK cells to promote DC maturation was explored by adding 
purified DC to the in vitro co-culture model that was used to assess NK-cell activation. Monocytes 
for DC generation were isolated from the same donor as the NK cells. iDC were incubated with 
NK cells and tumour target cells at 1:1:1 ratio in the presence of mAbs. The three-cell in vitro co-




















































4.4. In vitro assessment of DC maturation: purified DC 
It was important to obtain a pure population of DC for assessment of NK:DC crosstalk in the 
absence of other cell types. There are approximately 13-37 DC per µl in the peripheral blood of 
healthy adults, and numbers can be significantly reduced during infection and chronic disease. 
Thus DC constitute a maximum of just 0.5% of circulating white blood cells (WBC) 334. In addition, 
fresh purified DC isolates lack the characteristic morphology, phenotype, and immunostimulatory 
function of cDC 93. 
 
4.4.1. Monocyte-derived DC 
Because of the low frequency and heterogeneity of DC in peripheral blood, monocyte derived DC 
(moDC) generated ex vivo are often utilised in functional studies. There are many methods for in 
vitro moDC generation, which are comprehensively reviewed by Castiello et al 84. In essence, in 
vitro generation of moDC is a four-step process requiring: 
 
1. PBMC collection via apheresis 
2. Monocyte selection via elutriation, plastic adherence or magnetic bead isolation 
3. Differentiation from CD14+ monocytes to iDC, typically in the presence of: 
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 - serum (either human AB or FBS) 
- various concentrations of IL-4 and GMCSF 
4. Subsequent maturation of iDC, typically using cytokine cocktail combinations 
 
The protocols reviewed by Castiello et al had minor differences in step 3, related to the duration of 
differentiation; but differed most appreciably at step 4, in terms of duration of maturation, 
maturation agent used, and maturation agent concentration. The most frequently used moDC 









4.4.2. Generation of monocyte-derived iDC and mDC 
iDC were generated as described in materials and methods (section 2.8); requiring 6-8 day 
differentiation of monocytes to iDC in the presence of IL-4 and GMCSF. For the subsequent 1-2 
day step yielding mDC, two maturation cocktails were examined. The first utilised a standard, 
more widely used cytokine combination comprising complete RPMI supplemented with 
proinflammatory mediators IL-1β (10ng/ml), IL-6 (1000IU/ml), PGE2 (1µg/ml), and TNFα (10ng/ml) 
adapted from Dauer et al 265. This cocktail is widely referred to as TIP but designated DCM1 in this 
study. The second cocktail, DCM2, utilised a cytokine combination cited by the Ferris group as 
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producing DC with the most efficient cross presentation ability. DCM2 comprised complete RPMI 
supplemented with 25ng/ml IL-1β, 25ng/ml Poly I:C, 5500IU/ml TNFα, 1000IU/ml IFNγ and 
3000IU/ml IFNα 266. 
 
4.4.3. DC phenotyping and gating strategy 
The DC phenotyping panel and gating strategy was developed to achieve clear segregation of DC 
within a mixed population co-culture. The sequential gating strategy for DC is illustrated in Figure 
4.6, where DC were identified as CD11c+HLA-DR+ after exclusion of all other cell populations. The 
DC phenotyping panel also included markers to measure DC maturation. These were selected 
based on studies previously published that demonstrated surface expression of the markers 
CD80, CD83, CD86 and HLA-DR is upregulated upon iDC maturation; with results typically 
reported as a fold increase in median fluorescence intensity (MFI) and/or visually displayed as 
multiple peak overlays 73, 97, 335. Morphology of the monocyte derived iDC and mDC produced is 
shown in Figure 4.7 A, with DCM1 mDC appearing much less adherent than DCM2 mDC. The 
corresponding CD11c+HLA-DR+ phenotype is shown below in Figure 4.7 B. Surface maturation 
marker expression on iDC was compared to mDC using superimposed histograms. A 
representative example of expression of DC maturation markers CD80, CD83, CD86 and HLA-
DR by iDC and both versions of mDC is shown in Figure 4.7 C. DCM1 mDC were chosen as a 
positive control for DC maturation because upregulation of the maturation markers was higher 
and as they were much less adherent than DCM2 mDC, they did not require extensive trituration 
to harvest. As described in section 2.19, FMO controls were used to define background 
fluorescence for each of the DC maturation markers and the FMO gating strategy is illustrated in 
Figure 4.8. Gates were set using the FMO boundaries defined for each of the DC maturation 













































































Figure	 4.7.	 Morphology	 and	 CD11c+HLA-DR+	 phenotype	 of	 monocyte	 derived	 iDC	 and	 mDC.	 Representative	
example	of	expression	of	DC	maturation	markers	CD80,	CD83,	CD86	and	HLA-DR	by	iDC	and	mDC	
Panel	 A	 illustrates	 morphology	 of	 iDC,	 DCM1	 mDC	 and	 DCM2	 mDC	 with	 their	 corresponding	 CD11c+HLA-DR+	






























FMO	controls	were	used	 to	 identify	 and	gate	DC	 in	 the	 context	of	data	 spread	due	 to	 the	multiple	 fluorochromes.	
Compensation	 was	 correctly	 set	 using	 single	 stained	 controls	 and	 105	 mDC	 were	 stained	 as	 shown	 with	 all	
fluorochrome-conjugated	antibodies	except	CD80-PE	 (panel	A),	CD83-PE/Cy7	 (panel	B),	CD86-APC	 (panel	C)	or	HLA-





4.5. In vitro assessment of DC maturation: preliminary co-cultures 
with anti-EGFR mAbs 
To assess whether mAb-mediated activation of NK cells induced DC maturation, iDC were 
incubated with autologous NK cells and A431 tumour target cells at 1:1:1 ratio for 48 hours, with 
or without anti-EGFR mAbs. The cell ratio and assay duration used were those reported by the 
Ferris laboratory 97, 240. Cell numbers and mAb concentrations were based on those used for in 
vitro studies of samples from patients recruited to the clinical trials discussed in section 1.12.4. 
The particulars of the preliminary co-cultures are summarised in Table 4.2. Notably, each of the 





Condition Preparation Notes Medium 
Monocyte source PBMC plastic adherence RPMI 
iDC 6-day monocyte differentiation (to synchronise with mDC) DCD1 (with 2% hAB) 
a
 
mDC 6-day monocyte differentiation +2-day maturation 
DCD1 (with 2% hAB) a 
DCM1 (with 2% hAB) a 
NK Cell MACS negatively selected NK Cells (Straight ex vivo - NO recovery) - 
A431 Tumour Seeded night before assay DMEM (with 2% hAB) a 
Assay Details 96-well flat bottom RPMI (with 2% hAB) a 
Assay Duration 48 hours b 
Cell ratio | Cell number  (1:1:1 ratio) b  | 105 of each cell type c 








4.5.1. Positive and negative controls for assessment of DC maturation 
The positive control for maturation using cocktail DCM1 is referred to in figures as [mDC 
POSITIVE CONTROL]. As a negative control, maturation marker expression on iDC immediately 
post-harvest was compared to iDC cultured alone for the duration of the assay, to assess any 
165 
 
spontaneous maturation in the absence of other cell types and in the absence of mAbs. These 
DC are referred to in figures as [iDC TIME ZERO] and [iDC NEGATIVE CONTROL] respectively. 
Apoptosis of JY cells in the absence of NK cells was induced by epitope ligation with GA101GE 
and was exploited to demonstrate that apoptotic tumour particulate was phagocytosed by iDC 
(Figure 4.4). Studies have demonstrated that DC phagocytosis of tumour particulate containing a 
high proportion of apoptotic material can induce DC maturation 324, 325. Consequently, it was 
important to include a control to assess any maturation of DC in co-culture with tumour cells and 
mAb in the absence of NK cells. This presence and absence of NK cells in test conditions is 
referred to in figures as “+NK’ and ‘NO NK’ respectively. 
 
4.5.2. Preliminary results showed high levels of spontaneous DC maturation 
DC maturation in the absence of stimulus has been observed for in vitro assays and attributed to 
changes in cytokine levels (personal communication with Dr Nathalie van Leeuwen and Dr 
Rebecca Prue - KCL). Preliminary results showed a substantial increase in expression of DC 
maturation markers in the iDC negative control (iDC cultured alone, without mAb) compared to 
iDC at time zero (immediately post-harvest), indicative of spontaneous maturation. This result is 
illustrated in Figure 4.9 using MFI peak overlays. CD86 showed the largest difference between 
iDC and mDC. Indeed, expression levels in the iDC negative control culture exceeded the positive 
control. CD80 and CD83 expression also appeared increased in the iDC negative control 
compared to iDC at time zero. When iDC, NK cells and A431 tumour cells were co-cultured in the 
presence of 10µg/ml imgatuzumab, the increase in expression of DC maturation markers did not 












105	 DC	 post-harvest	 [iDC	 TIME	 ZERO]	 and	 cytokine	 matured	 mDC	 [mDC	 POSITIVE	 CONTROL]	 were	 screened	 for	
expression	of	maturation	markers	CD80,	CD83,	CD86	and	HLA-DR	and	compared	to	iDC	incubated	for	48	hours	either	















4.6. In vitro assessment of DC maturation: optimisation of co-cultures 
with anti-EGFR mAbs reduced spontaneous DC maturation 
A series of assay refinements were undertaken to reduce spontaneous maturation of iDC. 
Optimisation of the three-cell co-culture was undertaken in conjunction with the two-cell co-culture 
optimisation described in Chapter 3 (section 3.4) and details are as follows: 
 
4.6.1. NK-cell recovery prior to co-culture 
NK cells were recovered overnight in complete RPMI supplemented with low dose IL-2, prior to 
use in co-cultures rather than being used immediately after MACS isolation. The overnight 
recovery step minimised spontaneous NK-cell activation (Figure 3.7) and any potential for 
subsequent non-specific DC maturation. 
 
4.6.2. Monocytes purified by magnetic cell separation as the source for moDC 
The population of monocytes used to create moDC were originally obtained by plastic adherence 
of PBMC, but still contained small numbers of contaminating B, T and NK cells after washing. 
Therefore, monocytes isolated from PBMC by MACS rather than plastic adherence were used to 
create moDC for subsequent co-cultures. The MACS CD14+ monocyte population obtained was 
of high purity (average 92.4% +/- 1.4% sd - 3 independent experiments). After differentiation, 
these purified monocytes yielded populations of CD11c+HLA-DR+ iDC with average purities of 
96.5% (+/- 1.2% sd - 3 independent experiments) compared to an average purity of 78% (+/- 
4.2% sd - 3 independent experiments) for pre-optimisation iDC, borne of plastic adhered 
monocytes.  
 
4.6.3. Media standardisation and removal of human AB serum 
Although 2% v/v hAB serum was the initially chosen to avoid xenoactivation of effector cells, 
reported protocols for DC maturation studies typically used 10% FBS 265, 266. The media used in all 
cell preparations was standardised so that cells were not subjected to the shock and potential 
stimulatory effects of a media change when combined for co-culture and also to eliminate the 
detrimental affects of hAB on NK cells and A431 (detailed in section 3.4.2). The generation of 
iDC, in vitro maintenance of the A431 cell line and recovery of NK cells were all performed in 




4.6.4. Reduction of co-culture duration and cell numbers 
An assay duration of 18 hours was selected because there was less spontaneous NK-cell 
activation and NK-cell death (Figure 3.7) as well as less spontaneous DC maturation compared to 







2.5x104	 iDC	 were	 incubated	 either	 alone	 or	 at	 1:1:1	 ratio	 with	 recovered	 NK	 cells	 and	 A431	 tumour	 cells	 in	 the	
presence	 or	 absence	 of	 mAb	 at	 10μg/ml.	 DC	 post-harvest	 [iDC	 TIME	 ZERO]	 were	 screened	 for	 expression	 of	













As detailed in section 3.4.4 (Chapter 3), cell numbers were decreased from 105 of each type to 
2.5x104 of each type (while the co-culture volume, mAb concentration and 1:1:1 cell ratio were 
maintained) to allow for more economical use of limited donor material, without unduly 
compromising the flow cytometry results obtained (data from a minimum of 10,000 events was 
always collected).  
 
4.6.5. Positive control: iDC matured in situ  
Preliminary co-cultures used day 8 mDC as a positive control. For subsequent assays, cocktail 
DCM1 was added to 6-day differentiated iDC directly in the co-culture to ensure that the iDC could 
mature during a shorter assay. Maturation in situ for 18 hours as opposed to 48 hours was still 
sufficient to promote increased expression of all maturation markers (illustrated in Figure 4.10) 
providing a distinct positive control population. 
 
4.6.6. Imgatuzumab induces DC maturation  
The cumulative effect of refinements detailed in sections 4.6.1 - 4.6.5 substantially reduced 
spontaneous DC maturation. Using the optimised assay conditions, the ability of imgatuzumab 
and cetuximab to induce DC maturation was assessed. Imgatuzuamb was found to promote 
expression of the DC maturation marker CD86 to the same extent as cetuximab at the mAb 







2.5x104	 iDC	 were	 incubated	 either	 alone	 or	 at	 1:1:1	 ratio	 with	 recovered	 NK	 cells	 and	 A431	 tumour	 cells	 in	 the	
presence	 or	 absence	 of	 mAb	 at	 10μg/ml.	 DC	 post-harvest	 [iDC	 TIME	 ZERO]	 were	 screened	 for	 expression	 of	




Results presented in chapter 3 showed that, at low concentrations, imgatuzuamb promoted NK-
cell activation and function to a significantly greater extent than cetuximab.  A comparison of the 
ability of imgatuzumab and cetuximab to promote DC maturation at lower concentrations was 
therefore performed. The results are displayed in Figure 4.12 and show the increase in 
expression of the DC maturation marker CD86 induced with mAbs at concentrations between 
10µg/ml and 1ng/ml relative to the iDC negative control. Imgatuzumab was found to promote DC 
maturation to a greater extent than cetuximab at the lower concentrations of 10ng/ml and 1ng/ml. 












Figure	4.12.	 Imgatuzumab	promotes	 increased	expression	of	 the	DC	maturation	marker	CD86	to	a	greater	extent	
than	cetuximab	at	the	lower	mAb	concentrations		




































































4.6.7. Promotion of DC maturation by mAbs is NK-cell dependent 
The mAb ligation of target antigen alone induced phagocytosis of apoptotic tumour particulate by 
DC (Figure 4.4). It was therefore important to assess whether the maturation of DC observed at 
low mAb concentrations was NK-cell dependent. Co-cultures were performed in the absence or 
presence of NK cells, with expression of DC maturation markers compared to the iDC negative 
control. Results presented in Figure 4.13 show that expression of CD80 was only detected when 
NK cells were present. Some upregulation for the maturation markers CD86 and HLA-DR was 
observed in the absence of NK cells (Figure 4.13 panel A), but was substantially higher when NK 
cells were present (Figure 4.13, panel B). Using CD86 as an example, in the presence of 
imgatuzumab the MFI was 191 arbitrary units (arbU) without NK cells and 913 arbU with NK cells; 
this 3.78-fold increase indicated that the DC maturation observed in these co-cultures was 
dependent on the presence of NK cells. The co-cultures without NK cells were included in all 



























Condition Preparation Notes Medium a 
Monocyte source Negatively selected monocytes isolated by magnetic cell separation - 
iDC 6-day monocyte differentiation DCD1 




Negatively selected NK cells isolated 
by magnetic cell separation and 
recovered for 16 hours 
NKRM 
A431 Tumour Seeded 4 hours before assay Complete RPMI 
Assay Details 96-well v-bottom Complete RPMI 
Assay Duration 18 hours  
Cell ratio | Cell number  (1:1:1 ratio) | 2.5x104 of each cell type  





4.7. Comparison of DC maturation induced by the anti-EGFR mAbs 
imgatuzumab and cetuximab 
 
4.7.1. Imgatuzumab-activated NK cells promote DC maturation to a greater extent than 
cetuximab at low mAb concentrations 
Using the optimised three-cell co-culture conditions summarised in Table 4.3, cells isolated from 6 
healthy donors were tested in the DC maturation assay. The effect of mAb-activated NK cells on 
DC are displayed in Figure 4.14 for the DC maturation markers CD80, CD83, CD86 and HLA-DR 
(rows) for all six donors (columns). The histogram overlays depict expression of the DC 
maturation markers for the DC alone negative control compared to DC maturation in the presence 
of mAb-activated NK cells (1ng/ml). For all donors, imgatuzumab consistently induced greater 

















Analysis of two donors was repeated in duplicate to assess intra-donor variability. The expression 
of CD86 is displayed in Figure 4.15 and demonstrates reproducibility of results using a single 
donor in two independent experiments. These results were echoed with all other DC maturation 
markers and at both mAb concentrations. In light of this, the average of the replicates for LC60 
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Statistical analyses were performed using fold change in DC maturation markers relative to the 
iDC negative control instead of absolute values because large variation in expression levels 
between different donor cell sources was observed (illustrated in Figure 4.14). Results for CD80, 
CD86 and HLA-DR are presented as fold change in MFI. Results for CD83 are presented as fold 
change in percentage positive due to a bi-modal expression profile (illustrated in Figure 4.14). The 
DC maturation results for six different donors tested with mAbs at 1ng/ml and 10ng/ml are 


































At the low mAb concentration of 1ng/ml, NK cells activated by cetuximab did not promote 
expression of DC maturation markers above that seen with the non-IgG1 panitumumab control. In 
contrast, imgatuzumab-activated NK cells induced significantly greater fold increase in the 
expression of DC maturation markers CD80, CD83, CD86 and HLA-DR than cetuximab-activated 
NK cells (p <0.05). When no NK cells were present, the same low level of DC maturation was 
observed with imgatuzumab, cetuximab and the panitumumab control. This showed that the DC 
maturation promoted by imgatuzumab was NK-cell mediated. Using CD86 as an example, 
imgatuzumab-activated NK cells induced a median 6-fold increase in MFI whereas median fold 
increase was 2.1 with cetuximab and 1.8 with panitumumab. At 10ng/ml, there was a trend to 
superior efficacy with imgatuzumab-activated NK cells compared to cetuximab, but differences 
were not statistically significant. Overall, there was less DC maturation at 10ng/ml than at 1ng/ml, 










Figure	 4.16.	 Imgatuzumab-activated	 NK	 cells	 promote	 expression	 of	 DC	 maturation	 markers	 to	 a	 significantly	
greater	extent	than	cetuximab	at	1ng/ml	
2.5x104	 iDC	 were	 incubated	 at	 1:1	 ratio	 with	 A431	 tumour	 cells	 and	 panitumumab,	 cetuximab	 or	 imgatuzumab	
(1ng/ml	and	10ng/ml)	in	the	presence	or	absence	of	2.5x104	recovered	NK	cells.	DC	phenotyping	was	performed	after	
18	 hours.	 Results	 shown	 are	 fold	 increase	 in	 (A)	 CD80,	 (B)	 CD86,	 (C)	 HLA-DR	MFI	 and	 fold	 increase	 in	%CD83+	 (D)	
calculated	 compared	 to	 the	 iDC	 negative	 control	 condition.	 Plots	 display	 median	 and	 interquartile	 range	 for	 6	







































































































































































4.8. Comparison of NK-cell activation and function induced by the 
glyco-engineered anti-CD20 mAb GA101GE with the unmodified 
equivalent GA101WT 
The ability of a GE-mAb to induce DC maturation was also assessed in the context of the anti-
CD20 mAb model. In this setting, comparison of GA101GE with GA101WT that share the same 
epitope specificity enabled evaluation of the impact of the GE-modification per se. Rituximab, the 
widely used anti-CD20 therapeutic mAb, was also studied. 
 
4.8.1. GA101GE-activated NK cells promote DC maturation to a greater extent than 
GA101WT at low mAb concentrations 
Akin to the three-cell co-culture assays with anti-EGFR mAbs, cells isolated from 6 different 
healthy donors were studied using mAbs at concentrations of 1ng/ml and 10ng/ml. Experiments 
were performed in duplicate for one donor to confirm intra-donor replicability and the results were 
averaged. The fold changes in expression of the DC maturation markers are shown Figure 4.17. 
 
At low mAb concentrations, neither GA101WT or rituximab promoted DC maturation above the 
background seen in control cultures without NK cells. In contrast, GA101GE induced significantly 
greater fold increases in expression of DC maturation markers at both 1ng/ml and 10 ng/ml 
compared to GA101WT.  At 1ng/ml, CD80 and CD86 MFI, and %CD83+ were significantly higher 
(p <0.05) compared to the non-GE mAbs. Using %CD83+ as an example, GA101GE--activated 
NK cells induced a median 6.3-fold enhancement in CD83 expression compared to 3.2-fold for 
GA101WT and 2.7 for rituximab. At 10ng/ml, CD86 and HLA-DR MFI, and %CD83+ were 
significantly higher (p <0.05) compared to the non-GE mAbs. Using CD86 MFI as an example, 
GA101GE--activated NK cells induced a median 5.2-fold enhancement in CD86 expression 
compared to 3.1-fold for GA101WT and 2.4 for rituximab. Of note, cells from donor LC64 were 
used in the anti-EGFR and anti-CD20 experiments, with superior DC maturation induced by GE-
mAbs in both contexts. When no NK cells were present, the same low level of DC maturation was 
observed with GA101GE, GA101WT and rituximab. This showed that the DC maturation 







Figure	4.17.	GA101GE-activated	NK	 cells	promote	expression	of	DC	maturation	markers	 to	a	 significantly	 greater	
extent	than	GA101WT	at	low	mAb	concentrations	
2.5x104	 iDC	 were	 incubated	 at	 1:1	 ratio	 with	 JY	 tumour	 cells	 and	 rituximab,	 GA101WT	 or	 GA101GE	 (1ng/ml	 and	
10ng/ml)	 in	the	presence	or	absence	of	2.5x104	recovered	NK	cells.	DC	phenotyping	was	performed	after	18	hours.	
Results	 shown	 are	 fold	 increase	 in	 (A)	 CD80,	 (B)	 CD86,	 (C)	HLA-DR	MFI	 and	 fold	 increase	 in	%CD83+	 (D)	 calculated	
















































































































































































The implications of NK:DC crosstalk and adaptive immune responses have been discussed for 
almost two decades, with activated NK cells regarded as pivotal to DC maturation, itself a 
precursor to antigen cross presentation 71, 85, 86, 96, 97, 263. Despite this, it is only relatively recently 
that investigations of T-cell mediated cancer immunity have assessed the impact of mAb-
activated NK cells on DC maturation and TA cross presentation 96, 97, 263, as earlier studies instead 
focussed on DC uptake of mAb-opsonised tumour cells in the absence of ADCC 239, 336.  
 
The results presented in this chapter have demonstrated that GA101GE-coated tumour cells were 
ingested by DC. In addition, this is the first report to demonstrate that GE-mAb-activated NK cells 
can induce DC maturation, which is important for cross presentation. 
 
4.9.1. GA101GE pre-treatment of tumour cells induces tumour phagocytosis 
The 10µg/ml mAb pre-treatment of tumour cells before incubation with DC was intended to 
generate a high amount of apoptotic material. Under these conditions tumour particulate 
generated by GA101GE-mediated apoptosis was phagocytosed by DC to a significantly greater 
extent than untreated tumour cells. Importantly, this occurred without the need for any further 
manipulation of the tumour cells. Dhodapkar et al demonstrated that the coating of myeloma cells 
with the mAb anti-syndecan-I for 30 minutes at 4°C promoted cross presentation of TA to TA-
specific T-cells by DC, in the absence of ADCC. They initially monitored DC uptake of mAb-
coated myeloma cells via flow cytometry. Notably, phagocytosis of untreated or mAb-coated 
tumour cells was not observed. It was found that an additional 30 Gy γ-irradiation step was 
required to observe tumour+DC and once irradiated, both untreated and mAb-coated tumour cells 
were ingested by DC to a similar extent. At a concentration of 1µg/ml, anti-syndecan-I mAb-
binding alone did not induce sufficient tumour-cell apoptosis to elicit measurable phagocytosis 239. 
Considering this point, it is perhaps surprising that untreated cells in this study were ingested by 
DC, albeit at low levels. This is perhaps due to the background level of apoptosis observed in JY 
cultures. Nevertheless, this was an indication that phagocytosis could occur in the co-culture 
model and was measurable, even with untreated tumour material harbouring a low percentage of 
apoptotic cells. Due to time constraints, a decision was taken not to include phagocytosis analysis 
that compared GA101GE and GA101WT mAbs in the presence of NK-cell mediated ADCC, 
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primarily because at the mAb concentrations required to generate large amounts of apoptotic 
material, it was assumed that there would be little measurable difference in apoptotic content of 
cell culture. However including all mAbs in this element of the study is a future consideration. 
 
4.9.2. Imgatuzumab significantly enhances DC maturation compared to cetuximab 
DC maturation was assessed via measurement of CD80, CD83 and CD86 expression. When 
compared to cetuximab, imgatuzumab-activated NK cells induced DC maturation marker 
upregulation to a significantly greater extent than cetuximab. Srivastava et al from the Ferris 
group demonstrated that cetuximab-activated NK cells induce DC maturation to a significantly 
greater extent than panitumumab-activated NK cells, by screening fold change of HLA-DR and 
CD80 expression 97. This study used the same DC maturation markers, cell ratios, readout and 
therapeutic mAbs that were used by the Ferris group, but has extended their observations by 
novel exploration of imgatuzumab. 
At 1ng/ml, only imgatuzumab-activated NK cells induced significant DC maturation and no 
differences were seen between panitumumab and cetuximab. While this trend of imgatuzumab-
induced maturation was reproduced at 10ng/ml, results were not significantly different between 
the mAbs, suggesting that higher mAb concentrations, such as 10µg/ml used by the Ferris group, 
would have shown equivalent DC maturation. 
 
Srivastava et al observed a mean 1.5-fold increase in DC CD80 expression and a mean 1.6-fold 
increase in DC HLA-DR expression induced by 10µg/ml panitumumab-activated NK-cells 
compared to control 97. Interestingly, results in this current study also showed small fold increases 
in DC CD80 and HLA-DR expression induced by panitumumab-activated NK-cells compared to 
control. Although panitumumab lacks the ability to activate NK cells, it did appear to mediate 
downstream DC maturation, albeit low levels; which was also seen by Srivastava et al. 
Panitumumab has been shown to bind the EGFR with an 8-fold greater affinity than cetuximab 337. 
It is possible that panitumumab induced a level of apoptosis in EGFR+ tumour cells that 
subsequently induced a small amount of DC uptake and maturation.  
 
By assessing DC maturation in the presence and absence of NK cells, this study was able to 
demonstrate that the significant level of GE-mAb-mediated DC maturation was NK-cell 
dependent. Srivastava et al did not include control conditions lacking NK cells, they did however 
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show that blocking of NKG2D abrogated IFNγ release and consequently DC maturation in 
transwell experiments. Transwell experiments are a possible future consideration for this study, 
since they indicate that maturation is also cytokine dependent and not just contact dependent. 
Another consideration for future experiments would be to assess DC functionality via 
measurement of IL-12 production. This could be achieved in the same way that NK cells were 
screened for intracellular cytokines in this study; and could potentially be correlated with DC 
ability to stimulate CD8+ naïve T cells. 
 
4.9.3. GA101GE significantly enhances DC maturation compared to GA101WT 
Despite demonstrating that GE-mAb activity provided apoptotic tumour particulate for 
phagocytosis by DC, it is important to remember that efficient induction of TA-specific T-cells by 
DC may be hampered by peripheral tolerance if the TA is presented by DC that have not 
undergone maturation. In the absence of appropriate maturation stimuli, iDC present TA in the 
context of inhibitory signals 80, resulting in anergy of TA-specific CD8+ T-cell clones and 
expansion of immunosuppressive T-regs 81, 82, 83. In the context of CD20-mAb-activated NK-cells, 
results presented in Chapter 3 showed that GA101GE promoted significantly greater apoptosis of 
tumour cells and significantly greater activation of NK cells than GA101WT. It was therefore 
predicted that GA101GE-activated NK cells could promote maturation of DC and results 
presented in this chapter have indicated this. At 1ng/ml, only GA101GE-activated NK cells 
induced significant DC maturation and no differences were seen between GA101WT and 
rituximab. The trend of significant GA101GE-induced maturation was reproduced at 10ng/ml in all 
but one of the maturation markers. 
 
These findings illustrate that the magnitude of NK-cell activation can directly affect the magnitude 
of DC maturation, and is important because maturation is a key stage of DC activity required for 
tumour-specific CD8+ T-cell priming. When Dhodapkar et al demonstrated that the coating of 
myeloma cells with the mAb anti-syndecan-I promoted cross presentation of TA to TA-specific T-
cells by DC, in the absence of ADCC it was of note that the coated myeloma cells induced only 
“partial” iDC maturation when compared to cytokine-matured iDC 239. Results presented in this 
chapter show that at equivalent concentrations, GE-mAb activated NK cells elicit significantly 
more DC maturation than the unmodified mAbs. Therefore, it is reasonable to speculate that GE-
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mAbs have better potential to present antigen in a context that will prime and activate TA-specific 
CD8+ T cells than non-GE mAbs. 
There are several concerns with the DC used in this study. The moDC may not be representative 
of all DC subtypes involved in antigen presentation. Although moDC are a gold standard and 
widely used in published literature because of their uniform phenotype and ease to obtain in 
sufficiently high numbers compared to DC directly isolated from peripheral blood 84, they may not 
provide the most appropriate setting for studying promotion of adaptive immunity. The majority of 
DC clinical trials to date have employed DC derived in vitro in the presence of IL4 and GM-CSF. 
In humans, most DC are derived from a common precursor; they do not arise from monocytes 
and are considered cDC. The moDC generated in vitro most closely resemble in vivo 
“inflammatory moDC”, a recently identified subset which are not present in the steady state but 
differentiate from monocytes during infection/inflammation 338. Despite their long history of use, 
there is a paucity of information on physiological mouse/human moDC equivalents and even less 
on the role of moDC in anti-cancer immune responses. A DC subtype resembling moDC in 
phenotype and morphology was recently found to be crucial for the induction of chemotherapy-
induced anti-cancer immune responses within the tumour site in mice, providing the first evidence 
for a role for moDC in tumour immunity 339. Conversely, an equivalent subset recently identified in 
the ascitic fluid from human breast and ovarian cancer patients was proposed to contribute to 
disease pathogenesis 338. Consequently, generalization of observations made using in vitro 
generated moDC to activity of in vivo DC should be viewed with caution. In mice, moDC can be 
distinguished from cDC by their expression of dendritic cell-specific intercellular adhesion 
molecule-3-grabbing non-integrin (DC-SIGN) 340, therefore studies using mice lacking cDC may 
help address whether inflammatory moDC are able to promote adaptive immunity. 
 
Another potential concern with studies involving moDC is the heterogeneity of the monocyte 
precursors used for in vitro generation of moDC. Passlick et al reported that human monocytes in 
the peripheral blood are heterogeneous. In addition to the classical CD14++ monocytes, which 
comprise the major subset in the circulation, a subset of CD14+CD16+ monocytes is present, 
which make up 2.2% of total PBMC 341. The CD14++CD16− subtype represent 80% to 90% of 
blood monocytes. CD16+ monocytes are usually divided into CD14highCD16low (CD14++CD16+) 
and CD14lowCD16high (CD14+CD16++) subsets 92, 341. Human CD14++ CD16− monocytes express 
high levels of CCR2 and L-selectin (CD62L) but lower C-X3-C chemokine receptor 1 (CX3CR1) on 
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their surface. They have higher phagocytic activity and when stimulated with LPS, the cells 
produce higher levels of IL-10, but lower levels TNF-α and IL-1. In contrast, human 
CD16+ monocytes express high levels of CX3CR1 but lower CCR2, and are responsible for the 
production of TNF-α in response to LPS stimulation 342, 343. Further studies have shown that 
CD16- and CD16+ moDC behave differently. The latter express higher levels of CD86 and CD11c, 
and show lower expression of CD32 compared to CD16− moDC. LPS-stimulated CD16- moDC 
express lower levels of IL-12 mRNA and secrete lower amounts of IL-12 than CD16+ moDC. 
Finally, CD4+ T cells stimulated with CD16+ moDC secrete increased amounts of IL-4 compared 
to those stimulated by CD16− moDC 343.  
 
It is speculated that the moDC used in this study lacked CD16 expression, because the MACS 
monocyte isolation kit eluted CD16- monocytes (confirmed by personal communication with 
Miltenyi BioTech) and because CD16 has previously been described as absent on moDC 344.  
The form in which tumour cells are ingested by DC influences the efficiency of TA presentation 326, 
336. DC express receptors that facilitate uptake of cells bearing specific moieties, such as the αvβ3  
and CD36 receptors for apoptotic bodies; the lectin receptors (mannose receptors and DEC205) 
for heat shock proteins (associated with cellular stress) and the FcγR for IgG 345. Despite variable 
expression, CD16-mediated internalisation very efficiently targets antigens to a unique DC 
specific antigen pathway that results in delivery to the cytosol 326, 336. 
In retrospect, the use of CD16- moDC may have limited this study to a DC subtype more 
amenable to upregulation of maturation markers but with lower capacity for cross presentation via 
IL-12 stimulation of naïve T cells. The use of an alternative monocyte isolation kit that yields 
CD16+ monocytes for differentiation to moDC could be a way of partially addressing this limitation. 
 
Peripheral blood DC are known to express 2 other activating Fcγ receptors that can bind IgG - 
CD32a and CD64; however the expression of these receptors in in vitro generated moDC is 
highly selective (comprehensively reviewed by Guilliams et al, 2014 346). CD64 has been 
documented as absent or unstably expressed in moDC, attributed to the use of IL-4 during 
differentiation, which is known to downregulate CD64 expression. CD32a and the inhibitory 
receptor FCγRIIb (CD32b) are co-expressed on moDC and co-ligated by mAbs, where CD32a 
has been shown to limit CD32a-induced DC maturation 344. In the co-culture model presented, DC 
maturation appeared to be NK-cell dependent. It was therefore speculated that the moDC used in 
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this study were limited in their capacity to be directly activated by the mAbs. It was felt that 
conducting these experiments in the presence and absence of NK cells adequately addressed the 
potential for direct mAb activation of DC and negated the need to screen extensively for activating 
receptors on DC.  
 
Finally, by investigating only DC the critical events occurring in concert with other APC were 
indubitably missed. Although NK:DC crosstalk has been well studied, it has been shown for 
example that monocytes and macrophages also play a part in tumour-antigen presentation, via 
ADCP 233. To enable a clearer picture of immune cell crosstalk, broader screening of a number of 
APC should be considered. For this to be adapted clinically however, more blood would be 
required and the impact of such sampling on cancer patients raises ethical concerns.  
 
The interpretation of these findings is subject to the same limitations previously detailed in 
Chapter 3, viz: except in the case of GA101GE and GA101WT, the mAbs were not normalised to 
account for the differences in their binding sites or isotypes, restricting this study to comparison at 
equivalent concentration. Only one cell type was used to assess the process of DC maturation in 
both EGFR and CD20 contexts, making it hard to draw conclusions on wider applicability. Ideally 
future studies will incorporate multiple tumour cell types, including low passage primary tumour 
cells, with larger numbers of donors. 
 
Despite these caveats, results obtained indicate that immunotherapeutic GE-mAbs specific for TA 
can induce efficient apoptosis of tumour cells and maturation of DC, so have the potential to elicit 
an adaptive response to TA. The results obtained herein support the findings of Srivastava et al, 
indicating that mAb-activated NK cells and dendritic cells collaborate to trigger TA-specific T-cell 
immunity 97. In the same report, the authors demonstrated that EGFR-specific T-cell frequencies 
in cetuximab-treated patients were significantly higher than those of cetuximab-naïve patients; 
indicating that their in vitro findings were translated to their clinical setting. 
Stimulation of an anti-TA reactive T-cell response remains challenging because most TA are self 
antigens to which the immune system is tolerant 347. Exploration of the ability of GE-mAbs to 





Chapter 5. Results III: Evaluation of the ability of glyco-
engineered monoclonal antibodies to promote tumour 
antigen cross presentation to CD8+ T cells 
 
5.1. Introduction 
Results presented in the previous chapters have shown that GE-mAbs are able induce NK-cell 
mediated apoptosis of tumour cells, that tumour particulate generated by apoptosis is 
phagocytosed by DC and that GE-mAb activated NK cells induced DC maturation. These findings 
suggest that GE-mAbs have the potential to promote cross presentation of antigen by DC to TA-
specific CD8+ T cells.  
 
Several studies have demonstrated cross presentation of TA to T cells by DC exposed to 
apoptotic tumour cells but, in most studies, the tumour particulate was generated in a non-
physiological setting using UV- or γ-irradiation or heat shock 70, 106, 325, 348, 349. Only the Ferris 
laboratory have previously described cross presentation of TA by DC in the setting where tumour 
particulate was generated by mAb-mediated ADCC 97. Using in vitro co-cultures of the PCI-15B 
EGFR+ cell line with NK cells, DC and EGFR-specific CD8+ T-cells from HNSCC patients, they 
showed that cetuximab-activated NK cells induced DC maturation, antigen presentation and 
stimulation of IFNγ production by EGFR-specific CD8+ T cells.  
 
The final objective of the study reported here was to add TA-specific CD8+ T cells to the in vitro 
co-culture model and assess whether GE-mAb-activated NK cells induce DC cross presentation 
of TA and stimulation of CD8+ T-cell responses. The four-cell in vitro co-culture model depicted in 
Figure 5.1 exploits HLA-mismatched cell types to assess antigen cross presentation. The tumour 
cells are HLA-A*02 negative whereas the NK cells, DC and TA-specific T-cells are from an HLA-
A*02 positive donor. In this setting, the T-cell is unable to recognise the tumour cell directly. The 
model is dependent upon ADCC-mediated lysis of HLA-A*02- tumour cells by NK cells, uptake of 
exogenous tumour particulate by DC, processing and binding of TA to HLA-A*02 and cross 
presentation by DC to HLA-A*02 restricted CD8+ T cells. HLA-A*02 restricted TA-specific CD8+ T 











5.2. Screening for HLA-A*02 restricted TA-specific CD8+ T cells in 
cancer patients treated with anti-EGFR mAbs 
A growing body of evidence from animal models 350 and in the clinical setting 351, 352, 353 indicates 
that TA-specific mAbs can elicit cellular immunity. Cancer patients treated with mAbs were 
therefore considered likely to have memory T cells specific for TA, and were investigated as a 
source of HLA-A*02 restricted TA-specific CD8+ T cells for use in this study. Peripheral blood 
samples from CRC or HNSCC patients participating in a clinical trial to evaluate treatment with 
either cetuximab or imgatuzumab were screened for presence of EGFR-specific CD8+ T cells.  
 
Two previous reports have described identification of EGFR-specific CD8+ T cells. Andrade Filho 
et al used in silico tools to predict the candidate HLA-A*02-binding peptide epitope EGFR853 
sequence ITDFGLAKL. After 10 days in vitro stimulation of peripheral blood from 5 HLA-A*02+ 
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healthy donors and 5 HLA-A*02+ HNSCC patients with the peptide, EGFR853-specific CD8+ T cells 
were detected at mean frequencies of 0.4% and 0.6% respectively using MHC tetramers 282. 
Schuler et al worked with two putative HLA-A*02-binding peptides, EGFR479 sequence 
KLFGTSGQKT and EGFR1138 sequence YLNTVQPTCV 240. These peptides were previously 
reported to be recognised by antibodies present in pancreatic cancer patients 354. Peripheral 
blood samples from 16 HLA-A*02+ HNSCC patients were stimulated in vitro with these peptides 
for four rounds and responses assessed by IFNγ enzyme linked immunospot (ELISPOT) assay. 
Mean T-cell frequencies of 0.28% specific for the EGFR479 peptide and 0.56% for the EGFR1138 
peptide were detected 240.  
 
In this study, peripheral blood samples from HLA-A*02+ CRC or HNSCC patients were stimulated 
in vitro with the previously reported HLA-A*02 restricted EGFR peptide epitopes and responses 
assessed after 10 days using MHC pentamers. Unfortunately, attempts to synthesise the HLA-
A*02 pentamer for the EGFR853 ITDFGLAKL peptide were not successful due to poor stability that 
was possibly the result of a low HLA-A*02 affinity score (ProImmune, personal communication). 
Therefore, only responses to EGFR479 KLFGTSGQKT and EGFR1138 YLNTVQPTCV were 
investigated. The work with patient samples was conducted in collaboration with Maeve McEnery 
(KCL - London, UK). 
 
5.2.1. Patient samples 
Samples available for study were unused frozen aliquots of PBMC remaining from other analytical 
studies after conclusion of three clinical trials involving imgatuzumb: BO21495 (ras mutant 
colorectal cancer), BP25438 (colorectal cancer) and BP22350 (HNSCC). PBMC numbers were 
low (1-2x106 per aliquot) and frequently of poor quality (haemolysed with cell aggregates).  Both 
the previously reported studies of EGFR-specific CD8+ T cells involved in vitro stimulation to 
promote proliferation and thereby increase numbers to a detectable range. Due to the low starting 
cell numbers available for this study, a protocol was devised that did not require purification of 
antigen-presenting cells or T cells and involved only minimal cell handling. The multiple rounds of 
in vitro stimulation conducted by Schuler et al 240 were not possible because all cells had to be 
committed to the initial stimulation. Thus, a protocol based on the study by Andrade Filho et al 282, 
using a single in vitro stimulation and assay with MHC-peptide multimers was employed. To 
assess whether anti-EGFR mAbs augment anti-tumour CD8+ T-cell immunity, PBMC samples 
189 
 
from each patient were tested at two time-points, one before and one during/after treatment with 
mAb infusions. Of 42 patients with appropriate paired samples, 18 were HLA-A*02+ and therefore 
suitable for study. These were 3 patients from trial BO21495, 3 from trial BP25438 and 12 from 
trial BP22350. All patients were treated with either cetuximAb or imgatuzumab. 
 
The baseline samples for patients from trials BO21495 and BP22350 were thawed and a small 
aliquot of 105 PBMC used to screen for HLA-A*02 type with an anti-HLA-A*02 specific PE-labelled 
mAb and analysis by flow cytometry. For those samples found to be HLA-A*02+, the PBMC paired 
sample during/after treatment was then immediately thawed and the antigen specific T-cell 
stimulation protocol performed simultaneously for the baseline and the during/after treatment 
samples. Patients from trial BP25438 had already previously been screened for HLA-A*02 type.  
 
5.2.2. HLA-A*02 peptide-binding assay 
The T2 assay was conducted to assess the HLA-A*02 binding ability of the EGFR-specific 
peptides relative to the highly immunogenic HLA-A*02 restricted peptide GILGFVFTL, derived 
from influenza A matrix protein-I (FLU.A-mp158). Stabilisation of the HLA-A*02 complex on the 
surface of TAP-deficient T2 cells correlates with the binding capacity of the specific peptide to 
HLA-A*02. In order to determine the binding capacity, the MFI of ‘T2 cells + peptide’ was divided 
by the MFI of ‘T2 cells alone’, resulting in a value between 1 and 2, in keeping with previous 
studies 240, 282. The results displayed in Figure 5.2 show that binding of the EGFR1138 
YLNTVQPTCV peptide to HLA-A*02 was detected, but binding capacity was lower than for the 
FLU.A-mp158 positive control. The EGFR479 KLFGTSGQKT peptide did not induce detectable 
stabilisation of HLA-A*02 expressed by T2 cells, indicating that it has much lower affinity for HLA-












5.2.3. Screening for HLA-A*02 restricted EGFR-specific CD8+ T cells in cancer patient 
samples 
There were insufficient patient PBMC to test the two HLA-A*02 restricted EGFR peptide epitopes 
individually, therefore, peptides were combined for in vitro stimulation. The EGFR479 peptide was 
added at 10µg/ml as described by Schuler et al 240, and EGFR1138 was added at the lower 
concentration of 5µg/ml in an attempt to limit dominance, as the results of the T2 peptide-binding 
assay indicated that EGFR1138 had higher affinity for HLA-A*02. This decision was agreed with 
Roche Glycart. Patient PBMC were cultured with peptides in the presence of 5ng/ml IL-7. Every 3 
days thereafter, IL-2 was added to a final concentration of 25U/ml. After 10 days, cultures were 
screened for the presence of EGFR-specific CD8+ T cells (EGFRT cells) using MHC class-I 
multimers (pentamers). PBMC from one healthy HLA-A*02+ individual and patient PBMC were 
also screened for the HLA-A*02 restricted peptide NLVPMVATV derived from CMV pp65 protein 
(CMVpp65495) as a positive control to validate the in vitro T-cell expansion protocol. Many 
individuals possess memory CMV-specific CD8+ T cells (CMVT cells) at frequencies detectable ex 









































MHC class-I multimer screening was performed according to the gating strategy illustrated in 
Figure 5.3. The antigen-specific T-cell phenotyping panel was designed to achieve clear 
segregation of Multimer+CD8+ T cells within a mixed population. Because of the potential for CD8 
downregulation after stimulation, CD4+CD8- cells were gated to determine fluorescence on 




























































CMVT cells were detected in the PBMC from one healthy individual ex-vivo (Day 0) and expanded 
robustly using the 10-day stimulation protocol. Results presented in Figure 5.4 A show expansion 
of CMVT cells from 0.776% at Day 0 to 30.5% of CD8+ T cells after 10-day in vitro stimulation. 
Sufficient PBMC were available from six patients for in vitro stimulation with the CMVpp65495 
peptide.  CMVT cells were detected in one culture established from BP22350 trial patient 1007. Ex-
vivo analysis of PBMC from this patient showed expansion of CMVT cells from 2.81% at Day 0 to 
21.7% of CD8+ T cells after 10-days in vitro stimulation. This result demonstrated that the protocol 
could promote substantial in vitro expansion of antigen-specific memory CD8+ T cells from patient 
PBMC. In vitro cultures were established from 18 HLA-A*02+ patients using baseline and 
during/after treatment PBMC samples. Due to low cell numbers in many samples, priority was 
given to performing the EGFR peptide pool stimulation and then the CMVpp65495 peptide culture if 
cell numbers were sufficient. Cultures performed are listed in Table 5.1. 
 
Unfortunately, no EGFRT cells were detected in any cultures. A representative example of EGFR 
pentamer screening of cultures from baseline and progression samples is shown in Figure 5.4 B 
for patient 1007, from which expansion of CMVT cells was successfully achieved. The composition 
of all patient cultures after in vitro stimulation with EGFR peptides is shown in Table 5.2. Of the 36 
cultures, 22 had a total cell viability below 50%, 27 had fewer than 100,000 viable T cells and 32 
cultures contained less than 27% CD8+ T-cells. Poor viability and limited cell numbers likely 
underlies the lack of detectable EGFRT cells in these patient samples. An alternative source of 
















Samples	from	trial	 HLA-A*02+	 EGFR	 CMV	
BP22350	 12/32	 12	 6	
BP25438	 3	 3	 0	
BO21495	 3/11	 3	 0	












































































Time	point	 Patient	ID	 %	Live	cells	 %	T	cells	 Number	T	cells	 %	CD8+	T	cells	
BASELINE	
1005	 79	 98	 161000	 13	
1007	 97	 98	 1680000	 23	
1037	 35	 94	 45431	 18	
1042	 94	 99	 142000	 18	
1051	 3	 92	 245	 87	
1057	 27	 96	 522	 1	
1065	 32	 99	 24150	 9	
1301	 0	 0	 0	 0	
1508	 0	 0	 0	 0	
2001	 4	 99	 7507	 21	
2037	 14	 0	 0	 0	
2039	 7	 93	 1206	 8	
2066	 2	 77	 128	 79	
3105	 14	 96	 8042	 7	
3304	 98	 99	 104000	 27	
3402	 69	 98	 32166	 10	
3502	 0	 0	 0	 0	
3503	 0	 0	 0	 0	
PROGRESSION	
1005	 95	 97	 173000	 10	
1007	 95	 98	 1250000	 23	
1037	 36	 99	 2862	 2	
1042	 90	 99	 167000	 23	
1051	 7	 91	 1244	 85	
1057	 40	 97	 7951	 12	
1065	 90	 98	 133000	 17	
1301	 0	 0	 0	 0	
1508	 92	 99	 885000	 27	
2001	 9	 99	 1858	 18	
2037	 12	 0	 0	 0	
2039	 0	 96	 22	 0	
2066	 1	 67	 58	 72	
3105	 73	 96	 47159	 14	
3304	 96	 99	 32690	 23	
3402	 80	 98	 52101	 14	
3502	 5	 75	 58	 0	




5.3. In vitro prime and expansion of HLA-A*02 restricted TA-specific 
CD8+ T cells from the naïve repertoire of healthy donors 
Because no HLA-A*02 restricted EGFR-specific T cells were detected in mAb-treated cancer 
patients, an in vitro prime of naïve T cells was attempted using PBMC from healthy donors. Many 
protocols have been described for in vitro expansion of antigen-specific T cells from the naïve 
repertoire, all involving the following steps: 
 
1. APC selection 
2. APC antigen loading  
3. Responder T-cell selection  
4. T-cell “prime” (initial combination of T cells and antigen loaded APCs) 
5. T-cell “restimulation” (repeated exposure of T cells to antigen loaded APCs)  
6. Screen for T-cell antigen specificity 
 
The protocols vary greatly in terms of media, cytokines use, T-cell:APC ratios and duration of 
stimulation. Wolfl and Greenberg published a prescriptive protocol detailing the robust and 
reproducible expansion of CD8+ antigen-specific T cells using IL-7, IL-15 and IL-21 to promote 
responder cells as opposed to the more widely used IL-2/IL-7 combination 264. Their protocol 
exploited the properties of MelanA, an antigen that is overexpressed by melanoma cells and 
recognised by a large number of tumour infiltrating T cells in melanoma patients 356. MelanA 
served as a model antigen because of the unusually high precursor frequencies of MelanA 
specific CD8+ T cells (MelanAT cells) found in HLA-A*02+ healthy individuals 357, 358 and the 
identification of a heteroclytic peptide MelanA26-35 ELAGIGILTV (A27L) that has enhanced HLA-
A*02 binding which greatly improves MelanAT-cell expansion 281. 
 
5.3.1. Naïve CD8+ T-cell priming and expansion protocol 
The MelanA antigen model was used to establish a modified version of the protocol described by 
Wolfl and Greenberg for use in this study. Purified naïve (CD45RO-CD57-CD62L+) CD8+ T cells 
were considered a more suitable responder population than more widely used total CD8 T-cell 
preparations because the fraction of naïve T cells varies considerably between donors. For 3 
independent experiments, the average isolation purities after 2 stage selection were as follows: 
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CD8+ fraction: 97.9% +/- 0.7% sd  
CD45RO- fraction: 96.8% +/- 1.8% sd  
CD57- fraction: 95.9% +/- 1.2% sd  
CD62L+ fraction: 68.9% +/- 2.9% sd  
 
As APC, DC were matured in the presence of MelanA26-35 peptide using an LPS/IFNγ cocktail as 
opposed to the more widely used TIP maturation cocktail to create MelanADC. The PGE2 
component of TIP inhibits DC IL-12 production in a dose-dependent manner 359, as a 
consequence such DC are prone to exhaustion and show limited priming capacity 360. In contrast, 
IFNγ primes the promoter region of IL-12 and LPS activates IL-12 production via TLR4 -triggering 
360, 361. A single stimulation of naïve CD8+ T cells with MelanADC was performed and MHC-
dextramers used to identify MelanAT cells. 
 
5.3.2. HLA-A*02+ T cells 
The frequency of HLA-A*02+ individuals is approximately 46% within the Caucasian population; 
the highest allele frequency of any ethnicity 362. 35 healthy donors were screened for HLA-A*02 
status by flow cytometry, with 17 (48.6%) identified as HLA-A*02+. 
 
5.3.3. Successful in vitro priming and expansion of HLA-A*02 restricted MelanA-specific 
CD8+ T cells 
The modified T-cell stimulation protocol was used to assess expansion of MelanA-specific CD8+ T 
cells from two donors in two independent experiments. Multiple cultures were set up for each 
donor and screened individually for expansion of MelanAT cells after 10 days using MelanA-
dextramer. The results displayed in Table 5.3 and Figure 5.5 show reliable expansion of MelanAT 
cells. The MelanAT-cell frequency increased from 0.18% to a maximum 15.6% for LC66 and from 
0.17% to a maximum 23% for LC97. The frequencies of MelanAT cells for LC66 and LC97 showed a 
median increase of 71- and 101-fold respectively; remarkable considering this was achieved 
without restimulation. There was variation in the frequencies of MelanAT cells attained in different 
cultures set up using cells from the same donor which indicated variation in the efficiency of in 







DONOR	 TIME	0	 CULTURE	1	 CULTURE	2	 CULTURE	3	 CULTURE	4	
LC66	 0.177	 9.24	 12.7	 15.6	 -	










5.3.4. No in vitro expansion of HLA-A*02 restricted EGFR- or CD20-specific CD8+ T cells 
In light of the success expanding MelanAT cells, the modified protocol was used to attempt in vitro 
priming of EGFR- and CD20-specific CD8+ T cells from healthy donors. MelanA stimulation was 
performed in parallel as a positive control. Duplicate cultures using cells from 3 healthy donors 
were screened on day 10 and the results for antigen-specific T-cell frequencies achieved are 
shown in Table 5.4 and displayed graphically in Figure 5.6. Although MelanAT cells were observed 









































DONOR	 CD20188-196	 EGFR479-488		 EGFR1138-1147		 MelanA26-35	
LC65		 0.361	|	0.278	 0.0254	|	0.0276	 	0.125	|	0.15	 17.3	|	27.6	
LC98	 0.658	|	0.372	 0.0142	|	0.0209	 	0.209	|	0.157	 11.4	|	11.1	










5.4. Modification of the four-cell in vitro co-culture model to assess 
cross presentation of MelanA 
Because attempts to generate EGFR- or CD20-specific CD8+ T cells were unsuccessful, the four-
cell in vitro co-culture model was adapted to exploit the MelanAT cells that were successfully 
generated. Figure 5.7 depicts the modified cross presentation model in the context of anti-EGFR 
mAbs. A variant of the EGFR+ tumour cell line A431 created to express MelanA protein was used 
so that NK-cell mediated lysis induced by an anti-EGFR mAb generates tumour particulate 














































5.4.1. Production of HLA*A-02-EGFR+ A431 tumour cells that express MelanA protein 
The EGFR+ cell lines A431 and H1299 were screened for expression of HLA-A*02 by flow 
cytometry and confirmed as HLA-A*02- and HLA-A*02+ respectively (Figure 3.8). HLA-A*02+ 
H1299 cells and a MelanA+ transfected version of this cell line were needed as negative and 
positive controls respectively to stimulate HLA-A*02 restricted MelanAT cells. A431 and H1299 cells 
were transfected with the plasmid construct shown in Figure 2.1 to generate HLA-A*02-
EGFR+MelanA+ tumour cells (A431MelanA) and HLA-A*02+EGFR+MelanA+ tumour cells 
(H1299MelanA). The DNA sequence for wild type MelanA was used because previous studies 
report that T cells generated using the heteroclytic peptide MelanA26-35 ELAGIGILTV (A27L) 
effectively respond to wild type MelanA expressed by tumour cells 363 364. Fusion of the MelanA 
sequence to GFP enabled visualisation of transfected cells and incorporation of a puromycin 
resistance gene facilitated drug selection of transfected cells. A ControlMA- plasmid containing all 
elements except the MelanA sequence was transfected into A431 cells (A431CTRL) and H1299CTRL 











The model plasmid “p-Select”, kindly provided by Dr Richard Beswick (KCL - London, UK) was 
used to optimise the transfection protocol. The p-select plasmid has previously been used to 
transfect a wide range of different cell types and produces high intensity expression of GFP 48 
hours after transfection (Dr Beswick, personal communication). HLA-A*02- A431 cells and HLA-
A*02+ H1299 cells were transfected with either the ControlMA-, MelanA or p-Select plasmids in 
parallel.  
 
Images presented in Figure 5.8 show successful transfection of adherent A431 and H1299 cells. 
Morphology of untransfected cells are displayed unfiltered in column 1 and compared to images 
taken 48 hours after transfection under either GFP daylight or GFP blackout filters. Transfection 
with the model p-Select plasmid elicited high intensity GFP+ cells that were visible in daylight 
(column 2-left) in both cell lines. GFP+ cells were present after transfection with ControlMA- or 
MelanA plasmids, but the signal was less intense requiring use of GFP blackout filters for 
visualisation. Transfection efficiency was lower for A431 cells (panel A) than H1299 cells (panel 
B). Mean transfection efficiency for the ControlMA- plasmid was 6.6% GFP+ (+/-2.9 sd) for A431 
cells and 10.6% (+/-1.8 sd) for H1299 cells. Transfection efficiency was higher for the ControlMA- 
plasmid than the MelanA plasmid. Mean transfection efficiency of A431 cells was 6.6% GFP+ (+/-
2.9 sd) with the ControlMA- plasmid and 3.6% (+/-0.6 sd) for the MelanA plasmid, with similar 











variants	 of	 the	 A431	 and	H1299	 cell	 lines	were	 produced	 by	 transfection	with	 the	MelanA	 plasmid	 and	 imaged	 in	
darkness.		
 
It was not possible to transfect suspension B-cell lines using calcium phosphate- or lipofectamine-
based protocols, therefore cross presentation studies were limited to the EGFR setting. It was 
speculated that suspension cells were less permissive to transfection when using reagents 
optimised for use with adherent cell lines. 
 
5.4.1.1. Selection of MelanA+GFP+ cells after transfection 
Cells were cultured in the presence of puromycin after transfection with the intention of selecting 
stably transfected cells that express the puromycin resistance gene. The puromycin concentration 
for selection was determined by dose titration of untransfected A431 and H1299 cells for 48 
hours, and the lowest concentration that induced death of all cells was used. The minimum 
concentrations were 0.3µg/ml and 0.6µg/ml for A431 and H1299 respectively. Unfortunately, none 
of the cells survived puromycin selection after transfection. This was possibly due to the large size 
of the puromycin-resistance gene (600bp). Kim et al have reported that the translation efficiency 
of a gene placed downstream of an IRES can be low, particularly if larger than 80bp 285. 
In the absence of puromycin selection pressure, the small percentage of transfected GFP+ cells 
disappeared after 6 days in culture (reduced to 2 days for frozen/thawed cells). Therefore, 
enrichment of GFP+ cells was attempted by FACS 48 hours post transfection, according to the 
gating strategy shown in Figure 5.9. The median post sort purity of GFPHIGH cells was 91.9% 
(Figure 5.10). GFPHIGH populations >90% pure were used in cross-presentation co-cultures 

















transfected	 cells	 were	 gated	 based	 on	 GFPHIGH	 expression	 (events	 >	 fourth	 log	 decade)	 and	 these	 events	 were	






104	 transfected	 cells	 were	 screened	 for	 GFP	 expression.	 Graph	 depicts	 GFPHIGH	 cell	 frequency	 before	 and	 after	














































5.4.1.2. Confirmation of intracellular MelanA expression 
The presence of MelanA protein within GFP+ sorted cells was confirmed by intracellular staining 
immediately after sorting. Untransfected cells were used as a negative control and the SKMEL30 
cell line that endogenously expresses MelanA was used as a positive control. The majority of the 
transfected GFP+ sorted cells expressed MelanA at levels equal to or above the levels in 
SKMEL30 cells. Representative examples of MelanA expression by transfected A431 and H1299 










5.5. HLA-A*02 restricted CD8+ MelanAT cells recognise MelanA+HLA-
A*02+ cells 
Recognition of antigen by the MelanAT cells generated by in vitro priming and expansion from the 
naïve T-cell repertoire of healthy donors (described in section 5.3) was assessed by stimulation 
with autologous DC loaded with MelanA peptide. Markers of T-cell activation shown in Table 5.5 




















MelanAT cells harvested after 10 days of in vitro expansion were restimulated with autologous DC 
pulsed with either MelanA peptide (MelanADC) or irrelevant EGFR1138 peptide (EGFRDC) in the 
presence of BFA. After 18 hours, IFNγ production by MelanAT cells was assessed. LAC was used 
as a positive control for T-cell activation and all results were compared to the negative control of 
unstimulated MelanAT cells. The results are displayed in Figure 5.13 and show that the majority of 
MelanAT cells expressed IFNγ after stimulation with MelanADC (71.6%) and there was no response to 
DC pulsed with the irrelevant EGFR peptide. T cells that did not bind the MelanA dextramer did 






































To avoid the logistical difficulties of co-ordinating MelanAT-cell harvests with A431MelanA sorting, the 
feasibility of using frozen batches of MelanAT cells was evaluated. Previously frozen MelanAT cells 
were thawed and screened for antigen recognition and cross reactivity. Results displayed in 
Figure 5.13 confirmed that the previously frozen MelanAT cells expressed IFNγ specifically in 
response to MelanADC in a similar vain to fresh MelanAT cells, but the number of T cells recovered 













To improve T-cell recovery, the response of thawed MelanAT cells was assessed based on 
increased expression of cell surface activation markers, thereby avoiding the 
fixation/permeabilization steps required for analysis of IFNγ that can cause cell loss. The results 
displayed in Figure 5.14 showed substantially better cell recovery and the MelanAT cells 
upregulated CD69, CD71 and CD137 specifically in response to MelanA antigen presented by 
HLA-A*02+ DC exogenously loaded with peptide. T cells that did not bind the MelanA-dextramer 


























Figure	 5.15.	 Previously	 frozen	MelanAT	 cells	 upregulated	 surface	 activation	markers	when	 stimulated	with	MelanA	
peptide	
MelanAT	 cells	 previously	 frozen	 were	 thawed	 and	 stimulated	 using	 mDC	 pulsed	 with	 either	 MelanA26-35	 peptide	
(MelanADC)	 or	 irrelevant	 EGFR1138-1147	 peptide	 (
EGFRDC),	 at	 a	 T-cell:DC	 ratio	 of	 4:1.	 The	 positive	 control	 was	 T	 cells	
stimulated	with	 LAC	 and	 the	negative	 control	was	unstimulated	MelanAT	 cells.	 After	 18	hours,	 cells	were	 stained	 for	




MelanAT-cell recognition of endogenously processed MelanA presented by HLA-A*02+ cells was 
assessed using the HLA-A*02+ cell line SK-MEL-30 that naturally expresses MelanA and the 
HLA-A*02+ H1299 cell line transfected to express MelanA (H1299MelanA). A representative result 
from one of two donors tested is shown in Figure 5.16. Substantial increases in expression of 
CD69, CD71 and CD137 by MelanAT cells were observed after stimulation with MelanA+ SK-MEL-
30 cells and H1299MelanA cells compared to unstimulated MelanAT cells or MelanAT cells stimulated 
with MelanA- HLA-A*02+ H1299 cells. The response to SK-MEL-30 cells showed that MelanAT cells 
recognised natural endogenously processed MelanA antigen presented by HLA-A*02+ tumour 
cells. The response of MelanAT cells to H1299MelanA cells shows that the artificially created MelanA+ 
EGFR+ HLA-A*02+ tumour cells generated by transfection with the MelanA plasmid also 

























CD8,	 MelanA-dextramer,	 CD69,	 CD71	 and	 CD137.	 Histograms	 show	 activation	 marker	 expression	 by	 MelanAT	 cells.	





5.6. Assessment of MelanA cross presentation to HLA-A*02 restricted 
MelanAT cells 
Having confirmed that MelanAT cells can recognise antigen processed and presented by HLA-A*02+ 
H1299MelanA tumour cells, the modified four-cell in vitro co-culture model (Figure 5.7) was used 
with HLA-A*02- A431MelanA tumour cells to evaluate whether anti-EGFR mAb-activated NK cells 
could induce DC cross presentation of TA and stimulation of CD8+ T-cell responses. MelanAT cells 


























MelanA+ EGFR+ HLA-A*02- A431 (A431MelanA) transfected tumour cells were incubated with NK 
cells, DC and MelanAT cells from the same HLA-A*02+ donor, in the presence of cetuximab or 
imgatuzumab. After 18 hours, the MelanAT cells were assessed for upregulation of surface 
activation markers. Negative controls were co-cultures performed in the absence of mAbs and co-
cultures conducted with A431CTRL. The positive control was MelanAT cells stimulated with 
autologous MelanA peptide loaded DC. Upregulation of surface T-cell activation markers was 
compared to unstimulated MelanAT cells 
 
5.6.1. MelanA can be cross presented to MelanAT cells in the absence of anti-EGFR mAb 
mediated tumour-cell lysis 
The assessment of tumour cell death by annexin V staining described in section 3.6.4 showed 
that there was some spontaneous apoptotic tumour cell death in the absence of mAbs (Figure 
3.21 C). Furthermore, in the analysis of phagocytosis by DC described in section 4.2.3, a low 
percentage of pHrodoRed+ DC was observed after culture with untreated tumour cells (Figure 4.4) 
indicating that there was some uptake of tumour particulate in the absence of mAb-mediated 
lysis. Consequently, in the four-cell co-culture, there was potential for cross presentation of 
tumour antigen to MelanAT cells without mAbs present, and this needed to be evaluated. Results 
shown in Figure 5.17 depict CD69 expression on MelanAT cells after co-culture with NK cells, DC 
and A431CTRL (5.17 A) or A431MelanA (5.17 B) tumour cells, in the absence of anti-EGFR mAbs. 
The frequency of CD69+ MelanAT cells was 3.2% without stimulation and 12.5% in the culture with 
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A431CTRL, indicating some non-specific activation. The frequency of CD69+ MelanAT cells increased 
to 29.1% in the culture with A431MelanA, with three possible explanations. Either some T-cell 
alloreactivity was observed upon incubation of HLA-A*02+ MelanAT cells and HLA-A*02- A431MelanA; 
or, some background cross presentation of MelanA antigen may have occurred without addition of 
anti-EGFR mAbs to promote tumour-cell lysis; or both of these scenarios occurred. The non-




Figure	 5.17.	MelanA	 antigen	 can	 be	 cross	 presented	 to	 MelanAT	 cells	 in	 the	 absence	 of	 anti-EGFR	mAb	mediated	
tumour-cell	lysis	
2.5x104	HLA-A*02-	A431CTRL	 (A)	or	HLA-A*02-	A431MelanA	 (B)	were	 incubated	with	HLA-A*02+	NK	cells,	 iDC	and	MelanAT	
cells	at	1:1:1:4	ratio.	After	18	hours,	cells	were	stained	for	CD3,	CD8,	MelanA-dextramer	and	CD69.	Histograms	show	




5.6.2. No detection of enhanced MelanA cross presentation to MelanAT cells in the presence 
of anti-EGFR mAb  
The anti-EGFR mAbs imgatuzumab or cetuximab were added to the four-cell co-culture to induce 
mAb-mediated NK-cell lysis of tumour cells. A high concentration of 20µg/ml was used with the 






















expression of the activation markers CD69, CD71 and CD137 on MelanAT cells after co-culture with 
NK cells, DC and A431CTRL (5.18 A) or A431MelanA (5.18 B) tumour cells in the presence of anti-
EGFR mAbs. In the cultures with A431CTRL that lack MelanA, CD69 was expressed by 39% of 
MelanAT cells in the presence of cetuximab and 40.9% in the presence of imgatuzumab, indicating 
very high non-specific activation. CD69 expression on MelanAT cells was only marginally higher in 
the cultures using A431MelanA, rising to 47.3% with cetuximab and 48.8% with imgatuzumab. No 

































Similar results were obtained with MelanAT-cell batches from a further two donors, using only the 






2.5x104	 HLA-A*02-A431MelanA	 were	 incubated	 with	 HLA-A*02+	 NK	 cells,	 iDC	 and	 MelanAT	 cells	 at	 1:1:1:4	 ratio	 in	 the	
presence	 of	 cetuximab	 or	 imgatuzumab	 (20μg/ml).	 After	 18	 hours,	 cells	 were	 stained	 for	 CD3,	 CD8,	 MelanA-





The following modifications to the four-cell co-culture model were investigated:  
 
1. Reduction of co-culture duration from 18 hours to 6 hours 
2. Titration of mAb concentrations from 20µg/ml to 1ng/ml 
3. Alteration of T-cell:DC ratios (2:1, 4:1, 10:1) 
 
Unfortunately, enhanced MelanA cross presentation to MelanAT cells in the presence of anti-EGFR 





























The role that anti-tumour mAb-therapy plays in initiating T-cell mediated cancer immune 
responses is still to be elucidated. The aim of the work presented in this chapter was to determine 
whether GE mAbs could induce cross presentation of TA to TA-specific T cells and the results 
and their limitations are discussed herein: 
 
5.7.1. EGFR-specific T cells were not detected in patients 
Attempts were made to generate EGFR-specific CD8+ T cells (EGFRT cells) for use in these 
studies. EGFRT cells were not detected in PBMC from any of the cancer patients after in vitro 
stimulation with peptides for 10 days. The T-cell expansion protocol and MHC-I multimer assay 
were successfully used to detect CMVT cells in healthy donor PBMC and also one of six patient 
samples. These results do not necessarily indicate that EGFRT cells were absent in these patients 
because the study had several limitations that may have prevented detection.  
Foremost was the low number of viable PBMC available in the clinical trial samples. This 
necessitated a single in vitro stimulation without T-cell selection. After 10 days, the majority of 
cultures had fewer than 100,000 viable cells. Furthermore the low proportion of CD8+ T cells 
meant the population screened for pentamer positivity was typically less than 25,000 cells. The 
only previous study describing detection of CD8+ T cells specific for the EGFR.479 peptide 
KLFGTSGQKT and the EGFR.1138 peptide YLNTVQPTCV was conducted by Schuler et al (2011) 
and involved undertaking four rounds of in vitro stimulation over 28 days. Even then, low mean 
frequencies of 0.28% and 0.56% respectively were observed and only in patients with tumours 
expressing high levels of EGFR 240. It seems likely that insufficient rounds of in vitro stimulation 
were performed in this study to increase the proportion of EGFRT cells to the range for detection 
using pentamers. It is also worth noting that samples in the Schuler et al study came from patients 
presenting with locoregionally advanced disease that was previously untreated. The samples 
available for this study came from patients who had failed 2nd line chemotherapy, the majority of 
whom presented with metastatic disease or disease progression. When compared, it was 
speculated that the cells of patients with more severe disease could be less viable, less amenable 
to long-term culture and less responsive. 
 
This study was also hampered by the inability to obtain the EGFR.853 ITDFGLAKL pentamer used 
by Andrade Filho et al (2010) who reported detection of these EGFR-specific CD8+ T cells after a 
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single 10-day in vitro stimulation 282. The evaluation of enhancement of TA-specific CD8+ T-cell 
responses in patients after GE-mAb therapy warrants further investigation, however larger 
numbers of PBMC (≥5x107) stored in multiple aliquots would be requisite to permit CD8+ T-cell 
isolation and repeated rounds of in vitro stimulation where necessary. 
 
5.7.2. EGFR-specific T cells were not detected in healthy donors 
Attempts to generate EGFRT-cell lines by stimulation of naïve T cells from healthy individuals were 
not successful. The TA EGFR is a ubiquitous self-antigen for which the majority of potentially 
reactive T cells will have been deleted during development or maturation in the periphery. The 
frequency of circulating self-antigen-specific naïve T cells in healthy individuals is therefore 
expected to be extremely low, and the ability of these cells to bind MHC-I multimers to be weak 
264. As a notable exception to this observation, efforts were made to exploit the self-antigen 
MelanA, because HLA-A*02+ healthy individuals possess unusually high precursor frequencies of 
MelanAT cells 358. The success of MelanAT-cell expansion in vitro was in part due to use of the 
heteroclytic peptide 281. If a heteroclytic peptide was available for EGFR or CD20 that showed 
similar success to MelanA, screening of patients for TA-specific T cells pre and post mAb-
treatment could be viable. 
 
5.7.3. MelanA-specific T cells recognise endogenous MelanA, but not processed MelanA 
When expanded in this study, MelanAT cells recognised endogenously processed MelanA, but not 
MelanA cross-presented within the four-cell co-culture model. The cross presentation assessment 
was an ambitious undertaking and this part of the study also had several limitations, particularly 
with regards to incorporating MelanA into the experimental model. Stable transfection requires 
that the introduced DNA enters the nucleus and is integrated into the host genome, thereby 
sustaining transgene expression even after replication. With an efficient transfection it is expected 
that roughly 10% of events will be stably integrated and can then be selected in long-term culture 
372. The problems with puromycin selection and loss of GFP signal indicate that the MelanA 
expression in A431 was not stable. A stable transfection could have potentially allowed long-term 
culture of A431CTRL and A431MelanA tumour cells, rather than having to transfect and sort the 
tumour cells each time they were required for co-culture, eliminating a source of experimental 
variation. It is possible that the transiently transfected cell line exhibited potent DAMPs causing 
DC maturation. Linearizing the plasmid DNA prior to transfection and including nuclear 
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localisation sequences within the DNA are methods of enhancing insertion events 372 and could 
be incorporated into future experiments although it is not clear if this would be effective in 
suspension cells which are typically less permissive to transfection (personal communication 
Richard Beswick, KCL).  
 
Another strategy to permanently modify a cell line is to use transduction. Transduction would have 
been applicable to both adherent and suspension cell types; allowing optimisation of this study in 
both EGFR and CD20 disease contexts. Ruben et al describe the use of MelanA transduced 
HL60 suspension cells in the study of induced T-cell immunity 106, monitoring IFNγ secretion by 
MelanAT cells after exposure to DC primed with MelanA+HL60 cell lysates. However, even if stable 
MelanA+A431 cells were achieved, detecting differences in the extent of cross presentation could 
still prove difficult because the MelanAT cells may have differentiated into an effector memory 
phenotype during expansion. Memory T cells have a lower threshold of activation and may have 
been triggered solely by the cytokines produced in the co-culture, an observation described by 
Geginat et al 373.  
 
If all of these issues are addressed and spontaneous activation reduced to a minimum, in addition 
to upregulation of T-cell activation markers, T-cell proliferation measured by CFSE dilution could 
be an appropriate in vitro readout for cross presentation before proceeding to in vivo assessment. 
 
5.7.4. Potential in vivo experiments to assess anti-tumour immunity 
Gerdes et al demonstrated superior in vivo ADCC activity compared to cetuximab using a human 
tumour xeongraft model. Briefly, human FcγRIIIA transgenic SCID mice (which express human 
FcγRIIIA-positive transgenic murine NK cells as effectors) were injected with tumour cells 
exhibiting various levels of EGFR expression. Once tumours were established, animals received 
weekly doses of either cetuximab or imgatuzumab and OS was monitored. Median OS was 
significantly increased in animals receiving imgatuzumab compared with cetuximab, 
panitumumab or vehicle control for models of lung-, colorectal-, pancreatic- and breast-cancer 205. 
At the time of writing, it was not possible to find a tumour xenograft mouse model assessing 
ADCC-induced anti-tumour immunity. It is instead proposed to adapt an established mouse model 




Chen et al (2016) observed tumourigenicity using LOVO CRC cells subcutaneously injected into 
BALB/c nude mice 374. Mice receiving cetuximab plus NK cells showed the greatest tumour 
inhibition effect compared with NK cells or cetuximab alone. Although they did not see complete 
tumour clearance in any of their test conditions, this could possibly be achieved via careful 
optimisation of effector/target cell numbers and mAb concentration. Adapting this model for 
measurement of tumour immunity would involve infusing HLA-A*02- tumour cells, followed by 
infusion of TA-specific mAb and adoptive transfer of NK cells, DC and a small percentage of TA-
specific T cells from the same HLA-A*02+ donor. Like the in vitro model depicted in Figure 5.1, in 
vivo T-cells are unable to recognise tumour cells directly and T-cell stimulation is dependent upon 
ADCC-mediated lysis of HLA-A*02- tumour cells, uptake of exogenous tumour particulate by DC 
and cross presentation by DC to HLA-A*02 restricted CD8+ T cells. Once the tumour is abolished, 
re-infusion of the same tumour could be a means of testing whether TA-specific T cells have 




Chapter 6. Concluding remarks 
 
6.1. Summary 
The genetic alterations that accumulate in tumour cells endow them with the ability to resist cell 
death and evade growth suppression and destruction by immune cells 2. An increased 
understanding of the tumour microenvironment and anti-tumour immunity has led to intense 
interest in manipulating the balance between the positive immune-stimulatory signals and 
negative regulatory signals involved in tumourigenesis 375. Several immunotherapeutic strategies 
have been developed that aim to harness the power of the immune system to overcome immune 
tolerance to tumour cells. Therapeutic anti-TA mAbs such as cetuximab and rituximab are at the 
forefront of these strategies, with substantial pharmaceutical investment driven by relative ease of 
production and administration 142. 
 
A major component of the therapeutic efficacy of these IgG1 mAbs is their ability to recruit CD16-
bearing NK cells to elicit ADCC. However, a common CD16 SNP (V158F) has been correlated 
with efficacy of clinical responses to these mAbs 210, 255. Mechanistically, this polymorphism was 
found to modulate the affinity of CD16 for antibodies, in turn affecting the potency of ADCC 205, 209. 
The observations connecting antibody/receptor affinity, ADCC efficiency and clinical outcomes 
were crucial, as they led to the prediction that enhancements of mAb affinity for CD16 would 
result in significant clinical benefits. GE mAbs show improved therapeutic potential because the 
glycosylation modification increases affinity for CD16 and leads to enhanced ADCC, irrespective 
of CD16 genotype 205, 232. Therefore, GE-mAb mediated ADCC enhancement has the potential to 
benefit those patients in whom unmodified mAbs are either partially or totally ineffective, such as 
individuals with the low-affinity CD16 polymorphism 205, 232, 376 or KRAS gain-of-function mutations 
377. 
 
Studies have shown that the immune-cell interactions that follow ADCC of tumour cells can lead 
to the generation of T-cell mediated cancer immunity, via DC cross presentation of TA to CD8+ T 
cells 97, 378. The aim and novelty of the work described in this thesis was to build on and extend 
the evidence described for conventional therapeutic mAbs by investigating whether ADCC 
mediated by GE-mAbs could also lead to cross presentation of TA. This was examined by 
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assessing tumour cell apoptosis and NK-cell activation in the presence of GE-mAbs and the 
subsequent impact of ADCC-activated NK cells on DC maturation, because DC maturation is a 
prerequisite for efficient T-cell stimulation 87, 90. The priming and establishment of TA-specific 
memory T cells is essential for long-term cancer immunosurveillance to prevent disease relapse 
164.  
 
The results detailed within this thesis have demonstrated that GE mAbs can induce the NK-cell 
activation, NK-cell function and DC maturation associated with adaptive cellular immune 
responses. Previous studies of GE-mAbs have been tumour-orientated and focused primarily on 
tumour:mAb interactions rather than the NK-cell activation and function associated with promoting 
adaptive cellular immunity. The work presented in this thesis has begun to elucidate the 
phenotype of primary NK cells activated by GE-mAb-mediated ADCC and their impact on DC 
maturation in vitro. Furthermore, the results presented have implied that, when compared at 
equivalent concentration, GE-mAbs promote NK-cell activity to a greater extent than unmodified 
mAbs. First, via enhanced NK-cell activation: the GE mAbs promoted expression of markers of 
NK-cell function and activation compared to unmodified mAbs, including significantly increased 
expression of CD107a, IFNγ, TNFα and CD69 and significant downregulation of CD16. Second, 
via enhanced provision of tumour particulate for DC: ADCC in the presence of GA101GE induced 
a significantly higher frequency of tumour-cell apoptosis compared to GA101WT. Importantly, it 
was also shown that GA101GE-treated tumour particulate was ingested by DC. Third, via 
enhanced DC maturation: GE-mAb activated NK cells induced DC maturation to a significantly 
greater extent than unmodified mAbs. These findings indicate that some of the essential pre-
requisite criteria for DC cross presentation of TA, namely provision of tumour particulate, NK-cell 
activation and maturation of DC were induced by GE-mAbs and to a significantly greater extent at 
low concentrations compared with conventional therapeutic mAbs. 
 
6.2. Limitations of the multi-cell in vitro co-culture model 
The conclusions that can be drawn from the reported findings are limited by several caveats that 
have been acknowledged previously, including: lack of mAb normalisation, use of only a limited 





6.2.1. Limitations of established cell lines 
Results chapters detailed some limitations of the effector cells used in this study however, it is 
also necessary to comment on the general use of established cancer cell lines as opposed to 
patient primary cancer cells as target populations. Although convenient, easy to handle and 
widely published, cell lines typically represent a single donor and are sometimes established from 
metastases raising debate about whether metastases will respond like their primary tumours. 
Serial passaging of cell lines over time can cause phenotypic and genotypic variation. Cells grown 
in vitro are subject to “selection pressure” where, for example, cells that gain mutations enabling 
faster growth will come to dominate a culture in time; or cultures grown at low density may select 
for cells capable of density independent growth. A widely cited bioinformatic analysis of proteomic 
phenotypes conducted by Pan et al revealed that the Hepa1–6 cell lines were deficient in 
mitochondria, reflecting rearrangement of metabolic pathways when compared to primary 
hepatocytes 379. Researchers should therefore be careful about relying solely on data generated 
with cell lines. Primary cells are believed to be more biologically relevant and the current 
recommendation from the scientific community is to conduct key control experiments with primary 
cells of low passage to qualify and/or verify the findings seen in cell lines. With the emergence of 
newer technologies such as 3D culture, the use of primary cells is becoming increasingly 
prevalent and has further improved disease modelling and high-throughput therapeutic screening 
380. In future, using a variety of low passage patient primary cells from many different donors and 
cancer subtypes should be considered, to assess wider applicability of results and clinical 
relevance. 
 
6.2.2. Limitations of the readout assay 
The use of flow cytometry enabled multiparametric assessment of each individual cell type in the 
co-culture, but the technique has relatively low sensitivity. For example, a frequency of 
approximately 100 per 106 cells (0.01%) is necessary to obtain a positive measurement of IFNγ 
by ICS 381, however as low as 5 spot forming units/106 PBMC can be reliably detected in IFNγ 
enzyme-linked immune absorbent spot assays 382. This increased sensitivity could be crucial in a 
setting where the population of interest is rare; such as the self-antigen specific T cells that 
proved difficult to obtain in this study. Another important consideration is that ICS measures the 
production and accumulation of a cytokine but not the release of it. Inhibition of protein transport 
is required for ICS analysis, but is non-physiological and can affect all cells. Notably, the protein 
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transport inhibitor BSA has been shown to prevent CD69 surface expression 288; highlighting that 
study design and the choice of reagents plays an important role in study outcome. 
 
An interesting advance in flow cytometric analysis is the development of Amnis® imaging flow 
cytometers (marketed by Merck Millipore). This technology combines surface and intracellular 
staining with the imaging of individual cells to enable assessment of internalisation, localisation 
and cell-to-cell interactions. Amnis® offers more economical use of study material as it removes 
the need for separate flow and microscopy staining; which could help to extend the results 
described herein as cell availability was a limitation. Future investigations should ideally include 
results reproduced using a variety of techniques that complement one-another. 
 
6.3. Future directions 
Although this study focused on mAbs used for malignancies expressing EGFR and CD20, in 
principle this glyco-engineering approach has wider applicability. Indeed, several other receptors 
are being targeted by anti-TA mAbs 141, notable examples of which include trastuzumab and 
daratumumab. Trastuzumab is currently approved for use in early stage and metastatic human 
epidermal growth factor receptor 2 positive (HER2+) breast cancer, either alone or in combination 
with chemotherapy 383. Trastuzumab is on the WHO list of essential medicines 384. Daratumumab 
targets CD38 and is indicated for use in multiple myeloma and potential use in diffuse large B-cell 
lymphoma, follicular lymphoma, and mantle-cell lymphoma, all considered rare conditions. 
Daratumumab was given breakthrough therapy status in 2013 385. Endowing ligand-blocking 
mAbs with enhanced ADCC-triggering capabilities in such diseases may prove beneficial. 
However, as mAb manipulation becomes increasingly common, the work described in this thesis 
provides a cautionary note on the importance of selecting suitable target antigens. Results 
demonstrated that the enhanced efficacy seen with imgatuzumab over cetuximab was also 
observed when EGFR was expressed at lower levels. This has implications for normal cells that 
may express TA at low levels and suggests that GE-mAb effects may not spare healthy tissues. 
 
Careful consideration must therefore be taken with antigen selection when using GE-mAbs. On 
this note, CD20 has proven to be an exemplary target because the expression of this glycoprotein 
is tightly restricted to B cells. In targeting CD20, GA101GE offers numerous advantages over 
rituximab. Cheadle and colleagues demonstrated that the induction of immunogenic cell death by 
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GA101GE had mechanistic differences compared with rituximab. After incubating CD20+ Daudi 
cells with mAbs at 10µg/ml, they measured the release of DAMP molecules in the supernatant via 
western blot. DAMP molecules such as heat shock protein 90 (HSP90) and high mobility group 
box 1 protein (HMGB1) can prime DC maturation and subsequent T-cell activation. GA101GE 
induced significant release of HSP90 and HMGB1 compared to rituximab, and significantly 
enhanced DC maturation when these supernatants were incubated with iDC 332. The comparison 
of GA101WT and GA101GE in this study has indicated that enhanced DC maturation is quite 
likely the result of glyco-engineering. When NK cells are present, these effects can be seen at 
lower mAb-concentrations than those used in the Cheadle study; concentrations that may more 
accurately represent the bioavailability of mAbs in tumour lesions 318, 319, 320. 
 
Recent reviews on the use of mAbs for the treatment of B-cell malignancies predict that 
GA101GE will replace rituximab in most of the combined immunotherapy/chemotherapy regimens 
297, 386. Importantly, GA101GE may be combined with other immunotherapies to further enhance 
its therapeutic effect. Engagement of TLR expressed on DC can trigger a cascade of signalling 
pathways that lead to production of proinflammatory cytokines and polarization of T-cell 
responses. Synthetic agonists of TLR7/8 have been shown to activate pDC and myeloid DC, 
stimulating the production of type I interferons, strong TH1 immunity and CD8+ T-cell responses 
387. In early 2017, Cheadle and colleagues used a murine lymphoma model to demonstrate that 
the addition of the TLR agonist R848 (Resiquimod) enhanced the therapeutic efficacy of 
GA101GE in an NK-cell-dependent manner. This lead to long-term survival and anti-tumour 
immunity, providing proof of principle and rationale for translation to the clinic 388. 
 
Other studies have shown promising results when combining rituximab with tyrosine kinase 
inhibitors (TKI). The Bruton TKI ibrutinib inhibits the migration and adhesion of CLL cells into the 
protective microenvironment, thereby leading to a redistribution and mobilization of these cells 
from the lymphoid tissue to the peripheral blood, which can be seen in the peripheral blood as 
transient lymphocytosis. Because lymphocytosis remains largely asymptomatic and can persist 
for long periods (up to 124 weeks), the combination of ibrutinib with other agents that clear the 
peripheral blood of CLL cells is a reasonable therapeutic approach 389. A recent phase II trial 
evaluated rituximab plus ibrutinib in 40 patients with high-risk CLL/small lymphocytic lymphoma. 
An ORR of 95% was achieved, with 3 complete remissions and 1 minimal residual disease 
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(MRD)–negative case 390. However, Cramer et al considered the combination of ibrutinib and 
GA101GE a more attractive option. They speculated that as ibrutinib redistributes the CLL cells 
from their homing organs to the peripheral blood, GA101GE would eliminate the leukaemic cells 
with greater efficiency than rituximab. Furthermore, they suggested that adding the Bcl-2 
antagonist venetoclax could further intensify this treatment in CLL patients with a specific 
chromosomal abnormality known as 17p deletion (del(17p)/TP53) and that this combination, in 
the absence of chemotherapy, may hold the potential to achieve a deep remission with an 
eradication of residual CLL cells, thus leading to long-term remissions of CLL 391. 
Cramer and colleagues recently reported the results of a sequential combination therapy 
comprising bendamustine debulking followed by ibrutinib and GA101GE (BIG regimen) in a 
heterogeneous group of 61 CLL patients 392. The BIG regimen appeared to improve the efficacy 
of CLL therapy in both a frontline and relapsed/refractory setting. An ORR of 100% and a MRD 
negativity rate of 47.5% compared favourably with ibrutinib monotherapy response rates of 86% 
in CLL: first-line treatment 393, and 71% in CLL: relapsed/refractory 394. A similar ORR of 95% was 
reached in a combination study using rituximab and ibrutinib in a high-risk CLL population, but 
only 1 out of 40 patients was MRD negative 395. 
 
Another promising direction in cancer therapeutics is the advent of ‘universal’ antibody-mediated 
cell therapy (uACT). The uACT comprises T cells engineered for use irrespective of HLA barriers 
and incorporating a signalling chimeric FcγRIIIa receptor (cFcR) for use in combination with 
existing therapeutic mAbs 396. Etuk et al recently generated a uACT by transduction of healthy 
donor cells with a self-inactivating lentiviral ‘terminal’ vector. This platform coupled cFcR 
expression with CRISPR/Cas9-mediated scission via precise incorporation of a single guide RNA 
element into the ∆U3 3’ lentiviral long terminal repeat. Delivery of Cas9 mRNA by electroporation 
resulted in highly efficient modification of the T-cell receptor (TCR) α-chain locus and automated 
magnetic bead-mediated depletion enabled enrichment of highly homogenous (>90%) FcγRIIIa+ 
(>99%) TCR- populations. In vitro cytotoxicity studies confirmed that uACTs specifically killed 
Daudi lymphoma cells in combination with rituximab or SKBR3 breast cancer cells in combination 
with trastuzumab. In contrast, uACTs alone or antibody alone produced no effect 396. Preliminary 
in vivo experiments investigated anti-leukaemic efficacy using serial bioluminescence in a 
humanised immunodeficient murine tumour model. Complete tumour clearance was observed in 
100% of mice (n=5) infused with uACT effectors in combination with rituximab when compared to 
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uACT alone, untransduced or vehicle control groups and sustained for 25 days post tumour 
challenge. Bone marrow harvests further corroborated these findings with an indication to extend 
experimental duration to assess whether rituximab per se can also sustain tumour clearance. The 
uACT production processes were scalable and adaptable to GMP compliant manufacturing 396, 
providing a route to clinical phase evaluation in an allogeneic setting, potentially in combination 
with GE-mAbs. 
 
A major challenge in cancer therapy is tumour escape, often characterised by treatment related 
loss or downregulation of TA 317. This may be overcome by simultaneously targeting receptors 
that are co-expressed on tumour cells. Antibodies harbouring dual specificities were briefly 
discussed in section 1.10.1.3, however these were standard, unmodified antibodies, which 
recruited T cells for ADCC via CD3 ligation 152, 153. Recently, Schanzer and colleagues from 
Roche-Glycart described the design and in vitro/in vivo characterisation of XGFR*, a novel GE-
bispecific antibody targeting both EGFR and the insulin-like growth factor-1 receptor (IGF-1R) 397. 
Mechanistically this antibody combines potent signalling and tumour growth inhibition with 
enhanced ADCC induction, mediated by an afucosylated Fc portion. XGFR* potently inhibited 
EGFR- and IGF-1R-dependent receptor phosphorylation, reduced tumour cell proliferation in cells 
with heterogeneous levels of EGFR and IGF-1R expression and induced strong ADCC in vitro. 
Pancreatic cancers frequently show a high degree of EGFR/IGF-1R co-expression, thus the 
authors employed the murine orthotopic MiaPaCa-2 pancreatic xenograft model to explore 
XGFR* in vivo efficacy. Administration of XGFR* resulted in nearly complete tumour growth 
inhibition, with a significant number of tumour remissions compared to control. Interestingly, 
several human colorectal carcinoma models showed minimal or no sensitivity to XGFR*, 
highlighting the importance of appropriate disease indications in addition to appropriate antigen 
selection 397. 
 
While in vitro and pre-clinical in vivo mouse studies are the first test of feasibility and a foundation 
from which to build upon, the ultimate test of any new agent is its clinical performance. Although 
novel anti-CD20 agents such as GA101GE are claimed to have high potency, it is a concern that 
much higher doses than those used in a standard rituximab regimen were chosen to show 
superior efficacy 398. Indeed a more recent clinical study comparing imgatuzumab and cetuximab 
has also perpetuated this dosing inequality 399. Chang et al highlight these points and emphasise 
223 
 
that clinical comparisons require parallel cohorts in which novel candidate mAbs are administered 
in similar or even lower doses and schedules to prove superiority 400. 
 
Studies of clinical effectiveness of novel immunotherapeutic strategies require accompanying 
research to obtain knowledge of the underlying immune-cell crosstalk mechanisms. The work 
presented in this thesis indicates that GE-mAbs may be able to promote CD8+ T-cell mediated 




Chapter 7. Appendix 
 
Details of the DNA sequences of the plasmid expression vectors, custom made by Oxford 
Genetics, are provided. The data were arranged using SnapGeneViewer Software, version 2.82 
(GSL Biotech LLC | Chicago, USA - 2016) and are displayed in the GenBank flat file format 
described by the National Center for Biotechnology Information (NCBI) 401. 
 
7.1. Control Plasmid “CMV-P2A.eGFP-IRES-Puro” 
 
LOCUS       pSF_CMV_P2A_eGFP_IRES_Puro   6164bp   DNA circular   16-MAR-2015 
DEFINITION   
ACCESSION    
VERSION      
SOURCE       
ORGANISM   
COMMENT     Oxford Genetics GenBank Format File 
 
FEATURES             Location/Qualifiers 
     source          1..6164 
                     /organism="E.coli" 
                     /strain="XL1 Blue" 
                     /mol_type="plasmid DNA" 
 
     misc_feature    18..89 
                     /note="BetaGlobin Insulator" 
 
     promoter        238..810 
                     /note="CMV" 
 
     RBS             893..906 
                     /note="KOZAK_ShineDalgarno" 
 
     CDS             907..1692  
                     /note="P2A_eGFP" 
 
     misc_feature    910..972 
                     /note="P2A Tag" 
 
     misc_feature    1717..1727 
                     /note="Stop codons x 3" 
 
     misc_feature    1768..2318 
                     /note="EMCV IRES" 
 
     CDS             2321..2920 
                     /note="Puromycin Resistance" 
 
     misc_feature    2928..2938 
                     /note="Stop codons x 3" 
 
     polyA_site      2961..3152 
                     /note="SV40 PolyA" 
 
     terminator      3206..3253 
                     /note="T7" 
 
     terminator      3283..3419 
                     /note="RrnG" 
 
     misc_feature    3463..3534 
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                     /note="BetaGlobin Insulator" 
 
     rep_origin      3700..4584 
                     /note="pUC Origin" 
 
     promoter        5009..5037 
                     /note="Selection Gene" 
 
     CDS             5094..5888 
                     /note="Kanamycin Resistance" 
 
     terminator      5902..6038 
                     /note="RrnG" 
 
ORIGIN       
        1 GCGATCGCGG CTCCCGACAT CTTGGACCAT TAGCTCCACA GGTATCTTCT TCCCTCTAGT 
       61 GGTCATAACA GCAGCTTCAG CTACCTCTCA ATTCAAAAAA CCCCTCAAGA CCCGTTTAGA 
      121 GGCCCCAAGG GGTTATGCTA TCAATCGTTG CGTTACACAC ACAAAAAACC AACACACATC 
      181 CATCTTCGAT GGATAGCGAT TTTATTATCT AACTGCTGAT CGAGTGTAGC CAGATCTAGT 
      241 AATCAATTAC GGGGTCATTA GTTCATAGCC CATATATGGA GTTCCGCGTT ACATAACTTA 
      301 CGGTAAATGG CCCGCCTGGC TGACCGCCCA ACGACCCCCG CCCATTGACG TCAATAATGA 
      361 CGTATGTTCC CATAGTAACG CCAATAGGGA CTTTCCATTG ACGTCAATGG GTGGAGTATT 
      421 TACGGTAAAC TGCCCACTTG GCAGTACATC AAGTGTATCA TATGCCAAGT ACGCCCCCTA 
      481 TTGACGTCAA TGACGGTAAA TGGCCCGCCT GGCATTATGC CCAGTACATG ACCTTATGGG 
      541 ACTTTCCTAC TTGGCAGTAC ATCTACGTAT TAGTCATCGC TATTACCATG CTGATGCGGT 
      601 TTTGGCAGTA CATCAATGGG CGTGGATAGC GGTTTGACTC ACGGGGATTT CCAAGTCTCC 
      661 ACCCCATTGA CGTCAATGGG AGTTTGTTTT GGCACCAAAA TCAACGGGAC TTTCCAAAAT 
      721 GTCGTAACAA CTCCGCCCCA TTGACGCAAA TGGGCGGTAG GCGTGTACGG TGGGAGGTCT 
      781 ATATAAGCAG AGCTGGTTTA GTGAACCGTC AGATCAGATC TTTGTCGATC CTACCATCCA 
      841 CTCGACACAC CCGCCAGCGG CCGCTGCCAA GCTTCCGAGC TCTCGAATTC AAAGGAGGTA 
      901 CCCACCATGG GAAGCGGAGA GGGCAGAGGA AGTCTGCTAA CATGCGGTGA CGTCGAGGAG 
      961 AATCCTGGAC CTATGGTGTC CAAGGGAGAA GAGCTGTTCA CGGGAGTTGT TCCAATTCTT 
     1021 GTTGAGCTGG ATGGGGATGT TAACGGCCAT AAATTCTCCG TAAGCGGGGA GGGCGAGGGA 
     1081 GACGCCACTT ACGGGAAGCT TACCTTGAAA TTTATTTGCA CTACAGGAAA GCTGCCAGTG 
     1141 CCCTGGCCTA CGCTGGTCAC TACCTTGACC TACGGGGTTC AGTGCTTCTC CAGGTATCCG 
     1201 GATCATATGA AACAGCATGA TTTCTTTAAA AGCGCCATGC CAGAGGGTTA TGTACAGGAA 
     1261 CGAACGATCT TCTTTAAGGA TGACGGGAAC TACAAGACCC GCGCAGAGGT GAAATTTGAA 
     1321 GGAGATACGC TGGTGAACAG AATAGAGCTG AAGGGGATCG ACTTCAAAGA AGATGGCAAC 
     1381 ATCCTGGGCC ACAAGCTTGA ATATAACTAC AACAGCCATA ACGTATATAT CATGGCTGAC 
     1441 AAGCAGCGAA ATGGAATTAA GGCCAACTTC AAGATTCGGC ACAACATCGA AGACGGGAGC 
     1501 GTGCAGCTGG CCGACCATTA CCAGCAGAAC ACCCCTATCG GGGATGGCCC AGTGCTGCTG 
     1561 CCTGATAATC ATTATCTCAG CACGCAGTCT GCCCTGTCTA AAGACCCCAA CGAGAAAAGG 
     1621 GACCATATGG TCCTGCTGGA ATTTGTGACA GCAGCTGGCA TCACCCTGGG AATGGATGAA 
     1681 CTCTACAAGT AGTCTAGAAG TTGTCTCCTC CTGCACTGAC TGACTGATAC AATCGATATG 
     1741 CCAAAAGCAA AGCGCTATCG CGCCTTACGT TACTGGCCGA AGCCGCTTGG AATAAGGCCG 
     1801 GTGTGCGTTT GTCTATATGT TATTTTCCAC CATATTGCCG TCTTTTGGCA ATGTGAGGGC 
     1861 CCGGAAACCT GGCCCTGTCT TCTTGACGAG CATTCCTAGG GGTCTTTCCC CTCTCGCCAA 
     1921 AGGAATGCAA GGTCTGTTGA ATGTCGTGAA GGAAGCAGTT CCTCTGGAAG CTTCTTGAAG 
     1981 ACAAACAACG TCTGTAGCGA CCCTTTGCAG GCAGCGGAAC CCCCCACCTG GCGACAGGTG 
     2041 CCTCTGCGGC CAAAAGCCAC GTGTATAAGA TACACCTGCA AAGGCGGCAC AACCCCAGTG 
     2101 CCACGTTGTG AGTTGGATAG TTGTGGAAAG AGTCAAATGG CTCCCCTCAA GCGTATTCAA 
     2161 CAAGGGGCTG AAGGATGCCC AGAAGGTACC CCATTGTATG GGATCTGATC TGGGGCCTCG 
     2221 GTGCACATGC TTTTCATGTG TTTAGTCGAG GTTAAAAAAC GTCTAGGCCC CCCGAACCAC 
     2281 GGGGACGTGG TTTTCCTTTG AAAAACACGA TGATAATAAC ATGACCGAGT ACAAGCCCAC 
     2341 GGTGCGCCTC GCCACCCGCG ACGACGTCCC CAGGGCCGTA CGCACCCTCG CCGCCGCGTT 
     2401 CGCCGACTAC CCCGCCACGC GCCACACCGT CGATCCGGAC CGCCACATCG AGCGGGTCAC 
     2461 CGAGCTGCAA GAACTCTTCC TCACGCGCGT CGGGCTCGAC ATCGGCAAGG TGTGGGTCGC 
     2521 GGACGACGGC GCCGCGGTGG CGGTCTGGAC CACGCCGGAG AGCGTCGAAG CGGGGGCGGT 
     2581 GTTCGCCGAG ATCGGCCCGC GCATGGCCGA GTTGAGCGGT TCCCGGCTGG CCGCGCAGCA 
     2641 ACAGATGGAG GGCCTCCTGG CGCCGCACCG GCCCAAGGAG CCCGCGTGGT TCCTGGCCAC 
     2701 CGTCGGCGTC TCGCCCGACC ACCAGGGCAA GGGTCTGGGC AGCGCCGTCG TGCTCCCCGG 
     2761 AGTGGAGGCC GCCGAGCGCG CCGGGGTGCC CGCCTTCCTG GAGACCTCCG CGCCCCGCAA 
     2821 CCTCCCCTTC TACGAGCGGC TCGGCTTCAC CGTCACCGCC GACGTCGAGG TGCCCGAAGG 
     2881 ACCGCGCACC TGGTGCATGA CCCGCAAGCC CGGTGCCTAG GCTAGCTTGA CTGACTGAGA 
     2941 TACAGCGTAC CTTCAGCTCA CAGACATGAT AAGATACATT GATGAGTTTG GACAAACCAC 
     3001 AACTAGAATG CAGTGAAAAA AATGCTTTAT TTGTGAAATT TGTGATGCTA TTGCTTTATT 
     3061 TGTAACCATT ATAAGCTGCA ATAAACAAGT TAACAACAAC AATTGCATTC ATTTTATGTT 
     3121 TCAGGTTCAG GGGGAGGTGT GGGAGGTTTT TTAAAGCAAG TAAAACCTCT ACAAATGTGG 
     3181 TATTGGCCCA TCTCTATCGG TATCGTAGCA TAACCCCTTG GGGCCTCTAA ACGGGTCTTG 
     3241 AGGGGTTTTT TGTGCCCCTC GGGCCGGATT GCTATCTACC GGCATTGGCG CAGAAAAAAA 
     3301 TGCCTGATGC GACGCTGCGC GTCTTATACT CCCACATATG CCAGATTCAG CAACGGATAC 
     3361 GGCTTCCCCA ACTTGCCCAC TTCCATACGT GTCCTCCTTA CCAGAAATTT ATCCTTAAGG 
     3421 TCGTCAGCTA TCCTGCAGGC GATCTCTCGA TTTCGATCAA GACATTCCTT TAATGGTCTT 
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     3481 TTCTGGACAC CACTAGGGGT CAGAAGTAGT TCATCAAACT TTCTTCCCTC CCTAATCTCA 
     3541 TTGGTTACCT TGGGCTATCG AAACTTAATT AACCAGTCAA GTCAGCTACT TGGCGAGATC 
     3601 GACTTGTCTG GGTTTCGACT ACGCTCAGAA TTGCGTCAGT CAAGTTCGAT CTGGTCCTTG 
     3661 CTATTGCACC CGTTCTCCGA TTACGAGTTT CATTTAAATC ATGTGAGCAA AAGGCCAGCA 
     3721 AAAGGCCAGG AACCGTAAAA AGGCCGCGTT GCTGGCGTTT TTCCATAGGC TCCGCCCCCC 
     3781 TGACGAGCAT CACAAAAATC GACGCTCAAG TCAGAGGTGG CGAAACCCGA CAGGACTATA 
     3841 AAGATACCAG GCGTTTCCCC CTGGAAGCTC CCTCGTGCGC TCTCCTGTTC CGACCCTGCC 
     3901 GCTTACCGGA TACCTGTCCG CCTTTCTCCC TTCGGGAAGC GTGGCGCTTT CTCATAGCTC 
     3961 ACGCTGTAGG TATCTCAGTT CGGTGTAGGT CGTTCGCTCC AAGCTGGGCT GTGTGCACGA 
     4021 ACCCCCCGTT CAGCCCGACC GCTGCGCCTT ATCCGGTAAC TATCGTCTTG AGTCCAACCC 
     4081 GGTAAGACAC GACTTATCGC CACTGGCAGC AGCCACTGGT AACAGGATTA GCAGAGCGAG 
     4141 GTATGTAGGC GGTGCTACAG AGTTCTTGAA GTGGTGGCCT AACTACGGCT ACACTAGAAG 
     4201 AACAGTATTT GGTATCTGCG CTCTGCTGAA GCCAGTTACC TTCGGAAAAA GAGTTGGTAG 
     4261 CTCTTGATCC GGCAAACAAA CCACCGCTGG TAGCGGTGGT TTTTTTGTTT GCAAGCAGCA 
     4321 GATTACGCGC AGAAAAAAAG GATCTCAAGA AGATCCTTTG ATCTTTTCTA CGGGGTCTGA 
     4381 CGCTCAGTGG AACGAAAACT CACGTTAAGG GATTTTGGTC ATGAGATTAT CAAAAAGGAT 
     4441 CTTCACCTAG ATCCTTTTAA ATTAAAAATG AAGTTTTAAA TCAATCTAAA GTATATATGA 
     4501 GTAAACTTGG TCTGACAGTT ACCAATGCTT AATCAGTGAG GCACCTATCT CAGCGATCTG 
     4561 TCTATTTCGT TCATCCATAG TTGCATTTAA ATTTCCGAAC TCTCCAAGGC CCTCGTCGGA 
     4621 AAATCTTCAA ACCTTTCGTC CGATCCATCT TGCAGGCTAC CTCTCGAACG AACTATCGCA 
     4681 AGTCTCTTGG CCGGCCTTGC GCCTTGGCTA TTGCTTGGCA GCGCCTATCG CCAGGTATTA 
     4741 CTCCAATCCC GAATATCCGA GATCGGGATC ACCCGAGAGA AGTTCAACCT ACATCCTCAA 
     4801 TCCCGATCTA TCCGAGATCC GAGGAATATC GAAATCGGGG CGCGCCTGGT GTACCGAGAA 
     4861 CGATCCTCTC AGTGCGAGTC TCGACGATCC ATATCGTTGC TTGGCAGTCA GCCAGTCGGA 
     4921 ATCCAGCTTG GGACCCAGGA AGTCCAATCG TCAGATATTG TACTCAAGCC TGGTCACGGC 
     4981 AGCGTACCGA TCTGTTTAAA CCTAGATATT GATAGTCTGA TCGGTCAACG TATAATCGAG 
     5041 TCCTAGCTTT TGCAAACATC TATCAAGAGA CAGGATCAGC AGGAGGCTTT CGCATGATTG 
     5101 AACAAGATGG ATTGCACGCA GGTTCTCCGG CGGCTTGGGT GGAGAGGCTA TTCGGCTATG 
     5161 ACTGGGCACA ACAGACAATC GGCTGCTCTG ATGCCGCCGT GTTCCGGCTG TCAGCGCAGG 
     5221 GGCGTCCGGT TCTTTTTGTC AAGACCGACC TGTCCGGTGC CCTGAATGAA CTGCAAGACG 
     5281 AGGCAGCGCG GCTATCGTGG CTGGCGACGA CGGGCGTTCC TTGCGCGGCT GTGCTCGACG 
     5341 TTGTCACTGA AGCGGGAAGG GACTGGCTGC TATTGGGCGA AGTGCCGGGG CAGGATCTCC 
     5401 TGTCATCTCA CCTTGCTCCT GCCGAGAAAG TATCCATCAT GGCTGATGCA ATGCGGCGGC 
     5461 TGCATACGCT TGATCCGGCT ACCTGCCCAT TCGACCACCA AGCGAAACAT CGCATCGAGC 
     5521 GAGCACGTAC TCGGATGGAA GCCGGTCTTG TCGATCAGGA TGATCTGGAC GAAGAGCATC 
     5581 AGGGGCTCGC GCCAGCCGAA CTGTTCGCCA GGCTCAAGGC GTCTATGCCC GACGGCGAGG 
     5641 ATCTCGTCGT GACCCACGGC GATGCCTGCT TGCCGAATAT CATGGTGGAA AATGGCCGCT 
     5701 TTTCTGGATT CATCGACTGT GGCCGTCTGG GTGTGGCGGA CCGCTATCAG GACATAGCGT 
     5761 TGGCTACCCG TGATATTGCT GAAGAGCTTG GCGGCGAATG GGCTGACCGC TTCCTTGTGC 
     5821 TTTACGGTAT CGCCGCGCCC GATTCGCAGC GCATCGCCTT CTATCGCCTT CTTGACGAGT 
     5881 TCTTCTGACC GATTCTAGGT GCATTGGCGC AGAAAAAAAT GCCTGATGCG ACGCTGCGCG 
     5941 TCTTATACTC CCACATATGC CAGATTCAGC AACGGATACG GCTTCCCCAA CTTGCCCACT 
     6001 TCCATACGTG TCCTCCTTAC CAGAAATTTA TCCTTAAGGT CGTTTAAACT CGACTCTGGC 
     6061 TCTATCGAAT CTCCGTCGTT TCGAGCTTAC GCGAACAGCC GTGGCGCTCA TTTGCTCGTC 







7.2. MelanA Plasmid “CMV-MelanA.P2A.eGFP-IRES-Puro” 
 
LOCUS       pSF_CMV_MelanA_P2A_eGFP_IRES_Puro  6515bp  DNA circular  17-MAR-2015 
DEFINITION   
ACCESSION    
VERSION      
SOURCE       
ORGANISM   
COMMENT     Oxford Genetics GenBank Format File 
 
FEATURES             Location/Qualifiers 
     source          1..6515 
                     /organism="E.coli" 
                     /strain="XL1 Blue" 
                     /mol_type="plasmid DNA" 
 
     misc_feature    18..89 
                     /note="BetaGlobin Insulator" 
 
     promoter        238..810 
                     /note="CMV" 
 
     RBS             893..906 
                     /note="KOZAK_ShineDalgarno" 
 
     CDS             907..2043 
                     /note="MelanA_P2A_eGFP" 
 
     misc_feature    1261..1323 
                     /note="P2A Tag" 
 
     misc_feature    2068..2078 
                     /note="Stop codons x 3" 
 
     misc_feature    2119..2669 
                     /note="EMCV IRES" 
 
     CDS             2672..3271 
                     /note="Puromycin Resistance" 
 
     misc_feature    3279..3289 
                     /note="Stop codons x 3" 
 
     polyA_site      3312..3503 
                     /note="SV40 PolyA" 
 
     terminator      3557..3604 
                     /note="T7" 
 
     terminator      3634..3770 
                     /note="RrnG" 
 
     misc_feature    3814..3885 
                     /note="BetaGlobin Insulator" 
 
     rep_origin      4051..4935 
                     /note="pUC Origin" 
 
     promoter        5360..5388 
                     /note="Selection Gene" 
 
     CDS             5445..6239 
                     /note="Kanamycin Resistance" 
 
     terminator      6253..6389 




ORIGIN       
        1 GCGATCGCGG CTCCCGACAT CTTGGACCAT TAGCTCCACA GGTATCTTCT TCCCTCTAGT 
       61 GGTCATAACA GCAGCTTCAG CTACCTCTCA ATTCAAAAAA CCCCTCAAGA CCCGTTTAGA 
      121 GGCCCCAAGG GGTTATGCTA TCAATCGTTG CGTTACACAC ACAAAAAACC AACACACATC 
      181 CATCTTCGAT GGATAGCGAT TTTATTATCT AACTGCTGAT CGAGTGTAGC CAGATCTAGT 
      241 AATCAATTAC GGGGTCATTA GTTCATAGCC CATATATGGA GTTCCGCGTT ACATAACTTA 
      301 CGGTAAATGG CCCGCCTGGC TGACCGCCCA ACGACCCCCG CCCATTGACG TCAATAATGA 
      361 CGTATGTTCC CATAGTAACG CCAATAGGGA CTTTCCATTG ACGTCAATGG GTGGAGTATT 
      421 TACGGTAAAC TGCCCACTTG GCAGTACATC AAGTGTATCA TATGCCAAGT ACGCCCCCTA 
      481 TTGACGTCAA TGACGGTAAA TGGCCCGCCT GGCATTATGC CCAGTACATG ACCTTATGGG 
      541 ACTTTCCTAC TTGGCAGTAC ATCTACGTAT TAGTCATCGC TATTACCATG CTGATGCGGT 
      601 TTTGGCAGTA CATCAATGGG CGTGGATAGC GGTTTGACTC ACGGGGATTT CCAAGTCTCC 
      661 ACCCCATTGA CGTCAATGGG AGTTTGTTTT GGCACCAAAA TCAACGGGAC TTTCCAAAAT 
      721 GTCGTAACAA CTCCGCCCCA TTGACGCAAA TGGGCGGTAG GCGTGTACGG TGGGAGGTCT 
      781 ATATAAGCAG AGCTGGTTTA GTGAACCGTC AGATCAGATC TTTGTCGATC CTACCATCCA 
      841 CTCGACACAC CCGCCAGCGG CCGCTGCCAA GCTTCCGAGC TCTCGAATTC AAAGGAGGTA 
      901 CCCACCATGC CAAGAGAAGA TGCTCACTTC ATCTATGGTT ACCCCAAGAA GGGGCACGGC 
      961 CACTCTTACA CCACGGCTGA AGAGGCCGCT GGGATCGGCA TCCTGACAGT GATCCTGGGA 
     1021 GTCTTACTGC TCATCGGCTG TTGGTATTGT AGAAGACGAA ATGGATACAG AGCCTTGATG 
     1081 GATAAAAGTC TTCATGTTGG CACTCAATGT GCCTTAACAA GAAGATGCCC ACAAGAAGGG 
     1141 TTTGATCATC GGGACAGCAA AGTGTCTCTT CAAGAGAAAA ACTGTGAACC TGTGGTTCCC 
     1201 AATGCTCCAC CTGCTTATGA GAAACTCTCT GCAGAACAGT CACCACCACC TTATTCACCT 
     1261 GGAAGCGGAG AGGGCAGAGG AAGTCTGCTA ACATGCGGTG ACGTCGAGGA GAATCCTGGA 
     1321 CCTATGGTGT CCAAGGGAGA AGAGCTGTTC ACGGGAGTTG TTCCAATTCT TGTTGAGCTG 
     1381 GATGGGGATG TTAACGGCCA TAAATTCTCC GTAAGCGGGG AGGGCGAGGG AGACGCCACT 
     1441 TACGGGAAGC TTACCTTGAA ATTTATTTGC ACTACAGGAA AGCTGCCAGT GCCCTGGCCT 
     1501 ACGCTGGTCA CTACCTTGAC CTACGGGGTT CAGTGCTTCT CCAGGTATCC GGATCATATG 
     1561 AAACAGCATG ATTTCTTTAA AAGCGCCATG CCAGAGGGTT ATGTACAGGA ACGAACGATC 
     1621 TTCTTTAAGG ATGACGGGAA CTACAAGACC CGCGCAGAGG TGAAATTTGA AGGAGATACG 
     1681 CTGGTGAACA GAATAGAGCT GAAGGGGATC GACTTCAAAG AAGATGGCAA CATCCTGGGC 
     1741 CACAAGCTTG AATATAACTA CAACAGCCAT AACGTATATA TCATGGCTGA CAAGCAGCGA 
     1801 AATGGAATTA AGGCCAACTT CAAGATTCGG CACAACATCG AAGACGGGAG CGTGCAGCTG 
     1861 GCCGACCATT ACCAGCAGAA CACCCCTATC GGGGATGGCC CAGTGCTGCT GCCTGATAAT 
     1921 CATTATCTCA GCACGCAGTC TGCCCTGTCT AAAGACCCCA ACGAGAAAAG GGACCATATG 
     1981 GTCCTGCTGG AATTTGTGAC AGCAGCTGGC ATCACCCTGG GAATGGATGA ACTCTACAAG 
     2041 TAGTCTAGAA GTTGTCTCCT CCTGCACTGA CTGACTGATA CAATCGATAT GCCAAAAGCA 
     2101 AAGCGCTATC GCGCCTTACG TTACTGGCCG AAGCCGCTTG GAATAAGGCC GGTGTGCGTT 
     2161 TGTCTATATG TTATTTTCCA CCATATTGCC GTCTTTTGGC AATGTGAGGG CCCGGAAACC 
     2221 TGGCCCTGTC TTCTTGACGA GCATTCCTAG GGGTCTTTCC CCTCTCGCCA AAGGAATGCA 
     2281 AGGTCTGTTG AATGTCGTGA AGGAAGCAGT TCCTCTGGAA GCTTCTTGAA GACAAACAAC 
     2341 GTCTGTAGCG ACCCTTTGCA GGCAGCGGAA CCCCCCACCT GGCGACAGGT GCCTCTGCGG 
     2401 CCAAAAGCCA CGTGTATAAG ATACACCTGC AAAGGCGGCA CAACCCCAGT GCCACGTTGT 
     2461 GAGTTGGATA GTTGTGGAAA GAGTCAAATG GCTCCCCTCA AGCGTATTCA ACAAGGGGCT 
     2521 GAAGGATGCC CAGAAGGTAC CCCATTGTAT GGGATCTGAT CTGGGGCCTC GGTGCACATG 
     2581 CTTTTCATGT GTTTAGTCGA GGTTAAAAAA CGTCTAGGCC CCCCGAACCA CGGGGACGTG 
     2641 GTTTTCCTTT GAAAAACACG ATGATAATAA CATGACCGAG TACAAGCCCA CGGTGCGCCT 
     2701 CGCCACCCGC GACGACGTCC CCAGGGCCGT ACGCACCCTC GCCGCCGCGT TCGCCGACTA 
     2761 CCCCGCCACG CGCCACACCG TCGATCCGGA CCGCCACATC GAGCGGGTCA CCGAGCTGCA 
     2821 AGAACTCTTC CTCACGCGCG TCGGGCTCGA CATCGGCAAG GTGTGGGTCG CGGACGACGG 
     2881 CGCCGCGGTG GCGGTCTGGA CCACGCCGGA GAGCGTCGAA GCGGGGGCGG TGTTCGCCGA 
     2941 GATCGGCCCG CGCATGGCCG AGTTGAGCGG TTCCCGGCTG GCCGCGCAGC AACAGATGGA 
     3001 GGGCCTCCTG GCGCCGCACC GGCCCAAGGA GCCCGCGTGG TTCCTGGCCA CCGTCGGCGT 
     3061 CTCGCCCGAC CACCAGGGCA AGGGTCTGGG CAGCGCCGTC GTGCTCCCCG GAGTGGAGGC 
     3121 CGCCGAGCGC GCCGGGGTGC CCGCCTTCCT GGAGACCTCC GCGCCCCGCA ACCTCCCCTT 
     3181 CTACGAGCGG CTCGGCTTCA CCGTCACCGC CGACGTCGAG GTGCCCGAAG GACCGCGCAC 
     3241 CTGGTGCATG ACCCGCAAGC CCGGTGCCTA GGCTAGCTTG ACTGACTGAG ATACAGCGTA 
     3301 CCTTCAGCTC ACAGACATGA TAAGATACAT TGATGAGTTT GGACAAACCA CAACTAGAAT 
     3361 GCAGTGAAAA AAATGCTTTA TTTGTGAAAT TTGTGATGCT ATTGCTTTAT TTGTAACCAT 
     3421 TATAAGCTGC AATAAACAAG TTAACAACAA CAATTGCATT CATTTTATGT TTCAGGTTCA 
     3481 GGGGGAGGTG TGGGAGGTTT TTTAAAGCAA GTAAAACCTC TACAAATGTG GTATTGGCCC 
     3541 ATCTCTATCG GTATCGTAGC ATAACCCCTT GGGGCCTCTA AACGGGTCTT GAGGGGTTTT 
     3601 TTGTGCCCCT CGGGCCGGAT TGCTATCTAC CGGCATTGGC GCAGAAAAAA ATGCCTGATG 
     3661 CGACGCTGCG CGTCTTATAC TCCCACATAT GCCAGATTCA GCAACGGATA CGGCTTCCCC 
     3721 AACTTGCCCA CTTCCATACG TGTCCTCCTT ACCAGAAATT TATCCTTAAG GTCGTCAGCT 
     3781 ATCCTGCAGG CGATCTCTCG ATTTCGATCA AGACATTCCT TTAATGGTCT TTTCTGGACA 
     3841 CCACTAGGGG TCAGAAGTAG TTCATCAAAC TTTCTTCCCT CCCTAATCTC ATTGGTTACC 
     3901 TTGGGCTATC GAAACTTAAT TAACCAGTCA AGTCAGCTAC TTGGCGAGAT CGACTTGTCT 
     3961 GGGTTTCGAC TACGCTCAGA ATTGCGTCAG TCAAGTTCGA TCTGGTCCTT GCTATTGCAC 
     4021 CCGTTCTCCG ATTACGAGTT TCATTTAAAT CATGTGAGCA AAAGGCCAGC AAAAGGCCAG 
     4081 GAACCGTAAA AAGGCCGCGT TGCTGGCGTT TTTCCATAGG CTCCGCCCCC CTGACGAGCA 
     4141 TCACAAAAAT CGACGCTCAA GTCAGAGGTG GCGAAACCCG ACAGGACTAT AAAGATACCA 
     4201 GGCGTTTCCC CCTGGAAGCT CCCTCGTGCG CTCTCCTGTT CCGACCCTGC CGCTTACCGG 
     4261 ATACCTGTCC GCCTTTCTCC CTTCGGGAAG CGTGGCGCTT TCTCATAGCT CACGCTGTAG 
229 
 
     4321 GTATCTCAGT TCGGTGTAGG TCGTTCGCTC CAAGCTGGGC TGTGTGCACG AACCCCCCGT 
     4381 TCAGCCCGAC CGCTGCGCCT TATCCGGTAA CTATCGTCTT GAGTCCAACC CGGTAAGACA 
     4441 CGACTTATCG CCACTGGCAG CAGCCACTGG TAACAGGATT AGCAGAGCGA GGTATGTAGG 
     4501 CGGTGCTACA GAGTTCTTGA AGTGGTGGCC TAACTACGGC TACACTAGAA GAACAGTATT 
     4561 TGGTATCTGC GCTCTGCTGA AGCCAGTTAC CTTCGGAAAA AGAGTTGGTA GCTCTTGATC 
     4621 CGGCAAACAA ACCACCGCTG GTAGCGGTGG TTTTTTTGTT TGCAAGCAGC AGATTACGCG 
     4681 CAGAAAAAAA GGATCTCAAG AAGATCCTTT GATCTTTTCT ACGGGGTCTG ACGCTCAGTG 
     4741 GAACGAAAAC TCACGTTAAG GGATTTTGGT CATGAGATTA TCAAAAAGGA TCTTCACCTA 
     4801 GATCCTTTTA AATTAAAAAT GAAGTTTTAA ATCAATCTAA AGTATATATG AGTAAACTTG 
     4861 GTCTGACAGT TACCAATGCT TAATCAGTGA GGCACCTATC TCAGCGATCT GTCTATTTCG 
     4921 TTCATCCATA GTTGCATTTA AATTTCCGAA CTCTCCAAGG CCCTCGTCGG AAAATCTTCA 
     4981 AACCTTTCGT CCGATCCATC TTGCAGGCTA CCTCTCGAAC GAACTATCGC AAGTCTCTTG 
     5041 GCCGGCCTTG CGCCTTGGCT ATTGCTTGGC AGCGCCTATC GCCAGGTATT ACTCCAATCC 
     5101 CGAATATCCG AGATCGGGAT CACCCGAGAG AAGTTCAACC TACATCCTCA ATCCCGATCT 
     5161 ATCCGAGATC CGAGGAATAT CGAAATCGGG GCGCGCCTGG TGTACCGAGA ACGATCCTCT 
     5221 CAGTGCGAGT CTCGACGATC CATATCGTTG CTTGGCAGTC AGCCAGTCGG AATCCAGCTT 
     5281 GGGACCCAGG AAGTCCAATC GTCAGATATT GTACTCAAGC CTGGTCACGG CAGCGTACCG 
     5341 ATCTGTTTAA ACCTAGATAT TGATAGTCTG ATCGGTCAAC GTATAATCGA GTCCTAGCTT 
     5401 TTGCAAACAT CTATCAAGAG ACAGGATCAG CAGGAGGCTT TCGCATGATT GAACAAGATG 
     5461 GATTGCACGC AGGTTCTCCG GCGGCTTGGG TGGAGAGGCT ATTCGGCTAT GACTGGGCAC 
     5521 AACAGACAAT CGGCTGCTCT GATGCCGCCG TGTTCCGGCT GTCAGCGCAG GGGCGTCCGG 
     5581 TTCTTTTTGT CAAGACCGAC CTGTCCGGTG CCCTGAATGA ACTGCAAGAC GAGGCAGCGC 
     5641 GGCTATCGTG GCTGGCGACG ACGGGCGTTC CTTGCGCGGC TGTGCTCGAC GTTGTCACTG 
     5701 AAGCGGGAAG GGACTGGCTG CTATTGGGCG AAGTGCCGGG GCAGGATCTC CTGTCATCTC 
     5761 ACCTTGCTCC TGCCGAGAAA GTATCCATCA TGGCTGATGC AATGCGGCGG CTGCATACGC 
     5821 TTGATCCGGC TACCTGCCCA TTCGACCACC AAGCGAAACA TCGCATCGAG CGAGCACGTA 
     5881 CTCGGATGGA AGCCGGTCTT GTCGATCAGG ATGATCTGGA CGAAGAGCAT CAGGGGCTCG 
     5941 CGCCAGCCGA ACTGTTCGCC AGGCTCAAGG CGTCTATGCC CGACGGCGAG GATCTCGTCG 
     6001 TGACCCACGG CGATGCCTGC TTGCCGAATA TCATGGTGGA AAATGGCCGC TTTTCTGGAT 
     6061 TCATCGACTG TGGCCGTCTG GGTGTGGCGG ACCGCTATCA GGACATAGCG TTGGCTACCC 
     6121 GTGATATTGC TGAAGAGCTT GGCGGCGAAT GGGCTGACCG CTTCCTTGTG CTTTACGGTA 
     6181 TCGCCGCGCC CGATTCGCAG CGCATCGCCT TCTATCGCCT TCTTGACGAG TTCTTCTGAC 
     6241 CGATTCTAGG TGCATTGGCG CAGAAAAAAA TGCCTGATGC GACGCTGCGC GTCTTATACT 
     6301 CCCACATATG CCAGATTCAG CAACGGATAC GGCTTCCCCA ACTTGCCCAC TTCCATACGT 
     6361 GTCCTCCTTA CCAGAAATTT ATCCTTAAGG TCGTTTAAAC TCGACTCTGG CTCTATCGAA 
     6421 TCTCCGTCGT TTCGAGCTTA CGCGAACAGC CGTGGCGCTC ATTTGCTCGT CGGGCATCGA 
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“Men have forgotten this truth,” said the fox. “But you must not forget it. You become responsible, 
forever, for what you have tamed.” 
 
The Little Prince - Antoine de Saint-Exupéry 
 
